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ABSTRACT
The mercapturic acid pathway is an important detoxication mechanism in mammalian 
cells/tissues. However, work over the last decade has shown that several halogenated 
alkenes, once processed via this pathway, become substrates for the enzyme cysteine 
conjugate (3-lyase. This latter enzyme cleaves these conjugates to ultimately yield potent 
nephrotoxins. The factors controlling the (3-lyase enzyme's cellular distribution and 
substrate specificity have, however, yet to be elucidated.
To this end, a cDNA for cysteine conjugate (3-lyase has been isolated from a rat kidney cDNA 
library using immunological screening. The cDNA was sequenced and found to be previously 
unreported. Northern blot analysis of rat kidney and liver RNA showed the cDNA to be 
highly specific for a single mRNA, of 1.9kb in length, in the kidney which was in agreement 
with the expected size for a 48kD protein.
This cDNA was used to investigate the tissue distribution of rat kidney (3-lyase. Northern 
blot analysis of tissue RNA was in close agreement with the Western blot finding that the 
kidney (3-lyase was of a structurally different form when compared to extrarenal forms of 
the enzyme. The cDNA was also used to examine the induction/reduction of rat kidney 13- 
lyase activity by pretreatment of rats with the (3-lyase substrate precursor NAc-PCBD. It 
was demonstrated that a non-toxic dose of 3 mg/kg NAc-PCBD caused a significant increase 
in kidney cytosolic (3-lyase as assessed by enzyme activity, enzyme protein levels and 
corresponding mRNA levels. In contrast, a toxic 10mg/kg dose caused a significant decrease 
in these latter parameters.
Further cDNAs were isolated by immunological screening of a separate cDNA library but 
failed to be identified as corresponding to (3-lyase. The possible reasons for this and the 
significance of the isolation and characterisation of the original cDNA are discussed at length.
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1CHAPTER 1 
INTRODUCTION
1.1 GENERAL INTRODUCTION
Due to the nature of the highly industrialised world in which we live, man is continuously 
being exposed to compounds foreign to the body (xenobiotics). During daily food intake many 
compounds (food additives, environmental pollutants and pesticide residues) may enter the 
body. At work, too, man may be exposed to a variety of chemicals. Finally, many drugs are 
used therapeutically in the treatment of diseases, or are abused. Such xenobiotics may 
disturb biochemical processes and may therefore be a threat to human health by causing 
adverse effects in essential organs and tissues.
The kidney is a frequent target organ for toxicity by such chemicals. Since normal kidney 
function is necessary to maintain life, the consequences of such chemical insults can well be 
fatal. However, the mechanism(s) by which chemicals produce their toxic effects on the 
kidney are, in general, poorly understood.
The elucidation of the molecular mechanisms leading to toxicity may be of great importance 
in strategies aiming at the prediction and the prevention of chemically induced toxicities 
(Vermeulen e t al, 1990) as may the investigation into the regulation of the principal 
enzymes involved. The science of molecular toxicology is one in which these and other 
mechanisms are investigated. The studies described in this thesis aim at a better 
understanding of the toxicologically important enzyme cysteine conjugate p-lyase and how it 
affects the toxicity to the kidney (nephrotoxicity) caused by halogenated hydrocarbons, a 
class of compounds which are of great economical importance and, yet, also of great 
environmental concern.
21.2 DRUG METABOLISM AND TARGET ORGAN TOXICITY
Tissues are, to varying degrees, susceptible to the toxic effects of chemicals to which man is 
exposed (Cohen and Moss, 1987). Many compounds cause toxicity to particular organs. A 
reason for this target organ specificity may be the tissue distribution of the toxic agent, i.e. 
accumulation of a xenobiotic in a specific organ leading to toxic concentrations in that organ. 
Many resorbed xenobiotics are only poorly excreted due to their hÿhlipophilicity and to be 
eliminated from the body, these compounds must be converted enzymatically 
(biotransformation) to more water-soluble products. These can then be excreted more 
readily into the bile or urine.
Xenobiotics undergo several types of metabolic reactions. These include oxidative, reductive 
and hydrolytic reactions (phase I reactions) as well as synthetic conjugative reactions 
(phase II reactions). Phase I reactions often, but not necessarily, precede phase II 
reactions. The most common metabolic pathways in xenobiotic metabolism are the oxidative 
and conjugative reactions. The oxidative reaction usually results in the formation of a polar 
functional group on the substrate molecule, which can then be the site of a subsequent 
conjugative reaction. Indeed it is recognised that the main function of phase I metabolism is 
to prepare the compound for phase II metabolism. The conjugative reactions appear to be 
largely processes of detoxication and give products that are generally water-soluble and 
easily excreted. Phase II reactions involve synthesis, catalysed by transferases, in which 
the xenobiotic (or a metabolite of the xenobiotic) is conjugated with endogenous compounds 
such as glucuronic acid, glycine, sulphate or glutathione. In most phase II conjugations, the 
acceptor is a foreign molecule containing a nucleophilic centre (eg. -OH, -SH or -NHz) and
the donor is an endogenous compound with an electrophilic group available for transfer.
Glutathione transfer, however, is a means for conjugation of xenobiotic compounds with 
electrophilic centres, e.g. epoxides, activated alkenes, alkyl-halides and related esters of 
strong acids, which react with the nucleophilic sulphydryl of glutathione. Thus (gSH conjugation 
is recognised as a protective mechanism within the body, for the removal of potentially toxic 
electrophilic compounds.
In general, the liver is the most important organ in the biotransformation of absorbed 
xenobiotics due to the relatively high levels of drug metabolising enzymes in this organ and 
also because the liver is the first organ to be reached after oral administration of 
xenobiotics. Most, if not all, drug metabolising enzymes, however, also have been detected 
in extrahepatic tissues such as the kidney, lung, intestine, heart and nervous system (Cohen 
and Moss, 1987; Litterst et al, 1975). Although extrahepatic metabolism may represent 
only a small percentage of the overall metabolism of a compound, it may be of particular 
toxicological significance under certain circumstances.
Previously it was assumed that toxic xenobiotics act directly by interacting with critical 
endogenous targets such as proteins, lipids and nucleic acids. However, over the last few 
decades, it has become increasingly clear that many chemicals are not in themselves toxic 
but that they are activated by biotransformation to reactive intermediates, which 
subsequently react or interact with endogenous macromolecules (Anders, 1985). Next to 
tissue distribution of the parent compound, the tissue distribution of the bioactivating 
enzymes may therefore be a major factor in determining the organ specific toxicity of 
xenobiotics. Reactive intermediates formed by biotransformation may involve electrophilic 
species, radicals or activated oxygen species. Highly reactive intermediates are usually 
formed in situ in target organs or tissues.
For less reactive metabolites, bioactivation may occur in distant organs with high metabolic 
activity, such as the liver, followed by transport of the reactive intermediate to the target 
organ. Some toxic chemicals require multistep metabolic activation, i.e. a stable proximate 
toxic metabolite may be formed in one organ and may be transported to the target organ, 
where it is bioactivated to the ultimate toxic metabolite. To protect against harmful 
interactions between reactive intermediates and critical cellular macromolecules, tissues 
possess several defense mechanisms. These systems may act by deactivation of the toxicant 
or by repair of the initially affected cellular elements. Therefore, next to tissue 
distribution of both the parent compound and bioactivating enzymes, the activity of 
deactivating systems plays an important role in determining target organ toxicity.
A major role in the protection against toxic species is played by the endogenous tripeptide 
glutathione (GSH; y-Glu-Cys-Gly), as shown in Figure 3.1 (Reed and Farris, 1984). 
Glutathione is present in most mammalian cells at millimolar concentrations. Reactive 
electrophilic species can be deactivated by conjugation to the nucleophilic sulphur atom of 
GSH, the reaction occurring spontaneously or being catalysed by the glutathione-S- 
transferase family of isoenzymes. The GSH-conjugate formed is generally further processed 
to a N-acetyl-L-cysteine conjugate (or mercapturic acid), which is excreted in the urine 
(figure 1.1). For this reason metabolism by GSH-conjugation is frequently known as the 
mercapturic acid pathway (Bakke and Gustafsenn, 1984). GSH may also detoxify compounds 
such as radicals, hydrogen peroxide and organic peroxides by reduction, GSH being oxidised 
concomitantly to the dimer GSSG. Some reactive intermediates may act by oxidation of 
essential protein thiol groups and so glutathione also plays an important role in the 
maintenance of the redox state of proteins by reduction of protein-disulphides.
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As stated previously, glutathione conjugation is catalysed by cytosolic, microsomal and 
mitochondrial glutathione-S-transferases present in several tissues (Jakoby et al,
1984a). Glutathione conjugates have the required physicochemical properties for biliary 
excretion and will, generally, together with their catabolites, be present in bile in 
relatively high concentrations. These catabolites include cysteinyl glycine, cysteine and N- 
acetyl cysteine (mercapturic acid) conjugates which are formed as outlined in figure 1.1. 
The first step in the metabolism of glutathione conjugates involves either hydrolysis or 
transamination by y-glutamyl transpeptidase and transfer of the y-glutamyl group to an 
appropriate acceptor. The enzyme y-glutamyl transpeptidase (GGT) is an ubiquitous 
enzyme (Tate, 1980), it is membrane bound and its active site is orientated on the outer 
surface of the cell membrane (Horiuchi et al, 1978). The kidney possesses the highest 
level of GGT specific activity followed by the pancreas. The product of the GGT-catalysed 
reaction is the cysteinyl glycine dipeptide which, in turn, is subjected to hydrolytic 
cleavage releasing the glycine residue. Several membrane enzymes may serve this function 
(Tate, 1980) of which aminopeptidase M and cysteinyl glycine dipeptidase have been 
purified and possess the requisite specificity. The detoxication function of mercapturic acid 
biosynthesis is completed by transfer of an acetyl group, from acetyl coenzyme A, to the S- 
substituted cysteine conjugate, catalysed by N-acetyl transferase (Duffel and Jakoby,
1982). This enzyme is located in the proximal tubule, in addition to GGT and cysteinyl 
glycine dipeptidase activities (Hughey eta!, 1978).
Thus, mercapturic acid formation is usually associated with the detoxication of xenobiotics, 
because mercapturic acids are polar, readily excreted from the body and are generally 
stable and non-toxic. However, over the last decade, evidence has been mounting that GSH 
conjugation and the subsequent processing may also be involved in a number of toxication 
reactions (Van Bladeren, 1988).
1.3 BIOACTIVATION AND NEPHROTOXICITY: THE ROLE OF GLUTATHIONE
The kidney is a very complex organ which has several physiologically important functions, 
such as water volume regulation, electrolyte regulation, excretion of waste products in the 
urine and endocrine functions. Toxicity to the kidney may therefore have severe or even 
fatal consequences to the organism (Hook and Hewitt, 1986). The kidney is exposed to high 
concentrations of chemicals due to several factors. The kidney receives approximately 25%  
of the cardiac output and is a major organ for the elimination of chemicals and their 
metabolites. Both by passive and active mechanisms, potentially toxic chemicals can be 
concentrated in the kidney to high concentrations. Furthermore, the kidney contains most of 
the drug metabolising enzymes found in the liver and is therefore also able to bioactivate 
foreign chemicals to reactive intermediates in situ.
As previously stated, conjugation to GSH may be involved in the bioactivation of toxic 
xenobiotics. Toxic GSH-conjugates can be divided into three groups as shown in figure 1.2 
(Van Bladeren, 1988), namely; 1. reactive, direct-acting GSH-conjugates, 2. GSH- 
conjugates in which GSH functions as a transporter molecule by releasing reversibly bound 
electrophilic compounds, and 3. GSH-conjugates which require further bioactivation by 
catabolism of the GSH-moiety or by activation of the xenobiotic derived moiety.
1. Direct Acting Glutathione S-conjugates
8
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Figure 1.2 The Three Classes of Reactive Glutathione Conjugate
1.3.1 Direct Acting Glutathione S-Conjugates
The best examples of this first group of compounds are 2-chloro and 2-bromoethyl 
glutathione (the GSH conjugates of 1,2-dichloroethane and 1,2-dibromoethane 
respectively) (Hill et al, 1978; Van Bladeren e t al, 1979). From these sulphur half­
mustards, highly reactive episulphonium ions may be formed by the internal displacement 
of the second halogen atom by the sulphur atom (Schasteen and Reed, 1983). These strong 
electrophiles may play an important role in the mutagenicity and nephrotoxicity of 1,2- 
dihaloalkanes and in the formation of DNA-adducts (Rannung et al, 1978; Van Bladeren et 
al., 1982). S-2-haloethyl-N-acetylcysteines, which are presumed to be formed by renal 
processing of haloethylglutathiones, were also found to be strong and direct acting mutagens 
(Inskeep and Guengerich, 1984).
1 .3 .2  Glutathione as a Transporter o f Electrophiles
When the time course of the conjugation reaction between equimolar amounts of GSH and 
benzyl /  allyl isothiocyanates was investigated, an equilibrium situation was reached where 
15-20% of the isothiocyanate was still present in the unconjugated form (Bruggeman e t al., 
1986). The position of this equilibrium could be influenced by pH and the concentration of 
the reactants. In agreement with these results it was shown that the conjugates of these 
isothiocyanates display toxicities very similar to the parent compounds (Temmink e t al, 
1986). In general the benzyl derivatives are slightly more toxic than the allyl derivatives 
and , while the cysteine conjugates are more toxic than the glutathione adducts, the 
mercapturic acids are the least toxic (Bruggeman e t al., 1986). The possible implications 
of this finding for the in vivo situation are that the isothiocyanates are detoxified at first, 
but could be released at some other site, where GSH concentrations are lower or conditions 
of pH are different. In this respect it is interesting to note that allyl isothiocyanate exerts 
its carcinogenic effect in the bladder of the rat (Dunnick et al., 1982), where the pH is 
usually acdicThus favouring release of the isothiocyanate.
1 .3 .3  Glutathione S-Conjugates Requiring Further Metabolism  
This third activation pathway involving GSH conjugation occurs during metabolism of 
several nephrotoxic and/or nephrocarcinogenic halogenated alkenes. McKinney e t al., 
(1 9 59 ) identified S-(1,2-dichlorovinyl)-L-cysteine (DCVC) as the toxic agent 
responsible for aplastic anaemia and kidney damage in cattle fed with soya bean extracted 
with trichloroethylene at high temperatures. In subsequent studies, using rats and other 
laboratory animals, DCVC caused severe tubular necrosis (Terracini and Parker, 1965). 
DCVC formation from trichloroethylene, via conjugation with GSH, has not been reported in 
vivo. However, DCVC nephrotoxicity and metabolic activation in the kidney is typical of 
several cysteine conjugates that are known to be formed as a result of GSH conjugation in 
vivo. The GSH conjugates formed are processed to cysteine conjugates which are finally 
acetylated to form readily excretable mercapturic acids (Jakoby et al., 1984b). However, 
thioethers of cysteine with electronegative and/or unsaturated substituents are also 
substrates for the enzyme cysteine conjugate p-lyase, which cleaves the conjugate to  
reactive sulphur-containing fragments (presumably thiols), pyruvate and ammonia. The 
reactive fragment formed during the activation of DCVC was shown to interact with protein 
and DMA (Anderson and Schultze, 1965; Battacharya and Schultze, 1972) and to inhibit 
mitochondrial respiration (Stonard and Parker, 1971). The thiol metabolite, which can be 
methylated by thiol S-methyl transferase (Weisiger and Jakoby, 1979), may be ultimately 
responsible for the toxicity. The major factors determining the toxic potential of this group 
of GSH conjugates are thus 1. their suitability as substrate for the cysteine conjugate p- 
lyase(s) and 2. the reactivity of their thiol products.
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The GSH conjugates of 2-bromohydroquinone, 1,4-benzohydroquinone and menadione all 
caused severe nephrotoxicity after administration to rodents. The toxication mechanism of 
the GSH conjugates of 2-bromohydroquinone (Monks e t al., 1988) and 
1,4-benzohydroquinone (Lau eta /., 1988) is proposed to involve intracellular oxidation of 
the hydroquinone moiety to an alkylating quinone, which subsequently may react with 
protein thiols. The nephrotoxicity caused by the GSH conjugates of menadione are believed to 
result from redox cycling of the (hydro)quinone moiety, leading to the formation of a 
reactive oxygen species (Wefer and Sies, 1983). Inhibition of y-glutamyl transpeptidase 
(GGT) by the compound AT-125 results in protection against the nephrotoxicity of these 
GSH-conjugates, indicating that catabolism of the GSH moiety may also be involved in the 
bioactivation of these toxic GSH-conjugates.
Thus, it is now recognised that the function of the glutathione conjugation pathway is no 
longer limited to facilitating the excretion and detoxication of xenobiotics. Biologically 
active GSH-derived adducts may be formed with xenobiotics and these may be further 
metabolised to sulphur-containing products with alkylating/mutagenic potential.
1.4 CYSTEINE CONJUGATE p-LYASE-MEDIATED NEPHROTOXICITY OF 
HALOGENATED ALKENES
Hexachloro-1,3-butadiene (HCBD) is used commercially in small amounts as a vineyard 
fumigant and in the recovery of chlorine gas during the manufacture of hydrochloric acid. 
More significant amounts of HCBD are found in industrial wastes, generated mainly as by­
products from the manufacture of tri- and tetrachloroethylenes and carbon tetrachloride 
(IARC, 1979). Due to the disposal of HCBD-containing wastes, HCBD is a serious 
environmental contaminant. As well as environmental exposure, man could potentially be 
subjected to occupational exposure during disposal of the by-products produced in the 
production of tri- and tetrachloroethylenes. Experimental studies using rodents showed that
the primary target for HCBD induced toxicity is the kidney (Lock and Ishmael, 1979).
HCBD was shown to be metabolised by glutathione (GSH) conjugation via an addition- 
élimination mechanism (Nash et al., 1984). The GSH conjugate and the corresponding 
cysteine conjugate of HCBD induced the same type of nephrotoxicity, suggesting that the GSH 
conjugation route might be responsible for the toxic effects (Lock and Ishmael, 1985). The 
mode of action of the cysteine conjugate of HCBD was proposed to be analogous to that 
proposed for DCVC, namely activation by cysteine conjugate p-lyase to an unsaturated thiol 
compound.
The fluoroalkenes, chlorotrifluoroethylene (CTFE), tetrafluoroethylene (TFE) and 
hexafluoropropene (HFP) are a group of commercially important monomers which have 
been manufactured for 20 to 30 years. CTFE and HFP are both gaseous fluoroalkenes used in 
the production of fluoropolymers and TFEC is the monomer used in the production of 
polytetrafluoroethylene (PTFE). Again, evaluation of the toxicological effects, if any, 
elicited by repeated exposure to these halogenated alkenes is therefore important because, as 
industrial chemicals, there is a potential for chronic human exposure.
1.4.1 Nephrotoxicity o f Haloalkene Glutathione Conjugates  
As stated above, a number of halogenated alkenes, namely HCBD (Lock and Ishmael, 1979), 
CTFE (Buckley e ta /., 1982), TFE (Odum and Green, 1984) and HFP (Potter e ta /., 1981), 
produce marked nephrotoxicity in experimental animals, with minimal or no liver injury. 
Renal injury produced by HCBD in the rat is restricted to the straight portion of the 
proximal tubules (pars recta or S3 segment), where it causes a distinct band of damage in 
the outer stripe of the outer medulla (Ishmael e t al., 1982). CTFE and TFE-induced renal 
injury is also localised to the pars recta (Potter et al., 1981; Odum and Green, 1984), 
where HFP has been reported to cause a more widespread injury involving the SI and S2 
segments (Potter et al., 1981).
Consistent with the pathological changes produced by these compounds, are changes in renal 
capacity, including decreased urine concentrating ability, glucosuria, proteinuria, elevated 
plasma urea and decreased renal function (Lock and Ishmael, 1979; Potter et al., 1981; 
Odum and Green, 1984). Administration of HCBD to adult male rats produced a depletion of 
hepatic, but not renal non-protein sulphydryl (GSH) content (Lock and Ishmael, 1981). 
Analysis of bile from [14C]-HCBD treated rats has shown a number of radiolabelled 
metabolites, with the major metabolite being identified as S-(l ,2,3,4-pentachloro-l ,3- 
butadienyl) glutathione and (1 ,2,3,4-pentachloro-l ,3-butadienyl) cysteinyl glycine 
(Nash et al., 1984). Cannulation of the bile duct of HCBD-treated rats prevents the 
toxicity, while administration of lyophilised bile, collected from HCBD-treated rats 
produced renal necrosis analogous to that seen with the parent compound (Nash e t al.,
1984). These findings support the hypothesis that a GSH-derived conjugate of HCBD is 
involved in the nephrotoxic response and this is supported by studies with chemically 
synthesised PCBDG, which caused a renal lesion identical to that seen with HCBD (Ishmael 
and Lock, 1986).
Several studies with other halogenated alkenes have provided evidence of glutathione 
conjugation in vivo. For example, analysis of the bile from rats exposed to TFEC showed the 
presence of the corresponding cysteine conjugate derived from glutathione (Odum and Green,
1984) and, following a single dose of trichloroethylene (TCE), the N-acetyl cysteine 
conjugate of TCE was detected in rat urine (Dekant e t al., 1986). Some of the GSH 
conjugates have been chemically synthesised and shown to cause nephrotoxicity similar to 
the parent haloalkene, for example, S-(2-chloro-l -2-trifluoroethyl) glutathione (DCVG) 
(Dohn et al., 1985; Anders et al., 1986).
The nephrotoxicity produced by DCVG can be partially prevented by prior administration of 
the y-glutamyl transpeptidase inhibitor AT-125 (Anders et ah, 1986), thus supporting 
the view that further metabolism of the glutathione conjugate is required in vivo to produce 
the toxicity. However, AT-125 treatment did not completely block the nephrotoxicity of 
DCVG (Anders e t al., 1986) and this result, together with the report that AT-125 does not 
protect against HCBD-induced nephrotoxicity (Davis, 1988), suggests that some glutathione 
conjugates may undergo non-enzymatic hydrolysis or that degradation of the GSH-conjugate 
by intestinal microflora may occur following biliary excretion. Alternatively, the y  
glutamyl transpeptidase activity remaining after AT-125 treatment allows sufficient 
processing of glutathione conjugates to produce cysteine derivatives in nephrotoxic amounts. 
The haloalkenes CTFE and TFEC undergo an addition reaction with glutathione (Dohn and 
Anders, 1982; Odum and Green, 1984), whilst HCBD undergoes both an addition and 
elimination reaction with glutathione (Wolf et al., 1984). All three chemicals are 
substrates for the glutathione-S-transferases(s) present in rat liver cytosolic and 
microsomal fractions, and it has been noted that the specific activity of microsomal 
glutathione-S-transferase is higher than the cytosolic transferase (Dohn and Anders,
1982; Odum and Green, 1984; Wolf et al, 1984). Kidney microsomal and cytosolic 
fractions contain glutathione-S-transferases capable of conjugating HCBD with glutathione, 
although their activity is lower than that of the liver (Wolf et al., 1984). The GSH- 
conjugate of HCBD is cytotoxic to isolated rat renal proximal tubular cells (Jones e t al.,
1986). The loss in cell viability is, however, only observed after a lag phase of about 30  
minutes. Inhibition of the enzyme y-glutamyl transpeptidase with anthglutin gave complete 
protection against the toxicity (Jones et al., 1986), thus supporting the hypothesis that 
metabolism to the corresponding cysteine conjugate is required.
S-(2-chloro-1,1 ,2-trifluoroethyl) glutathione is cytotoxic to isolated rat renal proximal 
tubular cells (Dohn e t al., 1985), and inhibits the active transport of the organic anion p- 
aminohippurate (PAH) and the organic cation tetraethylammonium (TEA) by rabbit renal 
tubules (Hassall e t al., 1984). This toxicity and that of DCVG could also be reduced by GGT 
inhibitors such as AT-125 (Hassall e t al., 1984; Dohn e t al., 1985). Lash and Anders 
(1986 ) have reported that DCVG is cytotoxic to isolated rat renal proximal tubular cells 
and that addition of glycylglycine, a y-glutamyl acceptor, potentiates DCVG toxicity, while 
addition of AT-125 protects. This indicates that metabolism of DCVG by GGT is required for 
the expression of toxicity and that the cysteinylglycine conjugate is the product of the 
reaction. These workers also showed that 1,10-phenanthroline, an inhibitor of 
aminopeptidase M, and phenylalanyl glycine, a competitive inhibitor of cysteinylglycine 
dipeptidase, protected the cells from DCVG toxicity, indicating that the ultimate toxin is 
generated by further metabolism of S-(1,2-dichlorovinyl)-cysteinylglycine. Studies with 
the renal epithelial cell line LLC-PK, have shown that PCBDG and DCVG are toxic to these 
cells and that this toxicity can be prevented by the addition of GGT inhibitors (Stevens e t al., 
1986a; Mertens e t al., 1988), again indicating the need for the degradation to the cysteine 
conjugates to exert toxicity.
It was reported that DCVG can be transported into isolated kidney cells by an electrogenic, 
Na+-coupled transport system located on the baso-lateral membrane (Lash and Jones,
1985). This baso-lateral transport system may therefore be very important in 
determining the selective nephrotoxicity of haloalkene glutathione conjugates.
Data from different studies are indicative for the following processes. The initial GSH 
conjugates are formed predominantly in the liver and exported in the blood and/or bile. The 
protection afforded by bile cannulation against nephrotoxicity induced by HCBD points to the 
importance of the biliary route (Lock, 1988). Peptidases present in the bile duct and small 
intestine are active in degrading the GSH conjugates to cysteine conjugates, which are 
subsequently resorbed into the blood (Lock,! 988). Via the portal vein, the cysteine 
conjugates first pass the liver, where N-acetylation takes place to form the corresponding 
mercapturic acid. The cysteine conjugates and mercapturic acids are transported in the 
blood to the kidneys where they are secreted by different active transporters into the 
proximal tubular cells (Schaeffer and Stevens, 1987). In these cells, the cysteine 
conjugates can be N-acetylated or be bioactivated by p-lyase. The mercapturic acid can be 
excreted in the urine, however it can also be deacetylated by renal deacetylases to the 
corresponding cysteine conjugates, which, again, can be bioactivated by p-lyase. Thus, the 
activity of the deacetylases may be a crucial factor in the observed nephrotoxicity of a 
number of mercapturic acids both in vivo (Commandeur e t al., 1988) and in vitro 
(Boogaard et al., 1989). A limited availability of acetyl coenzyme A, the cofactor for the 
deactivating N-acetylation step, also might direct biotransformation of the haloalkenes 
towards the bioactivation step (Commandeur e t al., 1989).
1 .4 .2  Nephrotoxicity of Haloalkene Cysteine Conjugates  
S-( 1,2-dichlorovinyl)-L-cysteine (DCVC) has been known for many years to cause 
nephrotoxicity in a number of animal species (Terracini and Parker, 1965). Recent 
studies have shown that the cysteine conjugates S -(1,2 ,3 ,4 ,4-pentachloro-
1 ,3-butadienyl)-L-cysteine (PCBDC), S -1 ,1 ,2,2-tetrafluoroethyl)-L-cysteine (TFEC) 
and S-(2-chloro-1,1 ,2-trifluoroethyl)-L-cysteine (CTFEC) are all nephrotoxic to the 
rat, producing an identical histopathological lesion to that seen with the parent 
haloalkene/GSH-conjugate (Odum and Green, 1984; Ishmael and Lock, 1986; Dohn e t al.,
1985). The mercapturates of many of these latter compounds cause a similar 
nephrotoxicity, for example, S -(1 ,2 ,3 ,4 ,4-pentachloro-l ,3-butadienyl)-N-acetyl 
cysteine (NAc-PCBD) (Nash et a/., 1984). Anders and coworkers have extended these 
studies by showing that S-(1,2-dichlorovinyl)-L-homocysteine (DCVHC), the 
homocysteine analogue of DCVC, is a potent nephrotoxic agent, while the «-methyl 
substituted analogues of both DCVC and DCVHC, where the y-hydrogen is replaced by a 
methyl group, are not substrates for cysteine conjugate p-lyase and are not nephrotoxic 
(Elfarra e t al, 1986a and 1986b). Prior treatment of rats with aminooxyacetic acid 
(AOAA), an inhibitor of pyridoxal phosphate-dependent enzymes (including p-lyase), 
afforded some protection against the nephrotoxicity elicited by DCVC and DCVHC (Elfarra et 
al, 1986a and 1986b). The in v/vo toxicity of DCVC, DCVHC, PCBDC and NAc-PCBD can be 
blocked by prior treatment with probenicid, an inhibitor of basolateral anion transport 
systems (Lock and Ishmael, 1985; Elfarra e t al, 1986a and 1986b). Probenecid protects 
against xenobiotic-dependent nephrotoxicity by reducing the renal cortical concentration of 
the chemical (Lock and Ishmael, 1985). These cysteine conjugates, in vivo, will undergo N- 
acetylation, mainly in the liver, and it is presumably the transport of the mercapturate into 
renal cells that is blocked by probenecid.
The toxicity of a number of haloalkene cysteine conjugates has been studied in vitro in renal 
slices and isolated renal tubule and cell preparations. In isolated rat renal cortical slices, 
haloalkene cysteine conjugates increased the production of pyruvate and ammonia, and 
generated a reactive moiety which inhibited renal PAH and TEA transport systems (Green 
and Odum, 1985): The cytotoxicity of DCVC, CTFEC and PCBDC has been studied in isolated 
rabbit renal tubules, while isolated rat renal proximal tubular cells have been employed to 
study the cytotoxicity of several of these conjugates (Hassal e t al., 1983a and 1983b; Jaffe 
et al., 1983; Schnellmann et al., 1987). DCVC and the glutathione/cysteine conjugates 
derived from HCBD and CTFE were all cytotoxic to rat renal proximal tubular cells in a time- 
and dose-dependent manner. The cytotoxicity could be reduced by inclusion of AOAA in the 
medium to inhibit p-lyase activity (Dohn et al., 1985; Anders et al., 1986; Jones e t al.,
1986). The homocysteine analogue of DCVC is also cytotoxic to isolated cells, which can be 
protected by treatment with inhibitors of pyridoxal phosphate-dependent enzymes (Anders 
et al., 1986; Elfarra et al., 1986b). The cysteine conjugates of HCBD and TCE are not 
organic anions but derivatives of amino acid zwitterions and, hence, metabolism to yield the 
mercapturate, an organic anion, may have occurred to enable their transport via this 
system.
These results indicate that the S-cysteine conjugates of these various haloalkenes are 
transported into cells, either directly via an L-amino acid transport system (Schaeffer and 
Stevens, 1987) or as mercapturates via a probenicid-sensitive transport system (Lock et 
al., 1986) and undergo further metabolism via cysteine conjugate p-lyase to yield the 
ultimate nephrotoxic agent (Pratt and Lock, 1988).
1.4 .3  The Ultimate Nephrotoxic Agent and It's  Action
The precise chemical nature of the toxic metabolite produced by p-lyase cleavage of cysteine- 
conjugates is not known in all cases. A toxic thiol or a rearrangement product of the thiol is 
thought to be responsible for the cytotoxicity. The activation of CTFEC has been studied in an 
in vitro model system (Dekant et al., 1987). These studies indicate that CTFEC activation 
by p-lyase involves the formation of an unstable thiol 2-chloro-1,1 ,2-trifluoro-ethane 
thiol which loses hydrogen fluoride to form the acylating agent chlorofluorothionoacetyl 
fluoride (Figure 1.3). Further hydrolysis of this yields the stable metabolite 
chlorofluoroacetic acid, inorganic fluoride and hydrogen sulphide. Flydrogen sulphide has 
been identified as a metabolite of DCVC (Anders e t al., 1987) which is consistent with the 
report that inorganic sulphate is a metabolite of DCVC in the rat (Derr and Schultze, 1963). 
Hydrogen sulphide is a known poison. However, it's role in the toxicity of these cysteine 
conjugates is unknown. Both sodium fluoride and chlorofluoroacetic acid are cytotoxic to 
isolated kidney cells suggesting that these metabolites, as well as the reactive intermediate, 
may contribute to the cytotoxicity of CTFEC (Dekant e t al., 1987).
Recently the p-lyase-dependent bioactivation of S-conjugates of tetrafluoroethylene by 
subcellular fractions from rat liver and kidney have been studied (Commandeur et al.,
1989). Incubation of both hepatic and renal cytosol with TFEC resulted in the formation of 
previously unidentified difluorothionamides, indicating difluorothionoacyl fluoride as the 
main reactive intermediate derived from the p-lyase dependent bioactivation of TFEC 
(Figure 1.4). The presence of N-difluorothionoacetyl-S-(1,1 ^^-te tra fluoroethyO -L- 
cysteine and difluoroacetic acid in urine of rats treated with N-acetyl-S-(1,1 ,2 ,2- 
tetrafluoroethyl)-L-cysteine (TFE-NAc) points to a similar mechanism in vivo.
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The presumed toxic thiol from PCBDC is S-(1,2,3,4-pentachloro-l ,3-butadienyl)-thiol 
which may tautomerise to form a thioacylating agent. Both of these products would be 
expected to be very reactive and unstable and metabolites of HCBD are known to alkylate 
tissue constituents (Lock and Ishmael, 1985: Reichert e ta /., 1985; Pratt and Lock, 1988). 
Recently the activation of PCBDC has been studied in an in vitro model system (Dekant e t a/., 
1988). The results obtained suggest that the formation of a thioacylating intermediate (a 
thioketene or thionoacyl chloride) may be the decisive reaction during the p-lyase dependent 
activation of PCBDC (Figure 1.5). Four metabolites of HCBD have been identified in rat 
urine, namely S-(1,2,3,4,4-pentachloro-1,3-butadienyl)-sulphenic acid (Nash e ta /.,
1984 ), pentachloro-1 -m ethyl-thio-1,3-butadiene, pentachlorocarboxy-1 -m ethyl-thio-
1,3-butadiene (Reichert e t a/., 1985) and NAc-PCBD (Reichert and Schütz, 1986). Two of 
these metabolites support the in vitro data indicating C-S bond cleavage had occurred 
followed by subsequent méthylation or oxidation. Studies on the mechanism of haloalkene 
cysteine conjugate induced cytotoxicity, in isolated kidney cells, have shown that exposure to 
PCBDG results in glutathione (thiol) depletion, prior to any loss of cell viability (Jones e t  
al., 1986; Schnellmann e t al., 1987). The thiol depletion suggests that reduced GSH may 
play some protective role against the reactive metabolite of PCBDC responsible for renal 
cell injury.
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Figure 1.5 Proposed Scheme for the Production of a Cytotoxic and Mutagenic 
Species from the Cysteine Conjugate of HCBD
Exposure of isolated rat renal cells to PCBDC results in a rapid appearance of plasma 
membrane blebs (Jones et al., 1986). This process is associated with cytoskeletal 
alterations caused by the disturbance of intracellular calcium homeostasis (Jewell e t al.,
1982). PCBDC and DCVC have been shown to deplete the mitochondrial Ca2+ pool (Jones et 
al., 1986; Lash and Anders, 1986) with a concomitant increase in cytosolic Ca2+ thereby 
providing some support for the proposed association between elevated cytosolic Ca2+ 
concentration and the process of membrane blebbing. However, the alteration in 
mitochondrial Ca2+ regulation does not appear to be a specific effect of these compounds as 
they produce a general impairment of mitochondrial function. Both cellular respiration and 
ATP content were generally reduced following PCBDC and DCVC exposure (Jones et al.,
1986; Lash and Anders, 1986; Schnellmann e t al., 1987). The disruption of mitochondrial 
energy metabolism may explain, or contribute to, the elevation in cytosolic Ca2+, the 
reduced organic anion/cation transport and the GSH depletion; all processes that require 
energy in the form of ATP.
The GSH and cysteine conjugates of HCBD are potent mutagens. Their mutagenic potential can 
only be detected when the drug metabolising system (S9) from rat kidney is used in the 
Ames test (Green and Odum, "\ 985). DCVC is also mutagenic under these conditions. HCBD 
caused an increased incidence of renal tumours, adenomas and adenocarcinomas in rats 
(Kociba e t al., 1977). HCBD is mutagenic due to its primary metabolism via 
GSH-conjugation (Vamvakas et al., 1987) and this potential is expressed in rats, where 
there is an increased incidence in renal tumours.
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1 .4 .4  Sex and Species Differences in Haloalkene-lnduced Nephrotoxicity  
In the male rat, renal damage produced by HCBD can be seen, functionally, as impairment of 
renal organic anion transport/excretion and, histologically, as necrosis of the straight 
portion (pars recta) of the proximal tubule (Lock and Ishmael, 1979). Some reports have 
indicated that female rats are four times more susceptible than males to HCBD-induced 
renal necrosis (Lock and Ishmael, 1982; Hook e ta /., 1983). The marked sex differences 
were not due to the formation of a different or additional lesion. In both sexes, HCBD 
produced histopathologically similar necrosis of the straight portion of the proximal tubule. 
Female rat kidney cytosol appears to be approximately three times more active than male 
rat kidney cytosol in the GSH-conjugation of HCBD (Wolf e t a/., 1984). HCBD conjugation 
in proximal tubular cells and subsequent activation in these cells may occur at different 
rates in females compared to males and hence contribute to the marked sex difference in 
nephrotoxicity.
Studies in the rabbit have shown that the primary target of HCBD-induced toxicity is the 
kidney and, more specifically, the proximal convoluted tubules (Duprat and Gradiski,
1978). Administration of DCVC (20-30m g/kg) to adult male guinea pigs killed all animals 
in 1 -5 days. Histological examination of the kidneys revealed necrosis of the tubular 
epithelium in both the inner and outer cortex, i.e. the pars recta and pars convoluta 
respectively (Terracini and Parker, 1965). HCBD administration to mice produced a dose- 
dependent renal tubular necrosis, similar to that seen in the rat (Ishmael e t al., 1984; Lock 
et al., 1984). Studies on the toxicity of DCVC in the cat and dog revealed necrosis of the 
kidneys in both species and involved a massive lesion of the proximal tubules (Terracini and 
Parker, 1965 ).
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1.5 CYSTEINE CONJUGATE p-LYASE
Cysteine S-conjugate p-lyase (EC 4.4.1.13; p-lyase) is a pyridoxal phosphate dependent 
enzyme that catalyses the cleavage of the C-S bond of S-conjugates of L-cysteine. S- 
conjugates of D-cysteine are not cleaved (Tateishi, 1983). The products of the C-S cleavage 
are thiol compounds and the acrylic compound, dihydroalanine, which very rapidly 
hydrolyses to ammonia and pyruvic acid, p-lyase activity has been shown to be present in 
several mammalian tissues such as kidney, liver, heart, muscle and brain (Stevens et al., 
1986b), as well as in intestinal microflora (Suzuki et al., 1981). In the rat, the highest 
specific activity of p-lyase towards DCVC is found in the kidney.
In the rat kidney, p-lyase is an intracellular enzyme present, mainly, in the cytosol and, to 
a lesser extent, in the mitochondrial outer membrane (Stevens e t al., 1986 and 1988). 
Cytosolic and mitochondrial p-lyase both appear to be identical to glutamine transaminase K 
(Figure 1 .6 ) . However the cytosolic and mitochondrial enzymes possess different substrate 
specificity, the cytosolic form having a higher affinity for DCVC whilst the mitochondrial 
form prefers benzothiazolyl-L-cysteine (BTC) (Stevens, 1985a). Several nephrotoxic 
cysteine conjugates have been shown to be substrates for the renal p-lyase enzyme, for 
example, PCBDC, TFEC, HFPC (Green and Odum, 1985), CTFEC (Lash e ta /., 1986a) and 
DCVC (Green and Odum, 1985).
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Cysteine conjugate p-lyase has been purified from the bacterial species Fusobacterium 
varium (Tomisawa et al., 1984), from rat (Stevens and Jakoby, 1983; Stevens, 1985b), 
and human liver cytosol (Tomisawa et al, 1986) and rat kidney cytosol (Stevens et al.,
1986b) and mitochondria (Stevens et al., 1988). Rat hepatic cytosolic p-lyase is a 
pyridoxal phosphate-dependent enzyme and is identical to kynureninase (Figure 1.6) 
(Stevens, 1985b). The liver and kidney cytosolic enzymes are distinct proteins in that the 
antibody to the liver cytosolic enzyme does not cross-react with the kidney cytosolic enzyme 
and only 10-15%  of the renal cytosolic p-lyase can be accounted for as kynureninase 
(Stevens and Jakoby, 1983; Stevens, 1985a). An antibody raised against the kidney 
cytosolic enzyme cross-reacted with its mitochondrial counterpart and both proteins have a 
similar monomeric molecular weight (50kD) as determined by SDS-PAGE analysis 
(Stevens et al., 1988; MacFarlane et al., 1989).
Rat renal p-lyase activity is potentiated by addition of the exogenous a-keto acid, a-keto-y- 
methiol butyric acid (KMB). This can be explained by the conversion of pyridoxamine 
phosphate (PMP) (figure 1.7) which results from the intrinsic transaminase activity of p- 
lyase to pyridoxal phosphate (PLP) which is the active form in p-lyase activity (Stevens et 
al., 1986a). The transamination reaction regulates the rate of p-elimination when an 
inadequate supply of cosubstrate i.e. a-keto acid is present, because the p-lyase enzyme 
accumulates in the (inactive) pyridoxamine form after half-transamination. The substrate 
DCVC cannot form a Schiff base with the pyridoxamine enzyme and therefore p-elimination 
is inhibited (Stevens et al., 1986a and 1986b). L-amino acid oxidase cooperates with 
cytosolic and mitochondrial glutamine transaminase K/p-lyase to support p-elimination in 
vivo by directly oxidising DCVC to S-(1,2-dichlorovinyl)-3-mercapto-2-oxo-propionic 
acid, which serves as a source of a-keto acid. Consistent with this hypothesis, addition of a- 
keto acid stimulates p-lyase activity, presumably by being transaminated to the amino acid 
(Stevens e t al., 1986a), and potentiates S-cysteine conjugate toxicity (Lash e t al., 1986b; 
Elfarra e t al., 1987).
Kynurenine
(3-hydroxykynurenine)
Anthranilic acid 
(3-hydroxyanthranilic acid)
+
C H g -C H  — COO 
NH3+
Alanine
b.
COO"
HgN —C - H
CH2 + 
I
c h 2 
o  n h 2
COO"
c=o
c h 3
Glutamine Pyruvate
COO"
C = 0
CH2
I
c h 2
nz' C'o  n h 2
COO"
c h n h 3
c h 3
a-Ketoglutaramate Alanine
c.
COO" ÇOO"
+H3N -C -H  COO" C = 0
CH2 + C = 0   ►  CH2 +
a t  f '  CH j
O'- SNHa ° '  NHz
Glutamine Phenylpyruvate a-Ketoglutaramate Phenylalanine
CHNH3
Figure 1.6 The Preferred Substrates for a. Kynureninase, b. Glutamine Transaminase L 
and c. Glutamine Transaminase K.
29
O
>
t\j
X
to
C£
Z - X
eu
<u ç
Eco ro 
x -C
O  Q .  x -v■n v) o.
X
ou
+
.12 eu
ro
>3
O
E !ê
z - x
O)c
Ero<ucLU
X
+
Cû
ZE
Cû
■O00ce
Q.
: - x
-  S
o  Q_ ^III
euc
: - x  . i4->eu
co
'+-»enc
E
eu àilIfc  en en eu
II
i  s
eu
o cû 
c  
o
'■M 3en O
il
E
en en en
eu
E
eu
(% "gen
N- ^  
<
E 23  3  O) O
en
I
&C
eu
■Mc
eu-oc
euQ.
euT3
euc
"Een
§73
^ •§  "O ro
S4É
lî
Q. E
I I
1  m
à i
30
By immunochemical examination, rat kidney p-lyase was shown to be evenly distributed 
along the different segments of the proximal tubule (S I , S2 and S3) but was absent in the 
glomeruli and distal tubule (Jones et al., 1988a). However, in contrast to these later 
findings, and using a highly purified antibody against renal cytosolic p-lyase, only the S3 
segment was shown to contain p-lyase (MacFarlane e t al., 1989).
The bacterial enzyme localised in the gut of mammals has a broader substrate specificity 
than the mammalian enzymes characterised to date (Tateishi, 1983). S-alkyl-cysteine 
conjugates are cleaved by bacterial enzymes but not by liver/kidney p-lyase. This may 
explain the importance of the gut flora in the production of thiomethyl metabolites from a 
variety of cysteine-S-conjugates which are not substrates for mammalian enzymes.
1.6 AIMS OF THE PRESENT INVESTIGATION
The studies presented in this thesis were undertaken with the aim of gaining a better 
understanding of the toxicologically important enzyme, rat kidney cysteine conjugate p- 
lyase by isolating both cDNA and human genomic probes to p-lyase with the particular end 
point of identifying and characterising the human enzyme.
The first phase was to screen a specific cDNA library using the available anti-p-lyase 
antibody (MacFarlane et al., 1989). This method was to yield the full-length cDNA which 
was then to be subcloned and screened to yield sufficient DNA for restriction enzyme 
analysis and sequencing by the dideoxy chain termination method. To ensure that the correct 
cDNA was isolated, the N-terminal amino acid sequence of the purified p-lyase protein was 
to be determined by the collaborating Industrial laboratory. Based on this sequence 
information oligonucleotide probes were also to be prepared by the Industrial laboratory to 
facilitate the second phase of the project.
In the second phase of the project, suitable cDNA fragments or appropriate synthetic 
oligonucleotides were to be used, under conditions of appropriate stringency, to probe a 
human genomic library to identify the human gene. The genomic material (containing the 5' 
upstream regulatory sections and intronic sequences in addition to the coding sequences) was 
to be further subcloned and sequenced as for the cDNA probe. Running concurrently with 
this second phase, suitable cDNA probes and/or synthetic oligonucleotides were to be used to 
screen DNA from human blood lymphocytes for the p-lyase gene in Southern blot analysis. 
This was to be performed to, hopefully, yield valuable information on human gene structure 
and the existence of genetic polymorphisms in the population at large, including workers 
who are environmentally exposed to substrates of the p-lyase enzymes.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 INTRODUCTION
In this chapter the experimental procedures used throughout this investigation are 
described in detail. Where a procedure is common to more than one of the protocols it is 
described in section 2.3. Recipes for the buffers, media and solutions used appear in 
alphabetical order in Appendix A. Most procedures used are modifications of previously 
reported methods and the original references are given, where appropriate. Details of all 
methods are given, along with a brief discussion of the major principles involved.
2 .2  MATERIALS
The suppliers of enzymes and kits are given in the appropriate methods sections, as are the 
suppliers of equipment and any other reagents specific to a relevant section.
2.2.1 Chemicals
All chemicals purchased were of the purest molecular biology grades available and, unless 
stated, were supplied by BDH Chemicals Ltd., Poole, Dorset.
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Sigma Chemical Company: Citric acid (trisodium salt, dihydrate), sodium chloride, 3-[N- 
morpholino] propane sulphonic acid (MOPS, free acid), ethylenediaminetetraacetic acid 
(EDTA), ethidium bromide (EtBr), Tween 20, bromophenol blue, bovine serum albumin 
(BSA) fraction V, isopropyl-p-D-thiogalactosidase (IPTG), Trizma™ base (Tris 
[hydroxymethyl] amino-methane), diethyl pyrocarbonate (DEPC), spermidine trichloride, 
5-bromo-4-chloro-3-indolyl phosphate (BCIP, p-toluidine salt), nitro-blue tétrazolium  
(NBT), ampicillin, a-keto-y-methiolbutyric acid (KMB, reduced form), p-nicotinamide 
adenine dinucleotide (p-NADH, reduced form), pyruvic acid, deoxycholic acid, Folin and 
Ciocalteu's phenol reagent and 4-chloronapthol.
National Diagnostics (New Jersey. USA): 30% (w /v ) acrylamide solution, 2% (w /v ) N,N' 
Methylene bisacrylamide solution.
BRL: N, N, N', N'-tetramethylethylenediamine (TEMED), agarose, low melting point (IM P) 
agarose, guanidinium thiocyanate and urea.
ICI Central Toxicology Laboratories. Macclesfield: S-(2-benzothiazolyl)-L-cysteine 
(BTC), S-(1, 2-dichlorovinyl)-cysteine (DCVC), S-(1, 1, 2, 2-tetrafluoroethyl)-L- 
cysteine (TFEC) and N-acetyl pentachloro-1, 3 butadiene (NAc-PCBD)
Boehringer-Mannheim. W. Germany: Calf liver tRNA
Oxoid Ltd: Bacto-tryptone and yeast extract.
Difco Laboratories USA: Bacto-agar.
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2 .2 .2  Radiochemicals
All procedures involving radiochemicals were carried out in accordance with the guidelines 
set out in "Local Rules for Protection against Ionising Radiation", published by the 
University of Surrey Safety Office. The radiochemicals were used within two weeks (for 
32p) or four weeks (for 35$) of the reference date.
ICN: Deoxycytidine 5'- [a32p] triphosphate, triethylammonium salt. Specific activity 
approximately 3 ,000  Ci/mmol, 10mCi/ml.
Amersham: Deoxyadenosine 5'- [a35$] thiotriphosphate, triethylammonium salt. Specific 
activity 1,200 Ci/mmol.
L- [35$] - Methionine. Specific activity approximately 1,000 Ci/mmol.
2 .2 .3  Antibodies
i. The primary antibody to p-lyase was kindly supplied by Dr. Marion MacFarlane, 
University of Surrey (MacFarlane e t al, 1989). The antibody was raised in a female Soay 
Tan sheep, by an intradermal injection of the electrophoretically homogenous antigen from 
rat kidney cytosol (250^g) in an emulsion of Freund's complete adjuvant containing heat 
killed BCG mycobacteria. The sheep was boosted 12 months later with 125^g of antigen and 
large bleeds collected.
ii. The secondary biotinylated anti-sheep IgG (H and L), rabbit, affinity purified, was 
obtained from Sera Lab (1.5 mg/ml in PBS/glycerol).
35
iii. The tertiary streptavidin-biotinylated-horseradish peroxidase (HRP) complex (55  
peroxidase units/ml. Affinity isolated antigen specific antibody solution in 0.01 M PBS, pH
7.4 containing 1% (w /v ) BSA and 0.01%  (w /v ) thimerosal) and ExtravidinTM-alkaline 
phosphatase (AP) conjugate (whole molecule, 5.0 mg conjugate/ml in 0.05M Tris-HCI 
buffer, pH 8.0 containing ImM MgClz, 1% (w /v ) BSA and 0.1%  (w /v ) sodium azide as
preservative) were obtained from Sigma.
2 .2 .4  cDNA probes and libraries
cDNA probes: To monitor/standardise the levels of RNA assayed by Northern and slot blots, 
human^àctin cDNA was kindly provided by Dr. D. Earnshaw (as described by Gunning e t al,
1 9 8 3 ).
cDNA libraries: The p-lyase antibody (see section 2.1 .3) was used to screen a Xgtl 1 Wistar 
albino rat kidney poly A+ cDNA library that was a kind gift of Dr. Mike Muekler, Washington 
University School of Medicine, USA. The antibody was also used to screen a Xgtl 1 Sprague- 
Dawley rat kidney poly A+ cDNA library that was purchased from Clontech, USA.
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2 .2 .5  Bacterial strains
£  coli bacterial strains Genotype
TB1 used in the preparation of 
competent cells as hosts for 
recombinant plasmids.
ara hsd R. thi, s tr  A 
Alac-pro rk+ 08OdlacZ  
M l 5
Y 1090 host for Xgtl 1 Mac U169 pro A+ Mon
araD139 str A sup F 
trpC 22::Tn10(tetr) pMC9
Y1089 host for Xgtl 1 lysogen formation Alac U169 pro A+ AI on
araDI 39 str A M A I 50  
[chr::Tn10(tetr)] pMC9
2 .2 .6  Cloning Vectors
Plasmids: The plasmids pUCl 9 and pGEM™-7Zf(+) were used in several of the cloning 
techniques to be described. Restriction maps of these plasmids are shown in figures 2.1 and 
2.2.
Phaae: To immunoscreen the cDNA library and produce lysogens, the bacteriophage Xgtl 1 
was used. A detailed restriction map of this phage is shown in figure 2.3.
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Figure 2.1 : Restriction Map of pUC19
The multiple cloning site is shown in full below the plasmid, giving all of the restriction 
endonuclease sites including the unique EcoRl site into which the inserts are cloned 
(Sambrook et al, 1989)
Ndel, HgiEU 185
Nart 237
' .Bgl\ 252 
Z  259
280
Z L -  -Pvull 309
2622 Aafll EcoO109 2674
2501 Sspl
2299 Xmnl Polycloning site
2180 Seal
toe
Pvull 631
pUCl 9 
(2.69 kb)2000
Afnn 806
on
1000
HgiEtt 1387
1 2 3 4 1 2 3 4 5 6 7 6 9 10 11 12 13 14 15 16 17 18 5 6 7 8
Thr Met We Thr Pro Ser Leu His Ala Cyl Arg Ser Thr Leu Glu Asp Pro Arg Val Pro Ser Ser Asm Ser Leu Ala
ATG ACC ATG ATT ACG CCA AGC TTG CAT GCC TGC AGO TCG ACT CTA GAG GAT CCC COG GTA CCG AGC TCG AAT TCA CTG GCC
I_____ I I______I I______ I I I ' I______ I
I______ I I______ I I______ I I______I______ |______ |
H/ndlll SpM Pstt San Xbal SamHI Sma\ Kpnl Sad EcoRl
Acci Xmal
HincH
Figure 2 .2 : Restriction Map of pGEMm-7 Z f(+ )
The multiple cloning site is again shown in full below the plasmid. The sequence shown 
corresponds to RNA synthesised by T7 RNA polymerase and is complementary to RNA 
synthesised by SP6 RNA polymerase. The strand shown is complementary to the ssDNA 
strand produced by this vector (Promega catalogue, 1991).
Xmn I 1991
Nae I 
2692 T7 1Sea I 1872 1 start
Apa I 
A afll 
Sph I 
Xba I 
Xho I 
EcoR I 
Kpn I 
Sma I 
Csp 45 
Cla I 
Hind III 
BamH I 
Sac I 
BstX I 
A/s/1
f1 ori
lacZ
100
109
123
î  SP6
17 Transcription Start
5 ' . . .  TGTAA TACGA CTCAC TATAG GGCGA ATTGG GCCCG ACGTC GCATG CTCCT CTAGA
T7 Promoter I I I_______ I I I I 1
Apa I Aafll Sph I Xbal
CTCGA GGAAT TCGGT ACCCC GGGTT CGAAA TCGAT AAGCT TGGAT CCGGA
Xho I EcoR I Kpn I Sma I Csp451 C/a I Hind III BamH I
SP6 Transcription Start
GAGCT CCCAA CGCGT TGGAT GCATA GCTTG AGTAT TCTAT AGTGT CACCT AAAT. . .  3'
I_______ I I 1 I______ I SP6 Promoter
Sac I BstX I Nsi\
Figure 2.3: Restriction Map of X g tl 1 (Sambrook et al, 1989).
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2.3  GENERAL PROCEDURES
The following methods were routinely used in a number of different experiments. They are 
described here and will be referred to in the individual procedures.
2 .3 .1  S terilization
For all nucleic acid procedures the solutions, glassware and plasticware used were sterilised 
for 20 minutes at 120°C in a RSI series 32 automatic autoclave to destroy nucleases, unless 
otherwise indicated. Most solutions (except those containing Tris buffer) were treated with 
DEPC (final concentration of 0.1% (v /v )) and left to stand for approximately 2 hours 
before autoclaving to help destroy nucleases.
2 .3 .2  Phenol Extraction
All phenol was redistilled prior to use to remove any impurities. Where no details of phenol 
extraction are given the procedure was as follows : An equal volume of cold TE-saturated 
phenol, pH 8.0 was added to the aqueous solution and vortexed thoroughly. The emulsion was 
centrifuged at 9,000rpm, 4°C for 10 minutes in a Beckman J2-21 centrifuge, JA20.1 
rotor (or 14,000rpm in a microfuge if smaller volumes were used) to separate the phases. 
Proteins, SDS and agarose were extracted into the lower phenol phase, while the nucleic 
acids remained in the upper aqueous phase. Often a white protein interphase was also 
present. The top phase was then removed and was further extracted with phenol/chloroform 
(a 1:1 (v /v ) mixture of TE-saturated phenol and 24:1 (v /v ) chloroform/isoamyl alcohol), 
followed by a 24:1 (v /v ) chloroform/isoamyl alcohol extraction to remove the residual 
phenol.
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2 .3 .3  Ethanol precipitation
Where no details of the precipitation method are given the procedure was as follows: The 
DNA or RNA was precipitated from aqueous solution by the addition of 0.1 volume of 3M 
sodium acetate, pH 7.0 and 2 volumes of 100% (v /v ) ice-cold ethanol. If the DNA/RNA 
concentration was high the mixture was left at -70°C for 30 minutes, lower concentrations 
were precipitated overnight at -20°C. The precipitated nucleic acids were pelleted by 
centrifugation at 14,000rpm for 10 minutes at 4°C. The supernatant was removed 
immediately, the pellet washed in 70% (v /v ) ethanol and briefly centrifuged. The 
supernatant was again removed and the pellet dried for the minimum length of time in a 
Univap.
2 .3 .4  Use of the Univap
The Univap (Uniscience Ltd) is a centrifugal evaporator that dries samples by heating them  
whilst centrifuging at a low speed under vacuum. There are two rotors that take either 
microcentrifuge tubes or 14ml Falcon/Greiner tubes. The sample to be dried is placed in 
the Univap, which is set at a temperature of approximately 45°C and the vacuum applied 
from the vacuum pump (Aquavac, Uniscience Ltd) once the centrifuge has reached 
1,OOOrpm. The rotor spins at approximately 2,000rpm  and samples of 50^1 are usually 
dry after 15-20 minutes.
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2 .3 .5  Agarose Gel Electrophoresis
DNA: Agarose gel electrophoresis of DNA was carried out by the standard method described 
in Sambrook e t al, 1989. All gels were electrophoresed in TAB buffer. The agarose was used 
at concentrations of between 0.5% and 3.0% (w /v), depending on the size of molecules to be 
seperated. For most purposes 1.0% (w /v ) agarose was used. Preparative 1.0% (w /v ) LMP- 
agarose gels were run in the cold room (4-8°C) at 100mA whereas analytical agarose gel 
electrophoresis was performed at room temperature and 150mA. The majority of the work 
was carried out using the Pharmacia GNA-100  submarine apparatus. However, for 
preparative gels and Southern blots, the BRL H5 submarine gel apparatus was used. 
Appropriate DNA markers were run at the same time so that the length of the DNA molecules 
could be estimated. X DNA, Hind III fragments (Amersham) were used for sizing DNA 
molecules between 0.5 and 9.0Kb in length, while <j>X174 DNA, Hae III fragments 
(Amersham) were used for sizing DNA molecules between 0.2 and 1.4Kb in length. The 
marker dye for electrophoresis comprised of 10% (w /v ) bromophenol blue in 50% (w /v ) 
sucrose. Prior to electrophoresis the DNA/marker dye mixture was heated to 65°C for 3 
minutes to denature any tertiary structure or aggregations of the DNA.
RNA: RNA was electrophoresed in formaldehyde denaturing gels as originally described by 
Lehrach et al, 1977 and modified by Sambrook e t al, 1989. All gels were run in 1x MOPS 
running buffer. The marker dye contained 4% (w /v ) bromophenol blue, 4% (w /v ) xylene 
cyanol and 10mM EDTA, pHB.O in 50% (v /v ) glycerol. The 1.2% (w /v ) agarose gels were 
run at room temperature and 50mA, until the more rapidly migrating bromophenol blue 
marker had moved approximately 3 /4 of the way down the gel. The buffer had to be
regularly cycled as large pH changes occurred at the electrodes and these could cause the gel 
to "melt".
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RNA markers were run at the same time for sizing of the RNA between sedimentation rates 45  
and 288 ('Electran' RNA molecular weight calibration kit, BDH). Again, prior to 
electrophoresis, the RNA solution was heated to 65°C for 15 minutes to denature it. The 
marker dye was added after this heating.
2 .3 .6  Visualisation of DNA/RNA
To visualise either DNA or RNA in agarose gels, the fluorescent dye ethidium bromide was 
routinely used. The gels were immersed in the appropriate running buffer containing
0.5ng/ml of ethidium bromide for approximately 20 minutes. The gel was then destained in 
deionised water for the same length of time and the nucleic acid bands visualised by UV- 
irradiation (Sharp e ta /, 1973) using a model TM20 transilluminator (Genetic Research 
Instrumentation Ltd). The UV radiation absorbed by ethidium bromide bound to the nucleic 
acid at 300nm was re-emitted at 590nm in the red/orange region of the visible spectrum.
2 .3 .7  Photography
Ethidium bromide stained agarose gels were photographed through an orange filter using a 
Polaroid Land Speed MP-4 camera and Polaroid type 665 positive/negative or type 667  
positive only film. The film was exposed for approximately 15 seconds with an aperture of 
f4.5 (positive/negative film) or f32 (positive only film). Negatives were soaked in water 
for 1 hour then air dried and stored.
2 .3 .8  Recovery of DNA from Agarose Gels
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DNA was electrophoresed as described in section 2.3.5, after which the gel was stained with 
ethidium bromide (section 2.3.6) and the bands of interest excised with a scalpel on the UV 
transilluminator. The DNA could then be extracted by one of the following methods;
Phenol extraction: The agarose slice was placed in a preweighed Greiner tube, its weight 
determined and an equal amount of water added. The gel was melted at 70°C in the minimum 
amount of time and allowed to equilibrate to 37°C. The DNA was extracted by the addition of 
an equal volume of ice cold TE-saturated phenol as described in section 2.3.2. However, 
before the DNA was precipitated (section 2.3.3) the volume was reduced to approximately 
10O i^l by sequential extractions with equal volumes of butan-2-ol (Sambrook e t al, 1989).
Geneclean™: This procedure is used to extract small samples of DNA from agarose gels and 
also to remove unwanted salt and RNA from DNA samples. The range of DNA fragments for 
which this method is effective is between 1 OObp and 1 Okb. The reagents are supplied in kit 
form by Bio 101 Inc, USA.
2.5 volumes of 6M sodium iodide solution was added to the DNA sample either in solution or 
in agarose. If in agarose, the mixture was then heated to 55°C until the agarose had 
completely melted. Glassmilk™ solution was then added (approximately 1 1^ per ^g of DNA 
with a minimum volume of 5^1). The solution was then mixed and left at room temperature 
for at least 5 minutes, during which time the DNA was adsorbed onto the silica matrix in the 
glassmilk solution. The glassmilk™ was pelleted by centrifugation at 14,000 rpm in a 
microfuge for 5 seconds. The supernatant was removed and the glassmilk™ washed by 
resuspension in 500^1 of NEW™ wash solution (a sodium chloride/ethanol buffer) and 
recentrifuged for 5 seconds. This washing procedure was repeated twice more and the final 
pellet resuspended in an appropriate amount of sterile water (usually an equal volume of 
water to the volume of glassmilk™). The mixture was incubated at 55°C for 3 minutes to 
elute the DNA from the matrix and then centrifuged at 14,000rpm for 30 seconds. This 
elution procedure was usually repeated once, the supernatants containing the purified DNA 
pooled and measured spectrophotometrically (section 2.3 .10).
Soin-X™: Again, this procedure is used to extract small samples of DNA from agarose gels. 
The gel slice was placed in the top section of the spin-X™ column (Costar). The column was 
then centrifuged at 14,000rpm, in a microfuge, for 40  minutes at 4°C. During 
centrifugation, the gel slice is compressed onto the support membrane in between the upper 
and lower sections of the column. The electrophoresis buffer, together with the DNA sample, 
is thus eluted in to the lower section. Whilst it is impossible to extract all of the buffer and 
DNA from the gel, a good yield can be obtained, particularly of small molecules.
This is the least labour intensive of the three methods outlined and it has the added advantage 
that ordinary agarose gels, rather than the fragile LMP gels, can be used. However, good 
yields from large DNA molecules, such as phage arms of 20kb or more, was not obtained 
from this method.
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2 .3 .9  Autoradiography
For all procedures Kodak X-Omat AR high speed x-ray film was used. For autoradiography 
of 32p (Northern, Southern and slot blots) the filters were placed inside thin plastic and 
placed, with the film, in a film cassette (X-ray Accessories Ltd) containing Croner 
Lightening Plus intensifying screens. Exposure was at -70°C for an appropriate amount of 
time. For autoradiography of 35$ (sequencing and in vitro translation gels) the film was 
placed directly onto the dry gel in the cassette and exposed at room temperature overnight 
for sequencing gels or up to a month for the in vitro translation gels.
For developing, the films were allowed to return to room temperature (if they had been at 
-70°C) and put through a Fuji Medical Film Processor RGII. This developed, fixed, washed 
and dried the film automatically. The chemicals used in the Processor were RG developer 
and RG fixer from Wardray Products Ltd.
2 .3 .1 0  Spectroscopic Determ ination of Nucleic Acid Concentration
The accurate determination of sample concentration is required for comparative expression 
studies and in a number of reactions where relative amounts of components need to be 
maintained. Throughout this investigation the spectrophotometric determination of Azso and
A280 levels were used to measure the concentration and assess the purity of nucleic acids,
according to the following relationships (Sambrook et al, 1989);
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1 absorbance unit (Agso) -  50|ig/ml dsDNA
40^g/m l RNA 
ZO^g/mi oligonucleotides
A260/A 280 = 1 -8 for pure DNA 
2.0 for pure RNA
(deviations are usually due to impurities such as salt, protein 
or phenol contamination).
2 .4  RESTRICTION ENZYME DIGESTS
Where no specific details of restriction enzyme digests are given these were carried out as 
follows: 1 fxl of enzyme (of varying specific activities) was used to digest each 1 fig DNA in a 
total volume not less than 1 Ox the volume of enzyme used (usually 20-30fil, except in the 
case of genomic digests). An appropriate amount of 1 Ox enzyme reaction buffer was 
included in order to provide optimum salt concentrations for the enzyme along with 0.1 
volume of spermidine (4mM final concentration) to stabilise the net negative charge carried 
by the DNA. The reaction mixture was incubated at 37°C for a minimum of 90 minutes, but 
usually overnight. After incubation, if electrophoresis was to take place, 3fil (greater than
0.1 x the reaction volume) of marker dye was added (section 2.3.5) to stop the reaction and 
facilitate the loading of the samples to the gel. Where two enzymes requiring different salt 
conditions were used, equal volumes of each 10x buffer was combined and this appeared to 
work satisfactorily.
Genomic DNA (section 2.9.3) was digested in a total volume of 120[il, with half of the total 
volume of enzyme being added, the mixture being stirred with a sterile Gilson pipette tip at 
37°C and then the second half of the enzyme added. The DNA/enzyme mixture was then 
incubated at 37°C overnight and then 100% (v /v ) ethanol precipitated at -20°C overnight. 
All restriction enzymes were stored at -20°C and kept on ice during use. A list of the 
enzymes (with their recognition sites) used during this work is shown in table 2.1.
Table 2.1 : Restriction Enzymes
Enzyme Recognition Site (5 '-3 ')
EcoRl G’AATTC
BamHI G'GATC
Hmdlll A’AGCTT
Pstl GTGCA'G
Sad GAGCTC
Xbal TCTAG
Bgll GCCNNNN'NGGC
where N = A, G, T or C.
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2.5 ENZYMOLOGY AND PROTEIN PROCEDURES
2.5 .1  Protein Determ ination
The protein content of tissue cytosol preparations (section 2.5.2) was determined by a 
method modified from Lowry et al (1951). A standard curve was generated using duplicate 
dilutions, in the range of O-25O^g, of bovine serum albumin (BSA). The test samples were 
diluted in the range 1:50 to 1:1000. The protein standards, samples and blanks (0.5ml) 
were mixed with 2ml of protein buffer and allowed to stand for 10 minutes. Folin-Ciocalteu 
reagent was diluted 1:1 with distilled water and 0.25ml added to the protein solution and was 
vortexed thoroughly. After a 30 minute incubation at room temperature the absorbance at 
720nm was read on an Uvikon 860 spectrophotometer (Kontron Instruments), blanked 
against the O^g standard.
2 .5 .2  Isolation of Tissue Subcellular Fractions
The following protocol was based on the method of Omura and Sato (1964). The tissues were 
rapidly excised (the kidneys were also decapsulated), placed in ice-cold 0.9%  (w /v ) NaCI 
until use, blotted dry and weighed. All subsequent steps were carried out at 4°C. The 
kidneys were made up to a 15% or 20% (w /v ) solution in 0.25M sucrose containing 10mM 
Tris-HCI, pH7.5. The tissues were scissor minced and homogenised using a Potter- 
Elvehjem glass/teflon homogeniser (6 return strokes). The homogenates were centrifuged 
at 2,800rpm for 10 minutes at 4°C (J2-21 centrifuge, JA20.1 rotor). The supernatant 
was decanted and centrifuged at 10,000rpm for 20 minutes at 4°C.
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In the induction studies (section 2.15), the mitochondrial pellet was then resuspended in 
10ml of 0.25M sucrose, 10mM Tris-HCI, pH7.5 and recentrifuged at 10,500rpm for a 
further 20 minutes. The washed mitochondrial pellet was resuspended in 2ml of the above 
sucrose/Tris solution per gram of kidney weight and aliquots frozen at -70°C.
For all tissues, the supernatant from the mitochondrial pellet was decanted and centrifuged 
at 40,000rpm  for 60 minutes at 4°C (Beckman L7-65 ultracentrifuge, 60Ti rotor). 
Aliquots of the resulting supernatant, the cytosol, were frozen at -70°C.
2 .5 .3  Assessment of Glutamine Transaminase K (GTK) A ctiv ity
GTK activity was determined by the method of Cooper and Meister (1985). It is based on a 
transamination reaction between L-phenylalanine and a-keto-y-methiol-butyric acid (a - 
KMB) with the production of phenylpyruvate and L-methionine;
L-Phenylalanine + «-KMB ----------------------► Phenylpyruvate + L-m ethionine
In ammediol buffer, pH 9.0, the transaminase activity in rat kidney is due solely to GTK. 
The product of the reaction, phenylpyruvate, absorbs strongly at 322nm (in 3.33M NaOH. 
E=24,000 M-1cm -i) whereas the absorbance due to a-KMB is negligible.
Standard incubation mixtures of lOOjil at 37°C contained 0.2M ammediol buffer, pH 9.0, 
10mM L-phenylalanine and 5mM a-KMB. An appropriate amount of enzyme (0.1 mg 
protein for mitochondrial samples and 0 .1- 0.3 for cytosolic samples) was used to initiate 
the reaction. The tubes were incubated at 37°C for 10 minutes in a shaking water bath and 
the reaction terminated by the addition of 0.9ml of 3.33M NaOH. The absorbance at 322nm  
was measured using a Uvikon 860 spectrophotometer. The enzyme was added after NaOH in 
the control reactions and this absorbance used as the blank for subtraction.
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A unit of enzyme activity was defined as the amount of enzyme catalysing the formation of 
1 nmol of product per min under standard assay conditions. The specific activity was defined 
as units of activity per mg protein.
2 .5 .4  Assessment of Cysteine Conjugate p-lyase (p -lyase) A c tiv ity
p-lyase activity was determined by either of two methods, both of which were based on that 
of Stevens and Jakoby (1983). These allowed continuous spectrophotometric estimation of 
activity with time and used the substrates DCVC, TFEC or BTC.
i. DCVC/TFEC as substrates:
1. DCVC/TFEC + p-lyase --------
2. Pyruvate + NADH/H+ + LDH
Where R = halogenated alkene moiety.
The resultant decrease in absorbance at 340nm is a function of pyruvate formation and, 
hence indirectly, p-lyase activity.
Standard incubation mixtures of 1ml (final volume) at 37°C consisted of 0.1 M sodium 
phosphate buffer, pH 7.4, 5mM glutathione (GSH), 140^M NADH/H+, 4 units of lactate 
dehydrogenase (LDH), O.ImM a-KMB and 5mM of either substrate. The reaction was 
initiated by an appropriate amount of enzyme. The change in absorbance at 340nm was 
measured for 3.0 min against 0.3% (w /v ) potassium dichromate as reference. The 
difference between reaction rate when substrate was present and reaction rate when 
substrate was omitted was taken as a measure of p-lyase activity.
■>- R-SH + Pyruvate  
 Lactate + NAD+
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All mitochondrial samples were sonicated for 1 minute in a Kerry sonicator to break the 
mitochondrial membrane. This was done to ensure that the substrate would have facile 
access to the enzyme, irrespective of its location within the mitochondria. Mitochondrial 
fractions were incubated for 10 min on ice and 5 minutes at 37°C with 4mM rotenone (a 
potent inhibitor of mitochondrial NADH-reductase) to decrease the endogenous utilisation of 
NAOH.
ii. BTC as substrate:
The method used was based on that of Stevens and Jakoby (1983) and MacFarlane et al 
(1989). This involved the direct measurement of the formation of 
2-mercaptobenzothiazole (MET) from BTC at 3 1 6nm (E = l9 ,600  M ^cm -i).
BTC + HgO + p-lyase ------------------------------- > -  MBT + Pyruvate + NHg
Standard incubation mixtures of 1ml (final volume) contained 0.1 M phosphate buffer, pH 
7.4, 5mM GSH, 1 mM BTC and 1 mM a-KMB. The reaction was initiated by the addition of an 
appropriate amount of enzyme and the increase in absorbance at 3 1 6nm with time (room 
temperature) was recorded on an Uvikon 860 spectrophotometer against 0.1 M sodium 
phosphate as reference. The reaction rate was taken as a measure of p-lyase activity.
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2 .5 .5  Discontinuous Sodium Dodecyl Sulphate Polyacrylamide Gel 
E lectrophores is  (SDS-PAGE)
SDS-PAGE was carried out according to the method of Laemmli (1970 ). The protein 
samples were first made monomeric by solubilisation with SDS in the presence of 2- 
mercaptoethanol. The monomeric proteins were then separated on a polyacrylamide gel 
using a discontinuous buffer system.
Electrophoresis was performed at room temperature using a vertical slab gel assembly 
(Hoefer Scientific Instruments), in which the gel was contained within a glass-plastic 
cassette. The glass plates were washed in detergent, distilled water and acetone prior to use. 
The cassettes were assembled from the glass plates and plastic spacers and were then 
clamped in a vertical position. The lower, separating gel (20m l) was prepared to give a 
final acrylamide concentration of 10% (w /v ). Polymerisation was initiated by the addition 
of 20fxl of TEMED and 120^1 of freshly prepared 10% (w /v ) ammonium persulphate 
solution. This solution was then poured into the electrophoresis cassette to a height of 
80mm. A layer of distilled water was introduced above the gel mixture to ensure a flat 
interface between the stacking and separating gels following polymerisation.
When polymerisation was complete (20 -30  minutes) the water layer was removed. The 
upper, stacking gel (1 0ml) was prepared to give a final acrylamide concentration of 3%  
(w /v). Polymerisation was initiated as before (using only 60^1 of 10% (w /v ) ammonium 
persulphate this time) and the stacking gel was poured on top of the separating gel. The 
sample wells were formed by the introduction of a perspex comb prior to the completion of 
polymerisation. After polymerisation the sample comb was removed and the gel placed in 
the electrophoresis tank. Electrophoresis buffer was poured into the anode and cathode 
reservoirs. Any air bubbles trapped beneath the gel comb or underneath the gel were 
removed using a syringe.
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The samples to be analysed were diluted with 2x sample buffer (containing bromophenol 
blue dye) and placed in a boiling water bath for 3 minutes. After cooling to room 
temperature the samples were applied to the sample wells using a Hamilton syringe.
Protein molecular weight markers were run at the same time, to allow sizing of the sample 
proteins, between 180Kd and 26.6Kd. The samples were run through the stacking gel under 
a 20mA constant current until the bromophenol blue indicator dye entered the separating 
gel. At this point the current was increased to 40mA. The current was switched off when 
the dye front was within 5mm of the bottom of the gel. The gel holder was then removed 
from the tank, the plates separated and the lower gel carefully removed for transfer to  
nitrocellulose or drying down.
2 .5 .6  W estern Blotting
The method used was a modification of the basic procedures of Towbin et a / ( l  979) and 
Burnett (1981 ). Before transfer, the gels were immersed in transfer buffer for 45 
minutes to allow for any swelling or shrinkage to occur. Transfer was achieved by use of a 
plastic sandwich apparatus. A sheet of nitrocellulose (0.45^m  pore size) was cut to the 
appropriate size and laid on top of two sheets of Whatman 3MM blotting paper immersed in 
transfer buffer. The gel to be transferred was then placed on top of the nitrocellulose with a 
further two sheets of wet blotting paper being placed on top. The assembly was placed 
between two Scotch Brite scouring pads of a suitable size and then supported by a stiff 
plastic grid. The whole, immobilised assembly was then inserted into the electrophoresis 
transfer tank with the nitrocellulose paper facing the anode. The tank was filled with 
transfer buffer and electrophoretic transfer was achieved overnight at a constant potential 
of 20 volts.
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Following electrophoretic transfer, the nitrocellulose filter was washed in TBS-BT for 2 
hours to block any non-specific protein binding sites. The filter was then subjected to 
immunological analysis as in section 2.6.3. The reaction was terminated by rinsing the blot 
in several changes of distilled water. The developed blots were photographed (Polaroid type 
665 film, f8 , i / 6o second), covered in silver foil and stored damp, in the dark, at 40C.
2 .6  PROCEDURES WITH X g tl 1
There are two distinct life cycles in the growth of lambda phage, lytic and lysogenic. Both of 
these have been exploited in these studies. Lysogenic growth is established when a X 
repressor (Ci gene product) binds to the operators, QL and OR, that control the two early 
growth promoters PL and PR. This repression causes the phage DNA to be integrated into the 
host genome. In the absence of this repression, the phage will enter the lytic cycle in which 
reproduction occurs until approximately 100 progeny are formed. The host cell is then 
lysed and the progeny released.
Under normal conditions not all infecting phage will enter the lytic cycle of growth due to 
the expression of the O  gene product. Xgtl 1 phage has an altered Ci gene and the gene 
product is heat labile. Thus the repressor can be inactivated by heat shock at 42°C for 30  
minutes. Therefore, growth of Xgtl 1 is carried out at 42°C to prevent any phage entering 
lysogeny.
Magnesium-containing growth media and buffers were used throughout this section to  
produce conditions optimal for phage adsorption (phage need magnesium for tail 
production). Maltose was also added as bacteria grown in its presence adsorb phage more 
efficiently due to the maltose operon being induced. This contains the gene (lamb) coding for 
the X receptor.
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2.6.1 Assay of Xgtl 1 phage titre
To ascertain the correct number of phage for screening a library it is necessary to serially 
dilute the initial phage stock. This was routinely performed over the range ICH to i 0 -io in 
SM buffer. 100^1 was taken from each dilution and adsorbed to 100^1 of Y1090  prepared in 
the following way; 100^1 of Y1090 cell stock was used to inoculate 10ml of LB-broth and 
grown until late log phase (ODesonm = 0.5, approximately 3 hours) in a G25 rotating
incubator (New Brunswick Scientific Co. Inc.). The cells were harvested by centrifugation 
for 10 minutes at 2,000rpm (EC Centra-4X bench centrifuge) and resuspended in 0.1 
volumes of 10mM MgSC>4. The bacteria/phage mixture was incubated at 37°C for 10-15
minutes, added to 3ml of top agar (kept at 47°C) and poured immediately onto a prewarmed 
(37°C) L-agar plate (petri dish, 90mm diameter). The dish was gently rotated until the 
top agar evenly coated the L-agar and allowed to set. The plates were inverted and left at 
42°C overnight (Gallenkamp Incubator Plus Series incubator). The titre was calculated by 
counting the plaques and expressing them as plaque-forming units per ml (pfu/m l) of the 
undiluted phage suspension.
2 .6 .2  Preparation of High T itre  Phage Stocks
Isolated recombinant phage were grown on agar plates, as in section 2.6.1, using a high 
enough inoculum so that confluent lysis was seen. The top agar was scraped off the plate, 
mixed with 1.5ml of SM buffer/100^1 of chloroform and left at 4°C overnight. The agar was 
pelleted by centrifugation at 9,000rpm for 20 minutes at 4°C (J2-21 centrifuge, JA20.1 
rotor) and the supernatant removed. The supernatant was recentrifuged as before to remove 
any residual traces of agar and then stored over a drop of chloroform at 4°C. On titration 
this supernatant was usually in the range 1 0 8 to IQ iopfu/m l.
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2.6.3 Immunological Screening of Xgtl 1 Recombinant Libraries
To clone a low abundance mRNA from a given cDNA library (i.e. to have a 99% probability of 
obtaining a given clone in a given mRNA population) it is necessary to plate out and screen 
between 100 ,000 -200 ,000  plaques (Clarke and Carbon, 1976). The rat kidney cDNA 
libraries used here have been described in section 2.2.4. The method of Huynh e t al, 1985, 
was followed and figure 2.4 outlines the protocol. In practice, 1.7ml of Y1090 (see section 
2.6.1) was mixed with 50^1 of a dilution of the rat Xgtl 1 cDNA library to give 105 
pfu/plate and incubated at 37°C for 10 minutes. The bacteria/phage suspension was added to 
27ml of top agar, dried, inverted and incubated at 42°C until the plaques just became visible 
(usually 3-4 hour). The plate was removed to room temperature and a nitrocellulose 
filter, which had been soaked in 10mM IPTG ( a p-galactosidase inducer), was carefully 
overlaid. The plate was then incubated for a further 2 .5-3 .0  hours at 37°C thereby 
allowing the proteins encoded by the inserts, under the promotion of the p-galactosidase 
gene, to be expressed. The position of the filter was marked (so the correct orientation 
could be identified at a later stage) and transferred to 50ml of TEST. The agar plate was 
sealed and stored at 4°C until required.
The filter was washed in TEST for 10 minutes to remove any unbound protein, placed into 
fresh TBSBT (TBS containing 1 % (w /v ) BSA) and left overnight at 4°C or for 2 hours at 
room temperature to block any non-specific protein binding sites. The following steps were 
then performed:
Figure 2.4. immunologies! Screening o fe à g t i  /  cFAM L itre rg
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i) The filter was incubated for 1 hour (room temperature) with primary antibody to p- 
lyase (1 :2000  dilution in TBST).
ii) The filter was washed 3 times (5 minutes each) in TBST.
iii) The filter was incubated for 1 hour (room temperature) with biotinylated anti-sheep 
IgG (1 :500  dilution in TBST).
iv) Step ii) was repeated.
v) The filter was incubated for 1 hour (room temperature) with either streptavidin- 
biotinylated-horseradish peroxidase (HRP) complex (1 :500  dilution in TBST) or 
Extravidin™-alkaline phosphatase (AP) conjugate (1 :4 ,000  dilution in TBST).
vi) Step ii) was repeated.
vii) The filter was washed once in TBS (5 minutes) to remove Tween 20 (a detergent).
viii) The filter was developed by the addition of the enzyme substrate. For HRP, 4- 
chloronapthol was used as substrate and for AP a mixture of BCIP and NBT was used.
The HRP substrate was prepared by dissolving 30mg of 4-chloronapthol in 8 ml of methanol 
and diluting to 50ml with TBS. 20ml of hydrogen peroxide (30%  solution) was added just 
prior to use. The AP substrate was prepared by adding 165^1 of a 50mg/m! solution of NBT 
(in 70% (v /v ) DMF) and 82.5fd of a 50mg/ml solution of BCIP (in 100% DMF) to 25ml 
of AP buffer.
At each stage the filter was gently agitated on a Luckham rotary shaker. All times given for 
the antibody incubations are minimum times. All three antibodies were stored at 4°C after 
use and reused in later experiments.
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2 .6 .4  Plaque Purification
Positive recombinant cDNA clones were identified by the appearance of purple or brown 
spots on the filter (depending on the developing system used) after immunological analysis 
as described in section 2.6.3. The corresponding plaques were excised from the top agar and 
placed into 0.5ml of SM buffer. This was allowed to stand overnight at 4°C or for 2 hours at 
room temperature, thus enabling the phage to diffuse out. The cDNA clones of interest were 
further purified by repeated rounds (usually 2-3 ) of plating out and immunoscreening 
until individual positives could be cleanly picked. High titre phage stocks were then 
produced (section 2 .6 .2 ).
2 .6 .5  Isolation of Recombinant Phage DMA
Phage from positive cDNA clones were grown on agar plates, as described in section 2.6.2, to 
confluent lysis. The phage were eluted from the agar overnight at 4°C with 5ml of SM 
buffer. This buffer was transferred to a 14ml polypropylene Falcon tube and spun at 
8,000rpm for 10 minutes at 4°C (J2-21 centrifuge, JA20.1 rotor). Each supernatant was 
divided into 0.7ml aliquots and placed into 1.5ml Eppendorf microfuge tubes (Scotlab). 
RNAase A (5mg/ml) and DNAase 1 (5 mg/ml) were added and the tubes incubated for 30  
minutes at 37°C to destroy E. co//nucleicaciA.0.7ml of 20% (w /v ) polyethylene glycol 
(PEG)/2.5M NaCI was added and the mixture left on ice for 1 hour. The precipitated phage 
were collected by centrifugation in a microfuge at 14,000rpm for 1 minute (room 
temperature) and the supernatants removed. To the tubes 0.5ml of 10% (w /v ) SDS and 
0.5ml EDTA, pH 8.0, were added and the mixture incubated at 6 8 °C for 5 minutes to break 
open the phage and release the DNA. The phage DNA was isolated by phenol extraction and 
ethanol precipitation as described in sections 2.3.2 and 2.3.3 respectively.
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2.6.6 Large Scale Preparation of Recombinant Phage DNA
Recombinant phage DNA was prepared in bulk using a method adapted from that of Kaslow 
(1986). A cleared lysate of phage (i.e. the LB-broth was clear rather than cloudy) was 
prepared by mixing 10ml of Y1090 culture (see section 2 .6 .1 ) with 100^1 of high titre 
phage (108 pfu/ml) at 37°C for 10 minutes. This was added to 450ml of LB-broth and the 
culture was incubated with shaking at 42°C for approximately 4 hours (until lysis had 
occurred). A few drops of chloroform were added to kill any remaining bacteria and the 
culture was cooled on ice for 5 minutes. Debris was removed by centrifugation at 
8,000rpm for 10 minutes (J2-21 centrifuge, JA14 rotor). To the supernatant DNAase 1 
was added to give a final concentration of 10mg/ml. This was then incubated at 37°C for 30  
minutes to degrade any bacterial chromosomal DNA. 150ml of 1.5% (w /v ) SDS, 0.3M Tris- 
HCI, pH 9.0, 0 .15M EDTA was then added and the mixture heated to 70°C to dissociate the 
phage and inactivate the DNAase 1. The E coli, E. coli DNA fragments and phage proteins 
were precipitated from this mixture after incubation on ice (1 5 -3 0  minutes) by the 
addition of 110ml of 8 M potassium acetate. This cell debris was pelleted by centrifugation 
at 6,000rpm for 15 minutes at 4°C (J2-21 centrifuge, JA14 rotor). The supernatant was 
retained and the phage DNA precipitated by the addition of 0.6 volumes of isopropanol. After 
standing for at least 15 minutes at room temperature the DNA was pelleted by centrifugation 
at 9,500rpm for 20 minutes, The supernatant was discarded and the pellet resuspended in 
1-2ml of sterile water. RNAase A was added to 50^g/m l final concentration and the mixture 
incubated at 37°C for 30 minutes to degrade any residual bacterial RNA. This was followed 
by a further incubation with proteinase K (200ng/m l) under the same conditions as above. 
Phenol extractions and ethanol precipitation were then performed as described in sections
2.3.2 and 2.3.3 respectively. The final DNA pellet was resuspended in 200^1 of water and 
its concentration determined (section 2.3 .10).
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2 .6 .7  Generation of X g tl 1 lysogens
The formation of Xgtl 1 lysogens provides a method of expressing large amounts of foreign 
proteins in a bacterial environment. This allows the analysis of the protein of a given clone 
by Western blotting, thus confirming that it is the fusion probèln that interacts specifically 
with the antibody probe. This gives a good indication that the clone isolated codes for the 
protein of interest (i.e. p-lyase in this case).
V I089 is the £  coli host of choice for lysogen formation since, like Y1090, it has the lac 
repressor and the Ion protease mutation but, in addition, it has a mutation (hflAI 50) that 
enhances the frequency of phage lysogeny and is st/pF deficient, which allows the S I 00  
mutation of Xgtl 1 to render it lysis defective.
A single Y1089 colony was picked from an LB-broth agar plate and grown in LB-broth 
overnight at 37°C (Huynh e t al., 1985). The following morning 1 ml of this culture was 
used to inoculate 50ml of prewarmed LB-broth and this was incubated until the 
OD650nm=0.5 (approximately 3 hours). The cell culture was then supplemented with
1 OmM MgClg and 1 OOnl of the Y1089 cells were infected with the recombinant phage
(approximately 1.25x108pfu) for 20 minutes at 32°C. The cells were then plated out, at 
different dilutions, onto L-agar/ampicillin plates and incubated at 32°C overnight (a t this 
temperature, the temperature-sensitive phage repressor is functional, see section 2 .6 ). 
Colonies were tested for temperature sensitivity by replica plating the same colony onto two 
different LB-broth agar/ampicillin plates then incubating one at 32°C and the other at 43°C. 
Colonies that grew at the lower temperature were assumed to be lysogens.
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2.6.8 Crude lysate formation from Xgtl 1 recombinant lysogens
A single colony of recombinant lysogen (section 2.6.7) was grown to an absorbance of 
approximately 0.5 (600nm ) at 32°C in 100ml of LB-broth media. The temperature of the 
culture was then raised rapidly to 42-45°C and shaken with good aeration for 20 minutes 
(G25 rotating incubator, New Brunswick Scientific Co. Inc.). IPTG, to a final concentration 
of 10mM, was added and the culture incubated at 37°C for a further 1 hour. Cells were 
harvested by centrifugation at 5,000rpm for 5 minutes at room temperature (J2-21 
centrifuge, JA20.1 rotor). They were then resuspended in 1 /3 0  of the original volume in 
50mM Tris-HCL, pH 8.0. The resuspended cells were snap-frozen in liquid nitrogen and 
stored at -70°C until required. Thawing of the cells resulted in complete lysis and provided 
the crude lysate. Western blot analysis as described in section 2.5.5 was used to identify the 
p-galactosidase/p-lyase fusion protein.
2 .7  SUBCLONING IN PLASMID VECTORS
2.7.1 Subcloning o f DNA Fragments into Plasmid Vectors
The plasmid cloning vector pUC19 (figure 2 .1) was chosen for subcloning because it 
contains a large number of restriction sites in the multiple cloning site and transformants 
are selectable by ampicillin resistance. An additional advantage is that the cloning site is 
situated within the plasmid p-galactosidase gene. Thus, p-gal- £  coli transformed with 
native plasmid give blue, p-gal+ colonies when grow on X-gal plates. Recombinant 
plasmids, however, will give white, p-gal- colonies. In addition, sequencing can be 
performed directly on pUCl 9, from both ends of the DNA insert, as the universal primer 
and reverse primer binding regions are present at either side of the multiple cloning site 
(Sequenase™ 2.0 catalogue, 1990, United States Biochemical).
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The plasmid cloning vector pGEM™-7Zf(+) (figure 2 .2 ) was chosen for subcloning because 
it allowed use of the Erase-a-base™ sequencing system (Promega Corporation). This 
system is designed for the rapid construction of subclones containing progressive 
unidirectional deletions of any inserted DNA, thus allowing efficient sequence analysis of 
large DNA fragments (Henikoff, 1984).
Isolation of cDNA insert: To subclone phage cDNA insert prepared in section 2.6.6 the 
recombinant bacteriophage was cut with the restriction enzyme EcoRI (section 2.4). This 
released the cDNA insert from the two bacteriophage arms and the mixture was separated on 
a 1 % (w /v ) low melting point (LMP) gel. The rat kidney cDNAs were recovered by the 
Geneclean™ method (section 2.3.8).
Preparation of linearised plasmid oUCI 9: The plasmid vector pUC19 was prepared as 
described in section 2.7.4. SO^g was routinely digested with the enzyme EcoRI which 
linearised the plasmid (approximately lOOng was electrophoresed on a 1% (w /v ) agarose 
gel to confirm this). The enzyme was removed from the digest mixture by phenol extraction 
(section 2 .3 .2 ) and the linear plasmid recovered by ethanol precipitation (section 2 .3 .3). 
The precipitated DNA was resuspended in a volume of water to give an approximate final 
concentration of Sng/^il.
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Ligation: 10ng of cut plasmid was mixed with either the purified cut recombinant phage or 
purified cDNA insert to give varying molar DNA ratios (usually 1:1 or 1:3 respectively). 
The mixture was heated to 65°C for 2 minutes and then cooled on ice which ensured that all 
the "sticky ends" were available for the formation of recombinant molecules. 2 1^ of 5x 
ligase buffer, 1 n! of T4 DNA ligase (BRL) and sterile water were added and the ligation was 
allowed to proceed at 14°C overnight. Ligation mixes were kept at 4°C until required (but 
not longer than 24 hours). Controls of 1 Ong uncut plasmid (to check competency of cells), 
no plasmid (to check selection of cells) and 1 Ong cut plasmid (to check ligation efficiency) 
were included in all experiments.
Subcloninq into oGEM™: The cDNA inserts were subcloned into the plasmid pGEM™-7Zf(+) 
for sequencing following the methods in the Erase-a-Base™ system manual (Promega).
2 .7 .2  Introduction of Recombinant Plasmid DNA into Bacterial Cells
Preparation of competent cells: To identify the plasmids containing inserts, competent E  
coliTBI cells were prepared by a modification of the MgClg/CaClg method originally
described by Cohen e t al (1972). This procedure renders the bacterial cells capable of 
taking up DNA and was accomplished as follows;
TB1 cells (35ml) were grown to log phase (OD650nm=0.5) in TYN media and left to stand on
ice for 5-10 minutes. All subsequent steps were performed on ice. The cells were then 
pelleted by centrifugation (5 ,000  rpm for 10 minutes, JA17 rotor, J2-21 centrifuge), 
resuspended gently in V z  their volume of cold CaClz and left for 1 hour. The cells were then
centrifuged as above, resuspended in 2 ml of CaClg and left overnight on ice.
Transformation of Competent Cells: The competent cells (200m l) were then transformed 
with 5 ^  of the ligation mixture (section 2 .7 .) for 15-30 minutes at 37°C. The cells were 
then heat-shocked at 42°C for 2 minutes and 0.8ml of prewarmed (37°C) TYN added. The 
cells were incubated at 37°C for 1 hour with shaking and 100^1/200^1 aliquots were plated 
out on TYN/X-gal/ampicillin plates. The plates were allowed to dry and then incubated, 
inverted, overnight at 37°C.
Selection of Transformed Cells: pUCl 9 contains the la d  gene coding for the p-galactosidase 
gene. Therefore, insertion of a DNA fragment into the multiple cloning site of the plasmid 
causes the inactivation of this gene. The chromogenic substrate X-gal is cleaved by p- 
galactosidase releasing a blue indolyl derivative (and is thus used as a marker for the 
presence of the p-galactosidase gene). TB1 cells are constitutive for p-galactosidase 
induction but express a mutant p-galactosidase and so are not able to cleave X-gal. However, 
if they are transformed by a plasmid containing an active la d  gene, this complements the 
deficiency resulting in blue colonies when grown on X-gal plates. Therefore, by growing 
transformed bacteria on TYN/X-gal/ampicillin plates, any white colonies that appear should 
be recombinant i.e. containing the cDNA of interest. These were picked off the plates and 
replated until the colonies were completely white (and thus pure). Small scale plasmid 
preparations were then carried out (section 2 .7 .3).
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2 .7 .3  Small Scale Plasmid DNA Preparation
A rapid extraction of plasmid DNA from bacterial cells was used in a quick method to screen 
recombinant subclones. The protocol applied was based on the original procedure of Holmes 
and Quigley (1981 ). From a 10ml overnight culture, grown in TYN containing 1 SOng/ml 
ampicillin, 1.4ml was microfuged at 14,000rpm  for 15-30 seconds (to pellet the cells). 
The supernatant was discarded and the pellet resuspended in 100^1 of STET solution. 10fil 
of a freshly prepared lysozyme solution (lOm g/m !) was added and the tube left on ice for 
10 minutes. The tube was then boiled for 90 seconds and centrifuged at 14,000rpm for 15
minutes at 45°C in a microfuge. The supernatant (50-100^1) was carefully removed and
the plasmid DNA purified using Geneclean™ (section 2.3.8).
2 .7 .4  Large Scale Plasmid DNA Preparation
The following two different methods of plasmid isolation were employed, the Qiagen™ method 
superseding the caesium chloride/centrifugation method during the course of these 
investigations. The critical factor in plasmid DNA isolation is the separation of the low 
molecular weight plasmid from the higher weight bacterial genome.
Caesium Chloride Centrifugation Method: This method, originally described by Radloff et al 
(1967), relies on the principle that plasmid DNA saturated with ethidium bromide has a 
lower density than chromosomal DNA similarly saturated and can therefore be separated by 
isopycnic centrifugation. The disadvantages of this procedure are that it is time consuming, 
expensive and prone to contamination by the chromosomal band when removing the plasmid 
band.
The procedure used here is a modification of that reported by Sambrook e t a/ (1989). 
200ml of TYN containing 150^g/ml ampicillin was inoculated with 1 ml of a fresh overnight 
culture of E. coli containing the plasmid of interest. The culture was incubated, with 
shaking, overnight at 37°C and the cells harvested by centrifugation 3,000rpm for 10 
minutes (Beckman J6 centrifuge, JS4.2 rotor). The pelleted cells were resuspended in 
3.5ml of 25% (w /v ) sucrose in 50mM Tris-HCI, pH 8.0. Lysozyme (0.5m l of 20m g/m l 
solution) was added and the mixture left on ice for 10 minutes. 3.5ml of 0.25M EDTA, pH 
8.0, was then added and the mixture further incubated on ice for 5 minutes. The cells were 
lysed by the addition of 5ml of Brij/DOC solution and gentle repetitive pipetting. After 
another 30 minutes on ice the suspension was centrifuged at 15,000rpm (4°C) for 45 
minutes (J2-21 centrifuge, JA20.1 rotor). To every 5ml of suspension 4.5g of caesium 
chloride (CsCI) and 150ml of 1.5% (w /v ) ethidium bromide were added. The mixture was 
loaded into Beckman polyallomer "Quickseal" tubes (16 x 76mm). Light liquid paraffin was 
used to top up the tubes, thereby creating a 1/2 gradient of CsCI. The tubes were spun at
40,000rpm  overnight at 12°C (Beckman L7-65 ultracentrifuge, 70ti rotor). The lower, 
closed circular DNA was removed by side puncture using a 21G needle under UV light. The 
ethidium bromide was removed by sequential CsCI-saturated isopropanol extractions until 
the upper isopropanol layer was clear. The DNA was precipitated in 200^1 aliquots with 3M 
sodium acetate, pH 5.2 (50^1) and isopropanol (500|il) in a total volume of 1ml for at least 
30 minutes at room temperature. For sequencing procedures the pellet was ethanol 
precipitated a further 2-3 times (section 2.3 .3).
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Oiaaen™ method: This method separates high and low molecular weight DNA by filtration 
through prepacked gravity flow columns containing a silica anion exchange resin. For 
preparations of plasmid DNA used in labelling reactions the midi-Qiagen column (Hybaid 
Ltd.) was used with 150ml cultures of cells. The yield is sufficiently good to be comparable 
with the CsCI method.
In this method, the 150ml culture of cells were incubated and pelleted as before. They were 
then resuspended in 4ml of PI buffer. 4ml of P2 buffer was added causing the cells to lyse 
and the resulting suspension mixed gently and incubated at room temperature for 5 minutes^ 
4ml of P3 buffer was then added to the lysed cells and the suspension centrifuged at 
10,000rpm for 30  minutes at 4°C (J2-21 centrifuge, JA20.1 rotor). The supernatant 
(containing the nucleic acids) was immediately removed without disturbing the pellet of 
bacterial cell debris and applied to the pre-equilibrated (QB buffer) Qiagen midi-column. 
The sample was allowed to flow through the column under gravity and the column was 
washed with 2 x 4ml of QC buffer. This removed the cellular RNA and any remaining 
protein. The plasmid DNA was then eluted with 2ml of QF buffer leaving the bacterial 
genomic DNA on the column. The plasmid DNA was aliquoted into Eppendorf tubes (1 .5ml), 
precipitated with 0.5 volumes of isopropanol (room temperature for 30 minutes) and the 
precipitate collected by centrifugation a t 14,OOOrpm for 30 minutes at 4°C (microfuge). 
After washing the pellet in ice-cold 70% (v /v ) ethanol and drying in the Univap (section 
2.3.4), the DNA was resuspended in an appropriate amount of water, pooled and stored at 
-20°C for later measurement (section 2.3 .10).
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2 .7 .5  Preparation of Glycerol Stocks
For the long term storage of plasmids containing cONA inserts of interest, glycerol stocks 
were produced. 10ml overnight cultures of TB1 cells, transformed with the plasmid, were 
grown in TYN containing 1 SO^g/ml ampicillin as in section 2.7.3. 150^1 of sterile 
glycerol was aliquoted into sterile 1.5ml Eppendorf tubes and 850^1 of the overnight 
culture added. The mixture was vortexed for 5 seconds and frozen at -20°C for 10 minutes. 
The tube was then vortexed again for 5 seconds and stored at -20°C until needed. To grow up 
the cells a sterile loop of the still frozen stock was taken into 10ml of TYN plus 1 SO^g/ml 
ampicillin and the media incubated, with shaking, at 37°C overnight.
2 .8  PLASMID DNA SEQUENCING
Based on the original dideoxy sequencing strategy of Sanger e t al (1977 ), p-lyase inserts 
were sequenced using a modification of the protocol first reported by Chen and Seeburg 
(1985). Double stranded DNA sequencing was favoured because of its simplicity and the 
convenience of not having to subclone the insert into Ml 3. The Sequenase™ version 2.0  
sequencing kit (United States Biochemical Corporation) was used primarily as it possessed a 
genetically engineered form of T7 DNA polymerase (Tabor and Richardson, 1989). The 
genetic modifications of Sequenase™ 2.0 completely remove the 3'-5' exonuclease activity of 
native, wild-type T7 DNA polymerase. Its properties also include high processivity, high 
elongation rate, the ability to use short primers and the ability to use the nucleotide 
analogues used for sequencing (ddNTPs and dITP, for example). The Sequenase™ kit 
contained all the reaction components necessary for sequencing except for the Ml 3 reverse 
primer (USB Corp.), the oligonucleotide primers (section 2 .9 .9 ) and the [«35S]-dATP  
(section 2 .9 .2).
2.8.1 Sequencing Gel Electrophoresis Apparatus
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The sequencing apparatus for gel electrophoresis was manufactured in the Biochemistry 
Department workshop at the University of Surrey. The apparatus accommodated glass plates 
with the dimensions 58 x 20 x 0.5cm, the front plate being notched to allow insertion of the 
gel comb. Before use, the glass plates were scrubbed with detergent and water then rinsed 
with distilled water and allowed to air dry. The plates were then wiped with ethanol followed 
by acetone. After every 4-5 runs the gel side of one of the plates was siliconised with 3 ml 
of dimethyldichlorosilane and left to dry in a fume cupboard. The gel spacers and gel combs 
(0.4mm thick) were cleaned with water followed by ethanol. The gel spacers were then put 
in place and the plates assembled and sealed with waterproof sealing tape. Before gel 
pouring, the plates were firmly clamped with bulldog clips.
2 .8 .2  Preparation of DNA Sequencing Gels
6% (w /v) polyacrylamide gels were prepared according to the method of Sanger and Coulson 
(1978). 15.0ml of 30% (w /v ) acrylamide solution was added to 11.25ml of 2% (w /v ) 
bisacrylamide solution. This was added to 7.5ml of lOx TBE buffer and 31 .5g of urea. The 
solution was then made up to 75ml total volume with distilled water and the urea dissolved 
by heating to 37°C. The mixture was degassed and cooled on ice for 20 minutes. The 
assembled plates (section 2.9 .1) were inclined at approximately 30° to the horizontal and 
supported. This prevented the formation of air bubbles upon gel pouring. 450^1 of freshly 
prepared 10% (w /v) ammonium persulphate and 75^1 of TEMED were added to the 
acrylamide/urea solution. This was mixed quickly and the solution drawn into a prechilled 
50ml syringe. The gel was released gently from the syringe so that it flowed evenly between 
the plates. Once poured the flat edge of a sharkstooth comb was inserted into the top of the 
gel and the plate tops clamped firmly with bulldog clips. The gel was left to polymerise (1 -
2 hours) and stored in the cold room, wrapped in cling film, until required (not less than 1 
hour and not longer than 2 days). Prior to use the gel was positioned in the apparatus 
(section 2.9 .1) and allowed to warm to room temperature.
2.8.3 Preparation of Single Stranded Template DNA
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Double stranded plasmid DNA was denatured to provide a single stranded template for the T7 
DNA polymerase to copy. This was achieved by the addition of 2^ 1 of 2 M NaOH and 2^ 1 of 
2mM EDTA to 3^g of plasmid DNA (in a volume of 14.5^1 of sterile water) and incubation at 
room temperature for 5 minutes. The denatured plasmid was then precipitated by the 
addition of 2 til of 2M ammonium acetate, pH 4.6 and 60til of ice-cold ethanol. After 
incubation at -70°C for 15 minutes the sample was centrifuged at 14,OOOrpm in the 
microfuge for 15 minutes and the supernatant decanted. The pellet was washed briefly in 
SOttl of 80% (v /v ) ice-cold ethanol and recentrifuged. The supernatant was again removed 
and the pellet dried in a Univap (section 2 .3 .4 ) and stored at -20°C until use (usually 
overnight, but could be stored for up to 1 week).
2 .8 .4  Annealing of Primers
The denatured plasmid DNA was reconstituted in 7^1 of sterile water and 2^1 of sequencing 
buffer was added to this. The appropriate primer oligonucleotide was added in a volume of 
1 nl. For the Ml 3 universal and reverse primers this contained O.Spmol of oligonucleotide 
whereas for the p-lyase specific oligonucleotide primers (section 2 .9 .9 ) a range of 4- 
400ng was used. The mixture was heated to 65°C for 4 minutes in a beaker of water in the 
65°C water bath. The beaker was then removed and the water allowed to cool to less than 
37°C. The mixture was then placed on ice. This slow cooling of the mixture ensured that 
homologous base pairing and annealing took place.
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2 .8 .5  Labelling Reaction
In this reaction the primer was extended in the presence of limiting concentrations of 
deoxyribonucleoside triphosphates (dNTPs) and «35$ dATP. This ensured that initiation of 
polymerisation by the T7 DNA polymerase predominated over chain elongation, thus 
ensuring that each newly synthesised strand contained similar amounts of incorporated 
radioactivity, regardless of final length of the extension, enabling even the smallest 
fragments to be detected. 1 nl of 0.1 M DTT, 2 1^ of labelling mix (7.5^M dTTP, dCTP and 
dGTP), 0.5nl of «35$ dATP (5^Ci) and 2 1^ of Sequenase™ were added to the DNA/primer 
mixture. The labelling reaction was then allowed to proceed at room temperature (20°C)for 
2-5 minutes (no longer than 5 minutes).
2 .8 .6  Extension/Term ination Reaction
In this reaction the concentrations of the 4 dNTPs were much higher than in section 2.8.5. 
The reaction is very rapid and a ratio of ddNTPs to dNTPs is used that gives a broad range of 
product lengths. 3.5yd of the labelling reaction was added to each of four tubes containing 
2.5nl of the termination mixes (A, C, T and G) which had been prewarmed to 37°C. The 
termination mixes contain 80^M of each of the dNTPs and 8fxM of the appropriate 
dideoxyribonucleoside triphosphates (ddNTPs) to cause random chain termination. The 
reaction was allowed to proceed for 5 minutes at 37°C and then stopped by the addition of 4^ 1 
of stop solution. The solution was mixed and placed on ice immediately. The stop solution 
contained the marker dyes bromophenol blue and xylene cyanol. At this point the reaction 
mixtures could be stored for up to 1 week at -70°C.
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In some reactions an extension mix was added to the termination mix. This contained a 
higher concentration of dNTPs thus decreasing the relative proportion of ddNTPs. This 
results in an increase in the amount of long DNA strands synthesised and enabled the 
sequence to be read for a greater distance from the primer.
2 .8 .7  Electrophoresis of Samples
The samples in loading buffer were heated to 75°C for 2 minutes before loading onto the gel. 
The comb was removed from the gel, inverted and the teeth positioned so that they just 
entered the flat top surface of the gel. The wells so formed were rinsed thoroughly with the 
TBE running buffer to remove all traces of urea and the gels prerun at SOW for 30 minutes 
in order to heat the gel to the optimum temperature of 45 -55°C. 3 1^ of each sample was 
then loaded into the wells using a Drummond sequencing pipette (Drummond Scientific 
Company). A metal plate was secured to the back of the glass plates to ensure even 
temperature distribution over the surface of the plates (thus preventing "smiling" or 
"frowning" of the gel front) and the apparatus was run at SOW constant power. 
Electrophoresis was performed until either the bromophenol blue ("short" gel) or the 
slower migrating xylene cyanol ("long" gel) had travelled the length of the plates.
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2 .8 .8  Preparation of the Gel for Autoradiography
The clamps and sealing tape were removed and the plates gently prised apart so that the gel 
remained attached to one of the plates. The gel and plate were then placed carefully into a 
10% (v /v ) methanol/10% (v /v ) acetic acid solution for 20 minutes in order to fix the gel 
This was then rinsed with water for 20 minutes to leach out the urea which can interfere 
with autoradiography. A sheet of Whatman 3MM blotting paper was wetted and placed onto 
the gel. Two further, dry sheets were added and the gel peeled off the plate onto the paper. 
This was then covered in Saran wrap and dried in a gel dryer (Model 4823 Slab Gel Drier, 
Biorad) at 80°C for 45 minutes. Autoradiography was then performed as described in 
section 2.3.9.
2 .8 .9  Synthesis o f Oligonucleotides
Oligonucleotides (20mers) were synthesised on an Applied Biosystems Model 381A DNA 
Synthesiser in the Microbiology Department of the University of Surrey. To cleave the 
oligonucleotide from the column support 1 ml of neat 880  ammonia was drawn up through 
the column using a disposable 2.5ml syringe. A second 2.5ml syringe was inserted into the 
opposite end and the ammonia was slowly passed through the column (3 -4  times). The 
solution was left in contact with the column at room temperature for 45 minutes and the 
process repeated. After a further 45 minutes the solution was drawn up into one syringe 
and then transferred into a screw cap tube. At this stage the oligonucleotide had been 
liberated and the cyanoethyl group protecting the phosphate removed.
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The cap was sealed tightly and the tube was incubated at 55°C overnight This removed the 
benzoyl and isobutyryl groups present on the exocyclic amines of A and C (benzoyl) and G 
(isobutyryl) during synthesis, thus preventing side reactions from taking place. The 
solution was cooled on ice and the oligonucleotides precipitated with ethanol (section 2.3.3). 
The sample was washed and dried in the Univap before resuspending in sterile water. The 
concentration of the oligonucleotides was then calculated spectrophotometrically (section
2 .3 .1 0 ).
2 .8 .1 0  Use of Computers in Sequencing
In order to accurately document the sequence information gained in the above sections the 
MicroGenie™ database was used (Beckman Instruments Inc.). This is a program specifically 
designed for the recording, analysis and comparison of nucleic acid and protein sequences 
(Queen and Korn, 1984). All sequence information was entered into this database via a 
Viglen Viglll personal computer.
For comparison of the p-lyase nucleic acid sequences with larger numbers of other 
sequences the information was sent, via an Olivetti M28 personal computer, to the SEQNET 
database at the SERC Daresbury Laboratory, Warrington and to the GenBank database (U.S. 
Department of Health and Human Services). Over 70 ,000  verified DNA sequences are in 
publicly accessible databases at the present time. The purpose of sending the sequence data 
up to the above databases was to establish what, if any, existing gene the new sequence 
resembled. This is performed by comparing the new sequence, in ten base pair fragments, 
with all the sequences on the respective database and then identifying any closely related 
sequence.
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2 .9  PREPARATION OF TISSUE NUCLEIC ACIDS
2.9.1 Isolation of Total RNA
Total RNA was isolated by two methods, the second superseding the first during the course of 
this study.
Guanidinium thiocvanate/LiCI method: This method is a modification of the protocol first 
described by Cathala et a /(1 983). Whenever possible tissues were used fresh and were 
frozen, as soon after autopsy as possible, in liquid nitrogen. Tissues that had been stored at 
-70°C were also used on occasion. Prior to homogenisation the tissue was ground up in 
liquid nitrogen using a pestle and mortar. To 1g of ground tissue, 8ml of RNA lysis buffer 
and 0.5ml of 2-mercaptoethanol were added. The mixture was homogenised with a Polytron 
(Kinematica GmbH, Switzerland) for 20-30  seconds and allowed to stand at room 
temperature for 20 minutes to ensure complete dispersion. This homogenate was 
transferred to a 250ml centrifuge bottle and 50 ml of 4M LiCI was added and left at 4°C for 
approximately 20 hours to allow precipitation of all the RNA.
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The precipitate formed was pelleted at 4,200rpm for 90 minutes at 4°C (Beckman J-6B 
centrifuge, JS-4.2 swinging rotor) and the supernatant discarded. The pellet was rinsed by 
resuspension in 30ml of 3M LiCI and recentrifuged at 4,200rpm  for 30 minutes. The 
resultant pellet was resuspended in 5m! of TE buffer containing 0.1%  (w /v ) SDS and the 
RNA extracted with phenol and ethanol (sections 2.3.2 and 2.3.3 respectively). The RNA 
concentration was measured spectrophotometrically (2 .3 .10 ) and yields of 10O-5OO^g/g 
tissue were usual.
RNAzol™ B method: This single step kit method (Biogenesis Ltd) is based on the protocol of 
Chomczynski and Sacchi (1987 ) and is preferred over the previous method due to its speed 
(tissue to RNA in approximately 90 minutes) and high yield from small amounts of tissue 
(approximately 5-6ng/mg tissue). The method is based on the unique property of RNAzol™ 
which promotes formation of complexes of RNA with guanidinium and water molecules and 
abolishes hydrophilic interactions of DNA and proteins. In effect, DNA and proteins are 
efficiently removed from the aqueous phase, while RNA remains in this phase during the 
sample extraction with RNAzol™ (Chomczynski, 1991). RNAzol™ can also be used to 
extract RNA from agarose gels.
1 OOmg of tissue was ground up in liquid nitrogen as before. 2ml of RNAzol™ B solution was 
added and the mixture homogenised using the Polytron as before. 0.2ml of chloroform was 
added and the samples shaken vigorously before incubation at 4°C for 5 minutes. The 
suspension was centrifuged at 9,500rpm at 4°C (J2-21 centrifuge, JA20.1 rotor) for 15 
minutes. The colourless, upper phase was removed and an equal amount of isopropanol was 
added. The samples were stored at 4°C for 15 minutes and then centrifuged at 9,500rpm as 
before. The supernatant was removed and the RNA pellet washed in 75% (v /v ) ethanol. The 
pellet was recentrifuged for 8 minutes at 7,500rpm and the ethanol removed. The pellet 
was dried very briefly in a Univap (section 2 .3 .4) and resuspended in an appropriate 
amount of sterile water. If the RNA was hard to dissolve an incubation for 10-15 minutes at 
60°C was performed. Again the RNA was measured spectrophotometrically (section
2 .3 .1 0 ).
2 .9 .2  Selection of Polyadenylated RNA
Poly (A)+ RNA was selected by two methods, the second again superseding the first during 
the course of this study.
OuickPreo™ mRNA purification kit method: This kit method (Pharmacia LKB 
Biotechnology) was designed for the direct isolation of polyadenylated RNA from eukaryotic 
cells or tissues, bypassing the need for intermediate purification of total RNA.
0.5g of kidney tissue was ground up in liquid nitrogen as before (section 2 .9 .1 ) and 1.5ml 
of extraction buffer (heated to 37°C to dissolve any crystalline material and then chilled on 
ice) was added. The tissue was homogenised using the Polytron again as before and 3 ml of 
elution buffer was added and the solution vortexed thoroughly. The extract was centrifuged 
at 10,OOOrpm for 10 minutes at 4°C (J2-21 centrifuge, JA20.1 rotor).
During centrifugation an Oligo(dT)-Cellulose Spun Column was inverted several times to 
resuspend the matrix. Both the bottom and top closures were removed, the column placed in 
a 14ml Falcon tube and centrifuged at 1,420rpm in an EC Centra-4X bench top centrifuge 
for 2 minutes. The column was removed from the tube, the liquid discarded and the bottom 
closure replaced on the column. 4ml of the supernatant from centrifuged extract above was 
pipetted onto the surface of the column resin. The top closure was replaced and the column 
inverted for 10 minutes to resuspend the resin and allow binding of the mRNA to the resin. 
Leaving both top and bottom closures on the column the column was placed in a 14ml Falcon 
tube and again centrifuged at 1,420rpm for 2 minutes. The supernatant was discarded and 
3 ml of High-Salt Buffer added. The matrix was resuspended and the column recentrifuged at 
1,420rpm for 2 minutes. This washing step was repeated twice more with High-Salt 
Buffer and then once with Low-Salt Buffer. The bottom closure of the column was removed 
and 3ml of Low-Salt Buffer was added to the top of the resin. The column was centrifuged as 
before. To elute the mRNA, a sterile 1.5ml Eppendorf tube was placed inside the Falcon tube 
before the column was added. Three successive washes of 0.25ml of pre warmed (65°C) 
Elution Buffer were performed by adding the buffer and then centrifuging as before, 
collecting all 0.75ml of eluent in the Eppendorf tube. The Eppendorf tube was removed 
using sterile forceps and placed on ice. 0.25ml of the sample was used to quantitate the 
amount of mRNA (section 2 .3 .10) whilst the remaining 0.5ml was precipitated by adding 
50^1 of K Acetate Solution and 10^1 of Glycogen solution. 1 ml of ice-cold 95% (v /v ) 
ethanol was added and the sample incubated at -20°C overnight. The mRNA was collected as 
in section 2.3.3.
Oliao(dTVcellulose type 7 method: Unlike the last method, this protocol involved the 
isolation of total RNA (section 2.9.1 ) before poly(A)+ RNA selection could occur. The 
method is a modification of the protocol described by Aviv and Leder (1972 ) and uses 
oligo(dT)-cellulose type 7 and solutions appropriate to this material (Pharmacia LKB 
Biotechnology).
1g of oligo(dT)-cellulose powder was suspended in 5ml of sterile water. Two columns were 
poured, each with a bed volume of 0.5ml, by plugging two sterile 5ml pipette tips with 
DEPC-treated glass wool and the carefully pouring the cellulose solution onto the glass wool. 
Each column was washed with 5 bed volumes of 0.1 M NaOH and then 10 bed volumes of 
application buffer until the pH of the eluent was 7.5. RNA, isolated by either of the two 
methods in section 2.9.1 (1-3mg), was redissolved in 0.5ml of TE buffer. The RNA 
solution was heated to 65°C for 5 minutes, cooled quickly on ice and 0.5M of 1M NaCI added. 
This was mixed and applied to one of the columns at room temperature. The effluent was 
collected, heated to 65°C for 5 minutes, cooled quickly on ice and reapplied to the column. 
The column was washed with 5-10 bed volumes of application buffer and then with 5 bed 
volumes of wash buffer. The RNA was eluted with 3 bed volumes of TE buffer, collecting 
1.0ml fractions.
The RNA-containing fractions were identified by spectrophotometry (section 2 .3 .10 ) and 
these were pooled. The pooled fractions were heated to 65°C for 5 minutes and chilled on ice. 
1 volume of 1M NaCI was added and the sample applied to the second column prepared 
earlier. The same procedure was followed and the RNA-containing fractions pooled. 0.2  
volumes of 2M NaCI and 3 volumes of ice-cold ethanol were added. The mixture was 
incubated at -20°C overnight, pelleted at 14,OOOrpm, dried briefly and resuspended in 
200fxl of sterile water. The RNA concentration was measured spectrophotometrically 
(section 2 .3 .10).
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The oligo(dT)-cellulose was regenerated by washing with 0.1 M NaOH to strip off all the RNA 
and then with 5 bed volumes of 5mM EDTA and 5 bed volumes of sterile water. The gel was 
equilibrated with 0.5M NaCI and stored at 4°C until needed again.
2 .9 .3  Isolation of Genomic DNA
Genomic DNA for use in Southern blots was prepared from rat kidney, frozen in liquid 
nitrogen, by a modification of the method of Johns and Paulus-Thomas (1989). The sample 
(up to 1 g) was ground in liquid nitrogen with a pestle and mortar and the powdered tissue 
suspended in 9.8ml of DNA digestion buffer in a 50ml Falcon tube. 0.2ml of 10% (w /v)
SDS was added and the solution incubated at 37°C for 30 minutes. The solution was adjusted 
to 1.5% (w /v ) SDS by adding 1.5ml of 10% (w /v ) SDS and heated at 60°C for 10 minutes 
to denature the proteins. 2.5ml of freshly prepared 5M sodium perchlorate was 
immediately added and the solution mixed gently. An equal volume (14m l) of 24:1 (v /v ) 
chloroform/isoamyl alcohol was added and the tube rocked gently for 30 minutes in a fume 
hood. The tube was spun at 8,500rpm (J2-21 centrifuge, JA-17 rotor) for 10 minutes at 
4°C and the aqueous phase transferred to another tube. 2 volumes of ice-cold 100% (v /v ) 
ethanol were added and the DNA spooled out using a sterile glass sealed pipette. The DNA was 
spooled into 5ml of TE buffer at 4°C for 30 minutes. 0.1 volumes of 3M sodium acetate, pH
7.0 and 2 volumes of ice-cold 100% (v /v) ethanol was added and the DNA spooled into 1 ml 
ice-cold 70% (v /v ) ethanol. The DNA was washed twice with ice-cold 70%  (v /v ) ethanol, 
briefly dried in a Univap (section 2 .3 .4) and resolubilised in sterile water overnight at 
4°C. The concentration of DNA was determined as in section 2.3.10.
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2 .1 0  PREPARATION OF FILTERS FOR HYBRIDISATION
The following methods were used to prepare filters for hybridisation . Southern blotting 
was used both for the analysis of genes of interest in genomic DNA (section 2.9.3) and for 
comparison of homology between recombinant plasmid clones. Northern blotting was 
performed in order to determine the size of mRNAs of interest and to gain an estimate of 
their abundance in the total cellular RNA (section 2 .9 .1) when performing induction and 
tissue distribution studies. RNA slot blots were used , via use of a densitometer (section 
2.10.5), to quantitate mRNA abundance more precisely. RNA slot blots can be performed 
with only 1 ^g of total RNA per assay whereas Northern blotting requires 20^g, thus the 
former is the method of choice in situations where only low amounts of RNA are available. 
However, Northern blots are usually performed as well as slot blots to show that any 
differences in the mRNA abundance between samples is due to the single mRNA band.
2 .10 .1  Southern Blotting
The method was adapted from that reported by Sambrook et a /(1 982), after the original 
technique described by Southern et al (1975 ). Following electrophoresis of DNA, the 
agarose gel was stained and photographed (sections 2.3.5, 2.3.6 and 2.3.7 respectively). At 
least 10^g of genomic DNA was loaded on the gel if single copy genomic fragments were to be 
detected by hybridisation to 32p-|abelled DNA probes. For cross-hybridisation between 
clones 500ng of each insert was used.
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The gel was immersed in 5 volumes of 0.25M HCI and shaken slowly (Luckham rotary 
shaker) at room temperature for 15 minutes. This treatment partially depurinates the DNA 
breaking it down into smaller pieces so that the larger fragments of DNA can transfer more 
efficiently. The HCI solution was replaced by 5 volumes of Southern Blot Denaturing 
solution and the gel shaken slowly at room temperature for 45 minutes, followed by the 
same treatment with Southern Blotting Neutralising solution.
The DNA fragments were then transferred from the gel to a filter membrane by capillary 
action as in the original procedure using 20x SSC. Hybond N nylon transfer membrane 
(Amersham) was used to immobilise the DNA. After overnight transfer, the filter was 
rinsed briefly in 5x SSC and the DNA fixed in situ as detailed in section 2.10.4. The blot was 
stored at 4°C wrapped in Saran wrap until use.
2 .1 0 .2  Northern Blotting
20(.ig of RNA samples were electrophoresed on formaldehyde denaturing gels as described in 
Darbre (1988 ) and Sambrook et al (1989 ). After staining with ethidium bromide and 
photographing, the gel was soaked, with gentle shaking, in 0.05N NaOH for 20 minutes to  
partially hydrolyse the RNA and thus make the transfer of the larger RNA fragments more 
efficient. The gel was then soaked in sterile water for 20 minutes followed by soaking in 
20x SSC for 45 minutes (both with gentle shaking). The blot was set up in the same way as 
for a Southern Blot. After transfer the filter was rinsed briefly in 5x SSC and the RNA was 
fixed to the membrane (section 2.10.4). The blot was stored at 4°C wrapped in Saran wrap 
until use.
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2.10.3 RNA Slot Blots
RNA was denatured for binding to filters by the formaldehyde method of Lehrach e t al 
(1977). Total RNA (section 2.9 .1) was serially diluted with sterile water to give 100^1 
samples of 20, 10, 5, 2.5, 1.25 and 0.625fxg. The RNA was denatured by the addition of 
300^1 of 18.5% (v /v ) formaldehyde in lOx SSC (made by mixing equal quantities of 37%  
(v /v ) formaldehyde and 20x SSC) and heating to 65°C for 15 minutes.
A nylon filter (Hybond N, Amersham) was cut to size (8.5 x 11 cm) and two sheets of precut 
Millipore filter paper were soaked in 1 Ox SSC. The slot blot apparatus (Milliblot Systems, 
Millipore) was assembled with the sheets of filter paper followed by the filter being placed 
on the apparatus and then the lid firmly clamped down. Vacuum was applied slowly (such 
that a 400^1 sample took approximately 5 minutes to pass through the membrane) and the 
samples loaded into the wells. The samples were washed through with 400^1 of 10x SSC and 
the RNA fixed to the filter as in section 2.10.4.
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2 .1 0 .4  Fixing of Nucleic Acids onto Nylon Filters
Hybond N filters were used throughout the blotting experiments due to their resilience and 
reusability. The DNA and RNA was fixed to the filters by first drying the filter at 80°C 
(Gallenkamp Size 1 Economy incubator) for 10 minutes and then wrapping the filter in 
Saran wrap. The filter was then UV-irradiated for 3 minutes with the DNA/RNA side down 
(UV Transilluminator TM20, Genetic Research Instrumentation Ltd) in order to cross-link 
the nucleic acids to the filter. The filter could then be stored at 4°C until use.
Where a filter was to be reused it was necessary to remove all the hybridised radioactive 
probe (section 2 .11) from the previous experiment. Nylon filters were stripped by two 
washes in boiling 0.1% (w /v ) SDS. The filters were shaken vigorously until the SDS had 
cooled down. The filters were then checked using the Geiger counter and, usually, by 
autoradiography (section 2.3 .9) for a seven day period. Additional washes were performed 
if any probe was still present. The stripped filters were rinsed in 5x SSC and stored, 
wrapped in Saran wrap, at 4°C.
2 .1 0 .5  Use of the Densitometer
In order to quantitate the differences in specific mRNA abundance between samples a 
Shimadzu CS-9000 densitometer was used. This machine is a dual-wavelength flying spot 
scanner linked to an AP personal computer. The autoradiograph (section 2 .3 .9 ) of interest 
is scanned by the densitometer at 550nm and the optical density of each band is shown. The 
computer then calculates the area under the peak of each band and this information is used to 
determine any differences between the samples.
88
2.11 RADIOACTIVE LABELLING OF CLONED cDNAS
Two methods were used in the course of this study; nick translation (originally described 
by Rigby e t al, 1977) and random oligonucleotide priming of DNA synthesis (originally 
described by Feinberg and Vogelstein, 1983). The former incorporates radiolabelled 
nucleotide into existing DNA using DMA Pol 1, after the template is nicked by DNAase 1. The 
latter synthesises a new strand of DNA from a number of sites where random 
hexanucleotides bind to denatured, single stranded template. Synthesis, in this case, is 
performed by the Klenow fragment of DNA Pol 1. Specific activity is higher in the second 
method and so use of the Multiprime system (Amersham International) superseded use of the 
Nick Translation kit (Amersham International). In both cases the labelled DNA fragments 
produced are of the order of 200-300  bases in length and require purification from 
unincorporated radiolabelled nucleotides before use to prevent high levels of background 
signal in the subsequent autoradiography (section 2.3.9).
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2.11.1 Nick Translation
To the DNA to be labelled (approximately 200ng) was added 10fxl buffer/nucleotide mix 
(0.4nM dATP, dTTP and dGTP in 10mM Tris-HCI, pH 7 .0) and sufficient water to bring the 
volume up to 3 5 4  W  of 32p dCTP (lOO^Ci - section 2 .2 .2) and, finally, 5^ 1 of enzyme 
solution (1:1 mix of DNA polymerase 1: DNAase 1, 2511/^1) were added, the tube contents 
mixed gently, quickly centrifuged in a microfuge and incubated at 14°C for 3 hours. The 
reaction was stopped by the addition of 2 1^ of 0.5M EDTA. The DNA was then purified from 
unincorporated nucleotides using a NACS column (BRL). NACS is an ion exchange resin 
which binds nucleic acids at low salt concentrations and releases them at high salt 
concentrations. The column was hydrated by slowly pushing 10ml of 2M NaCI in TE buffer 
through using a 10ml syringe and then equilibrated with 10ml of loading buffer. 1 ml of 
loading buffer was added to the labelling reaction and the whole sample then pushed through 
the column. The first pass eluate was reapplied to the column and the buffer pushed through 
to waste. A t this point the DNA was firmly bound to the column and the unincorporated label 
was removed by 8x 1 ml washes with loading buffer. The DNA was then eluted by 3x 0.2ml 
washes of elution buffer. The probe was then boiled for 5 minutes to denature the DNA. It 
was then immediately added to the hybridisation buffer (2 .12) to ensure that the probe 
remained single stranded.
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2.11.2  Multiprime
Multiprime is the commercial name for the Amersham kit system for labelling DNA by 
random priming. 50pg of the DNA to be labelled was boiled for 3 minutes then cooled 
rapidly on ice. Water was added to a final volume of 23^1, then 10^1 of buffer containing 
unlabelled nucleotides (0.4jiM dATP, dTTP and dGTP in 333mM Tris-HCI, pH 8.0, 33.3 mM 
MgClz and 10mM 2-mercaptoethanol) and 5^1 of random hexanucleotide primer (3 .5  Azgo
units of random hexanucleotides in 10x reaction buffer) were added. 5 1^ of 32p dCTP 
(50pCi - section 2.2 .2) and then 2pi of exonuclease-free Klenow enzyme (2U/pl)were  
added, the components mixed, microfuged quickly and the mixture incubated at room 
temperature for 3 hours. If time was limited then the incubation time could be cut to 30  
minutes at 37°C. Unincorporated nucleotides were removed by filtration through NICK™ 
columns (Pharmacia LKB Technology). These are prepacked gravity flow one piece systems 
containing Sephadex G-50 and represent a considerable improvement in user safety over the 
push flow syringe-plus-column for the NACS system. The column was equilibrated using 3 
x 3.33ml of NICK column buffer. The reaction mix was then applied directly to the column 
and the column washed with 400pl of NICK column buffer. A second 400pl of column buffer 
eluted the labelled DNA which was subsequently boiled for 5 minutes before immediate use 
in the hybridisation buffer (section 2.12). A third 400pl wash from the NICK column also 
contained labelled DNA but was not usually used as it was contaminated with unincorporated 
nucleotides, the remainder of which could be eluted with a fourth 400pl wash.
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2 .1 2  HYBRIDISATION PROCEDURES
In the majority of hybridisation experiments involving radioactive DNA probes, the 
formamide method was used. However, towards the end of these studies, this method became 
unsatisfactory and so a different method (using SDS) was adopted. Both of these methods are 
described in detail in the following sections, along with the general methods used for washing 
the filters after hybridisation.
2 .12 .1  Formamide Method
This method was adapted from that reported by Anderson and Young (1985). The presence of 
deionised formamide reduces the melting temperature (Tm) of nucleic acid hybrids and 
enables hybridisations to be performed at lower temperatures. Filters were prewetted in 
5x SSC and then prehybridised for 7-16 hours at 42°C in approximately 1 ml of 
prehybridisation buffer per square cm of filter. This ensured that all the non-specific 
binding sites were blocked. This operation and the subsequent hybridisation reaction were 
initially performed in sealed bags in a vessel placed in a shaking water bath. However, the 
acquisition of a Hybaid incubator and rôtisserie (with the filters layered between mesh 
spacers and placed inside sealed rotating bottles) made this operation less hazardous and 
more easily reproducible.
The prehybridisation buffer was then removed and replaced with hybridisation buffer 
containing the freshly denatured probe (section 2.11). The filter and hybridisation mix 
were then incubated at 42°C, with rotation, overnight. Approximately 0.1ml of 
hybridisation buffer per square cm of filter was used.
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2 .1 2 .2  SDS Method
This method was adopted for a number of reasons; the inclusion of 0.5% (w /v ) SDS in the 
hybridisation buffer provided better blocking of non-specific binding than BSA alone 
(cutting prehybridisation time down to 2 hours or less), the Hybaid oven and sturdiness of 
nylon filters meant that hybridisation at higher temperatures was possible and so 
formamide was no longer needed (omitting the need to deionise formamide) and the 
prehybridisation/hybridisation buffer was the same solution thus saving time and reagents. 
The same procedure as in section 2.12.1 was followed except that the prehybridisation was 
performed whilst the radiolabelling reaction was taking place (section 2 .11 ) and the 
prehybridisation solution was reused as hybridisation solution by the addition of the labelled 
probe. The hybridisation buffer and filters were incubated at 65°C, with rotating, 
overnight.
2 .1 2 .3  Washing of Filters
The washing conditions used are described for each separate experiment in the results 
section as they vary according to the probe used and the samples being analysed. Unless 
otherwise stated, however, high stringency washes were conducted as follows:
i. 2 x 1 5  minute washes, room temperature in 2x SSC/0.1% (w /v ) SDS.
ii. 2 x 20  minutes, 42°C in 1x SSC/0.1% (w /v ) SDS.
iii. 2 x 20 minutes, 55°C in 0.5x SSC/0.1% (w /v ) SDS.
Occasionally, when the background radioactive signal remained high, the salt concentration 
was lowered to O.lx SSC and the temperature raised to 60°C for a further 20 minutes. After 
washing, all filters were rinsed in 5x SSC for 20 minutes at room temperature and then 
subjected to autoradiography (section 2.3.9).
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2 .13  HYBRID SELECTION OF mRNA
Any recombinant DNA sequence is able to form stable hybrids with its corresponding mRNA. 
This property was used for the identification of a cloned gene using the 
recombinant plasmid DNA (section 2.7) to select a specific mRNA from the total mRNA 
population (section 2.9 .2). This specific mRNA was then translated in a cell-free protein 
synthesising system (section 2.14). For this experiment the method of Jagus (1987 ) was 
followed.
The circular plasmid DNA (section 2.7) was first linearised by digestion with an 
appropriate restriction enzyme (section 2 .4) and this was then applied to a nylon filter 
(Hybond N). 40^g of linearised DNA was denatured in 80^1 of 0.4N NaOH at room 
temperature for 10 minutes and then placed on ice. Two squares of nylon filter per clone 
(5mm x 5mm) were soaked in water for 5 minutes, then in 0.4N NaOH for 30 minutes. The 
DNA solution was applied by spotting 10^1 onto the filter squares at a time,drying between 
applications, to give 20ng of DNA per filter. The filters were washed twice in 1M 
ammonium acetate, pH 5.5 followed by two rinses in 2x SSC. The filters were blotted dry 
and allowed to air dry overnight.
The filters were prehybridised by placing the filter in the bottom of a 1.5ml Eppendorf tube 
and adding 200^1 of prehybridisation buffer. The tube was angled at 45° to the horizontal in 
a polystyrene float and incubated in a 37°C waterbath overnight. Prior to hybridisation, the 
prehybridisation buffer was discarded and the filter washed ten times with wash buffer at 
60°C. The filter was washed briefly in hybridisation buffer. The filter was then hybridised 
in 50fxl of hybridisation buffer containing 10^g of mRNA (section 2 .9 .2) for 18 hours at 
37°C.
The filters were washed ten times with 1x SSC containing 0.5% (w /v ) SDS at 50°C, 
followed by five washes with 1 x SSC at 50°C. The filter was washed in Buffer A at 50°C for 
40 seconds and the mRNA eluted by boiling for 1 minute in Solution B followed by snap- 
freezing in dry ice/ethanol. The eluate was thawed, removed and the elution procedure 
repeated. The eluates were pooled, two volumes of ethanol and 0.1 volume of 2M potassium 
acetate added and the mixture incubated at -20°C overnight. The mRNA was recovered by 
centrifugation at 14,000rpm (Microfuge) at 4°C for 30 minutes. The pellet was washed in 
70% (v /v ) ethanol, dried briefly in an Univap (section 2 .3 .4) and reconstituted in 2\x\ of 
sterile water. This was stored at -70°C until use.
2 .1 4  mRNA TRANSLATION
Several cell-free protein synthesising systems have been used in recent years for the 
translation of mRNA isolated from various sources. Of these, the two most widely used are 
the rabbit reticulocyte lysate and the wheat germ extract. Both provide reliable, convenient 
and easy to use systems to initiate translation and usually produce full size polypeptide 
products. The reticulocyte lysate used in these studies is favoured for the translation of 
larger mRNAs (and is also recommended where microsomal membranes are to be added for 
cotranslational processing of translation products). The wheat germ extract is used to  
translate mRNA preparations containing low concentrations of double-stranded RNA 
(dsRNA) or oxidised thiols which are inhibitory to the reticulocyte lysate system.
The rabbit reticulocyte lysate (Amersham International) is prepared from New Zealand 
white rabbits injected with phenylhydrazine using the method of Pelham and Jackson 
(1976). The reticulocytes are purified and lysed, then treated with micrococcal nuclease to 
destroy endogenous mRNA and thus reduce background translation to a minimum. The lysate 
contains all of the cellular components necessary for protein synthesis such as tRNA, rRNA 
and amino acids. All that needs to be added is mRNA and a labelled amino acid.
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35S-methionine was used in this study because of its availability at a very high specific 
radioactivity (enabling a much higher incorporation of radioactivity into protein to be 
obtained, even though methionine occurs relatively infrequently in many proteins) and also 
because the endogenous pool size of methionine in the reticulocyte lysate is relatively low 
and therefore doesn't dilute the added 35S-methionine to any extent.
2 .14 .1  Translation Procedure
To ensure that a given mRNA will be efficiently translated using the rabbit reticulocyte 
lysate cell-free system, it is important to determine optimum values for the length of 
incubation time and the concentrations of both potassium and magnesium ions. mRNA 
concentration is also important but as this study was using hybrid selected mRNA, which is 
very hard to quantitate, this optimisation procedure was not performed. It is also vital to 
ensure that no calcium is introduced into the lysate, as this will reactivate the micrococcal 
nuclease (used to destroy the endogenous mRNA) and that the mRNA preparation is free of 
any trace amounts of ethanol, detergent or sodium ions (even residual amounts will cause 
inhibition of the translation system).
The lysate and tobacco mosaic virus (TMV) RNA (which is used as a positive control in this 
system) were removed from -70°C storage and allowed to thaw slowly on ice. The lysate is 
extremely sensitive to environmental conditions such that only the required amounts are 
thawed for each experiment with all additions being performed rapidly on ice. The template 
mRNA was heated to 65°C for 10 minutes and immediately cooled on ice. This increases the 
efficiency of translation, especially of GC-rich mRNA, by destroying local regions of 
secondary structure. The reaction components were then assembled as follows; 40^1 of 
message dependent lysate, 3^1 of mRNA and 7 til of L-[35S]-methionine (70tiCi - section
2.2.2), giving a total volume of SOjil in a SOOttl Eppendorf tube. The mixture was then 
vortexed gently (to avoid frothing) and placed in a 30°C water bath (Grant). The mixture 
was allowed to incubate for the optimum length of time (usually 1 hour).
At the end of this time 2 x 1 til aliquots were removed, one onto a 0.45tim filter disc 
(Millipore) and the other into 0.5ml of 1 m NaOH/HgOz solution in a glass test tube kept on
ice. To the remainder of the sample an equal volume of 2x protein sample buffer was added 
and the mixture boiled for 5 minutes. These samples were then loaded onto a 10%  (w /v ) 
SDS-PAGE gel (section 2 .5 .5) and run. The 1ml aliquot in 1M NaOH/HgOz solution was
placed in a 37°C water bath for 10 minutes to hydrolyse the aminoacyl-tRNA complexes.
The tubes were removed to an ice bucket and 2ml of ice-cold 25% (w /v ) TCA solution 
containing casein hydrolysate was added. The tubes were mixed and left for a minimum of 30  
minutes after which their contents were filtered through 0 .4 Sum filter discs (Millipore). 
The disc were washed with 2 x 3ml of ice-cold 8% (w /v ) TCA solution and 3ml of ice-cold 
70% (v /v ) ethanol. The discs were air-dried, placed in scintillation vials and 5ml of liquid 
scintillant added (Optiphase "Safe", LKB). The vials were then counted (along with the 1 |il 
samples placed directly on filter discs) using a LKB Wallac 1217 RackBeta scintillation 
counter linked to an Amstrad PC2086/30 computer.
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For every translation experiment two controls were used; a zero mRNA negative control and 
a TMV mRNA positive control. The SDS-PAGE gel was fixed in 30%  (v /v ) methanol, 10% 
(v /v ) glacial acetic acid and 10% (w /v ) TCA for 1 hour with shaking. The gel was then 
dried onto Whatman 3MM paper at 80°C for 90 minutes (Model 4823 Slab Gel Drier,
Biorad). Autoradiography was then performed as described in section 2.3.9.
2 .15  STUDIES ON p-LYASE INDUCTION
The regulation of p-lyase by the N-acetyl conjugate of HCBD, NAc-PCBD, was studied in the 
female rat (chapter 6 ) .  Many of the methods used have been described elsewhere in this 
methods section such as Western Blotting (section 2.5.6) and the measurement of GTK and p- 
lyase activities (sections 2.5.3 and 2.5.4 respectively). However, the following protocols 
were also followed throughout the course of the studies:
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2.15.1 Treatment of Animals
Female Wistar-derived albino rats (170-21 Og body weight) were used as a source of 
kidney tissue and blood. All animals were obtained from the University of Surrey Breeding 
Unit and housed at the University of Surrey in cages with sawdust beddings. A 12 hour 
light/dark cycle was in operation at 22°C and 50% relative humidity. They were given free 
access to water and, except where stated, food.
Where appropriate the rats were fasted for 24 hours prior to dosing and for the entire post- 
dosing period. The NAc-PCBD was dissolved in 0.9% (w /v ) saline and administered once or 
thrice intraperitoneally. Rats were given 3mg/Kg or lOmg/Kg in a saline vehicle of 
1 ml/Kg. Control animals were dosed with 0.9%  (w /v ) saline only. 24 -72  hours after 
dosing the animals were weighed and anaesthetised with ether. Blood was sampled by cardiac 
puncture into a tube containing sodium heparin. This was then centrifuged at 3,000rpm for 
20 minutes (IEC Centra-4X bench centrifuge) to isolate the plasma which was stored at - 
70°C. The animals were then killed by cervical fracture. The kidneys were carefully 
removed, decapsulated, blotted dry and weighed. The tissue was maintained on ice, in 0.25M  
sucrose solution containing 10mM Tris-HCI at pH 7.5, for subsequent fractionation (section
2.5.2). One pair of kidneys from each group of animals was frozen in liquid nitrogen and 
stored at -70°C for subsequent preparation of RNA (section 2.9.1).
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2.15.2 Determination of Renal Damage
Plasma urea levels were used as an index of renal damage and, hence, toxicity of the 
compounds given. Plasma urea concentration was determined by the method of Marsh et al 
(1965 ) using the Sigma kit (No. 535-A). This kit utilizes the reaction described by 
Fearon (1939 ):
Diacetyl Monoxime + Urea ------------------ >  Pink Chromagen + Hydroxylamine
Urea concentration is directly proportional to the intensity of the colour produced, which is 
measured spectrophotometrically (Uvikon 860  spectrophotometer, Kontron Instruments) 
between 514-540nm . The method is simple, rapid, highly sensitive and not influenced by 
the presence of ammonium ions.
A standard curve was first produced between 0 -75m g/100m l of urea nitrogen using the 
standard solution provided in the kit. 5ml of this solution was added to 3 ml of BUN acid 
reagent and 2 ml of BUN colour reagent. The solution was mixed thoroughly and boiled for 10 
minutes. The tubes were cooled quickly and read at 535nm within 20 minutes. The sample 
plasma (0.2m l) was precipitated first by the addition of 1.8ml of ice-cold 3% (w /v ) TCA 
solution and incubation at room temperature for 5 minutes. The clear supernatant was 
produced by centrifugation at 2,500rpm for 10 minutes at 4°C (J-6B centrifuge, JS-4.2 
rotor). 0.2ml of this supernatant was added to 2.8ml of BUN acid reagent and 2ml of BUN 
colour reagent and mixed thoroughly. The mixture was boiled, cooled and the absorbance 
determined as above. The urea nitrogen concentration of the samples was ascertained by 
reading off the values from the standard curve.
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2 .1 5 .3  Enzyme-Linked Immunosorbent Assay (ELISA)
(3-lyase levels were determined immunochemically by the ELISA method of Voiler et al 
(1976). The p-lyase antigen in cytosol or solubilised mitochondria (0.5%  (v /v ) Triton X- 
100  with stirring for 20  minutes on ice) was coated onto the wells of a microtitre plate 
(200^1/well) in 0.1 M sodium carbonate/bicarbonate buffer, pH 9.6 and left overnight at 
4°C in a humid environment. The plates were washed with PBS, pH 7.4 containing 0.1%  
(w /v ) gelatin and 0.05%  (v /v ) Tween 20 (PBS-GT). Anti-p-lyase antibody (section
2.2.3) was diluted in PBS-GT and 200^1 applied to the appropriate wells. The binding of 
the same volume of pre-immune serum was used as the blank control.
Following a 2 hour incubation at 37°C and subsequent washing with PBS-GT, a horseradish 
peroxidase-labelled donkey anti-sheep IgG (200^1/well) was added. After a further 2 hour 
incubation at 37°C and PBS-GT washing, the substrate (0.025M  citric acid, 0.05M  
disodium hydrogen phosphate buffer, pH 5.6 containing 0.4mg/ml orthophenylenediamine 
and 1:2500 30% (w /v ) hydrogen peroxide) was added to the plate (1 50fxl/well). The plate 
was incubated for 30 minutes at 37°C and the reaction terminated by the addition of 2.5M 
sulphuric acid (50^1/well). The plate was then read at 490nm using a Dynatech ELISA 
plate reader.
2 .1 5 .4  S tatistica l Analysis
Means and standard deviations were determined for each group and the Students "t"-test was 
used to estimate any statistical differences between groups. Statistically significant results 
between control and treated groups were taken as those with p values < 0.05.
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CHAPTER 3
THE ISOLATION, CLONING AND CHARACTERISATION OF THE p-LYASE GENE
3.1 INTRODUCTION
The results in this chapter are from experiments performed on a Wistar Xgtl 1 rat kidney 
cDNA library (section 2 .2 .4) to isolate a cDNA fragment of the p-lyase gene. Further 
experiments were undertaken to confirm the fragment's identity and to characterise the 
gene.
All the experiments presented in this chapter were carried out by the author, with the 
exception of the pGEM cloning and sequencing (section 2.6.3) which was performed by Dr 
Marion MacFarlane.
A postscript at the end of this chapter describes work performed subsequently by Miss 
Sandra Perry which confirms the identity of the cDNA fragment as part of the p-lyase gene.
3.2 ISOLATION OF A RECOMBINANT cDNA CLONE FROM A RAT KIDNEY 
LIBRARY
3.2.1 Verification of the Anti-p-Lyase Antibody
To check that the primary antibody and antibody detection system (section 2 .2 .3) were 
functioning satisfactorily, a Western blot was performed on rat kidney cytosol (1 5^g) and 
purified p-lyase protein (5^g). The Western blot was performed as section 2.5.6 and the 
kidney cytosol produced by the method in section 2.5.2. The purified p-lyase protein was a 
kind gift from Dr. M. MacFarlane (MacFarlane et al, 1989).
The antibody reacted with a single protein band in both lanes (figure 3.1 ) thus showing it to 
be monospecific for p-lyase as previously shown by MacFarlane e t al (1989 ). However, at 
43 kiloDaltons (kD), the molecular weight of this band was lower than previously reported. 
Stevens e t al (1 986b) showed the monomeric weight of p-lyase to be 55kD and MacFarlane 
et alO  989) found a weight of 50kD. The reason for this discrepancy is unknown and all 
subsequent Western blots (including some using different standards) have given the same 
result.
Because of this apparent discrepancy in the molecular weight of p-lyase it was decided to do 
a further verification experiment on the anti-p-lyase antibody. The glutamine 
transaminase (GTK) activity of the rat kidney cytosol, produced for the Western blot, was 
assessed as in section 2.5.3. A linear response curve was produced from the results (data 
not shown) and an appropriate protein concentration chosen (410^g/m l). This 
concentration of cytosol was then used to measure the inhibition of the assay by the anti-p- 
lyase antibody. The GTK assay was performed, as of section 2.5.3, but this time varying 
amounts of the antibody were added up to a concentration of 22.5ng/ml. The same volume of 
pre-immune serum was used to provide a negative control. A linear response curve was 
produced (not shown) and at the highest concentration of antibody (22.5ng/m l) an 
inhibition of 2 0 % over the pre-immune serum sample was seen, thus verifying that the 
antibody was active and specific. Pre-immune inhibition seen was 0 .1 
One possible reason for the differences in molecular weight between these and previous 
results is the use of different molecular weight markers which may have affected the 
protein sizing. It must also be noted that the molecular weight of the protein produced from 
transfected cells (postscript) is 48kD and, therefore, closer to the original values quoted.
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Fig. 3.1. Western Blot of Wistar Rat Kidney Cytosol and Purified Rat Kidney Cytosolic 
(3-lyase.
Lane 1 : Prestained protein molecular weight markers («2-macroglobulin, 180kD; p-
galactosidase, 116kD; fructose-6-phosphate kinase, 84kD; pyruvate kinase, 58kD; 
fumarase, 48.5kD; lactate dehydrogenase, 36.5kD).
Lane 2: Purified p-lyase (5^g).
Lane 3: Rat kidney cytosol (15^g).
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3 .2 .2  Isolation of a Recombinant Rat cDNA Clone Using the A nti-p -Lyase  
A ntibody
The Wistar rat kidney cDNA library in Xgtl 1 (section 2 .2 .4 ) was titred using the method 
detailed in section 2.6.1. This showed the library to have a titre of IxlO ^pfu/m l. The 
library was then screened for p-lyase expressing phage as shown in section 2.6.3.
Problems were encountered with high background, long development time and low numbers 
of apparent p-lyase positive recombinant plaques. The detection system was modified (the 
primary ànti-p-lyase antibody dilution increased to 1:40) and this improved the results. 
From this initial screening of approximately 100 ,000  plaques, two positive cDNA clones 
were identified and isolated. A second round of screening (section 2.6 .4) was performed on 
these clones and again similar problems, as stated above, were encountered. This time the 
dilution of the secondary anti-sheep antibody (section 2 .2 .3) was decreased to 1:500 (from  
1:2500 used initially) and a new staining system purchased. This was the Extravidin™- 
alkaline phosphatase conjugate (section 2.2 .3) which was chosen due to its increased 
sensitivity at low protein concentrations (Mierendorff e t al, 1987). The two clones were 
rescreened, along with a non-positive clone as a negative control. After two more rounds of 
screening only one of these clones was shown to react positively with the anti-p-lyase 
antibody (figure 3.2). Phage stocks of this recombinant clone were prepared as described 
in section 2 .6 .2 .
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Fig. 3.2. Filter from the Fourth Round of Screening of the Xgtl 1 cDNA recombinant showing 
the Positive Hybridisation Signals Produced by the Posistive Clonefwith the Anti-p-lyase 
Antibody.
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3.2.3 Determination of Size of the Phage cDNA Insert
Phage DNA was prepared from the recombinant plaque-purified clones as in section 2.6.5. 
The cDNA insert was released from Xgtl 1 (figure 2.3) by digestion of the phage DNA with 
the restriction endonuclease EcoRI (section 2.4) and the digested material (lO jig) run on a 
1% (w /v ) agarose gel (section 2.3.5). Figure 3.3 shows the agarose gel visualised by 
ethidium bromide staining (section 2.3 .6) and clearly demonstrates that the cDNA insert 
had been released. To determine the molecular weight of the cDNA, a graph (figure 3 .4) of 
the migration of X DNA fragments, digested with Hind III, against their known molecular 
weight (semi-log plot) was used. The molecular weight of the insert was then interpolated 
from this standard graph and shown to be approximately 0.9kb. Taking p-lyase to have a 
molecular weight of 43-50kd, the estimated length of the cDNA would be at least 1,2kb. 
Thus it was evident that this 0.9kb insert did not represent the full length cDNA. This cDNA 
fragment will be referred to as BL0.9.
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Fig. 3.3. Electrophoretic Analysis of the Positive cDNA Clone Containing BL0.9.
Lane 1 : Uncut phage DNA (1 ^g).
Lane 2: EcoRI cut DNA (lOfig) showing the insert size.
Lane 3: À, Hindlll DNA molecular weight markers (23.31 kb, 9.48kb, 6.56kb, 4.36kb, 
2.32kb, 2.03kb, 0.60kb).
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Figure 3.4. Semi-log Plot of the Rf Values* of the X Hind III DNA Fragments Against their 
Size.
Interpolation of the Rf value for the BL0.9 cDNA is shown.
*  Rf = Distance travelled by DNA fragment (mm) /  Distance travelled by dye front (mm)
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3.3 ISOLATION AND CHARACTERISATION OF A X g tl 1 RECOMBINANT LYSOGEN
To further characterise the coding potential of BL0.9 and to confirm that a cDNA 
corresponding to the p-lyase protein had been isolated, a lysogen was prepared using BLO.9 
as detailed in section 2.6.7. In an initial experiment 12 phage-infected E  coli (Y1089) 
colonies were tested for temperature sensitive growth at 43°C and 32°C. The results of this 
showed that 4  out of these 12 colonies grew at the lower temperature giving a lysogen 
frequency of 33%. All 4 colonies were used to prepare a crude lysate as detailed in section 
2.4.7. A crude lysate was also prepared from a colony that did not grow at 32°C and this was 
used as a non-lysogenic control for this experiment. The lysates were subjected to protein 
determination by the Lowry method (section 2.5.1) and 30fxg of each was loaded onto an SDS- 
PAGE gel and western blotted (along with rat kidney cytosol as a control) as detailed in 
section 2.6.6. Figure 3.5 shows the results of this Western blot and it can be seen that the 
antibody to p-lyase recognises a protein band which migrated more slowly than the p- 
galactosidase molecular weight marker. This is to be expected as the protein produced by 
the lysogen is a fusion peptide of p-galactosidase and part of the protein encoded by the cDNA 
insert. This therefore suggests that the BL0.9 insert does contain part of the p-lyase gene. 
Additional bands are seen on the Western blot due to the fact that Y1089 contains a number 
of biotinylated proteins which the Extravidin™-AP binds to. This can be seen in the non- 
lysogenic control lane. The banding in the cytosol lane is probably due to overloading of the 
sample and/or overdevelopment of the Western blot with the alkaline phosphate 
substrate.
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Fig. 3.5. Western Blot of the Agtl 1 recombinant Lysogen in £  coliY'\ 089.
Lanes 1 & 8: Protein molecular weight markers (as of Fig. 3.1.).
Lanes 2, 3, 6 & 7: Crude protein extract from lysogénie Y1089 (30^g). 
Lane 4: Control, non-lysogenic Y1089 extract (3O^g).
Lane 5: Control, rat kidney cytosol (15^g).
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mThe molecular weight of the fusion peptide was calculated using a semi-log graph of the 
migration of the protein molecular weight markers against their known molecular weights 
(not shown). This gave a weight of 140kD for the fusion peptide which, when the p- 
galactosidase weight (1 1 4kD) was subtracted gave a size of approximately 26kD. From the 
size of the cDNA insert and the known size of p-lyase this peptide is approximately 80% of 
that expected to be coded by BL0.9. This difference was probably due to the cDNA insert 
containing a certain amount of non-coding sequence.
3 .4  SUBCLONING OF BL0.9 INTO THE PLASMID VECTOR pUC19
To proceed with the characterisation of the cDNA insert BL0.9 it was subcloned from the 
bacteriophage Xgtl 1 into the plasmid pUCI 9 as described in section 2.7.1. pUCI 9 is a much 
smaller vector (2.7kb) than X.gt11 (44kb). Thus, with an insert to plasmid ratio of 1:3, it 
is possible to recover a substantial amount of insert DNA from a single plasmid DNA 
preparation (as opposed to the insert to phage ratio of 1:40). in addition, pUCI 9 is also an 
ideal vector for the sequencing of the insert using Ml 3 primers (section 3 .6 .1).
3 .4.1 Preparation o f Plasmid DNA and Recombinant Phage DNA for 
Subcloning
pUC19 plasmid DNA was prepared and linearised as described in sections 2.7.2 and 2.7.1 
respectively. The DNA was remeasured spectrophotometrically as the phenol extraction 
process can cause up to a 50% loss of DNA. The resulting DNA was resuspended in sterile 
water to give a final concentration of Sng/^l.
Recombinant phage DNA was also prepared by the method detailed in sections 2.6.6 and 2.7.1 
respectively. The 0.9kb BL0.9 insert DNA prepared by the method of section 2.7.1 was 
diluted with sterile distilled water to also give a final concentration of 5ng/nl.
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3.4.2 Results of Subcloning Experiments
Before subcloning, the T4 ligase enzyme and competent cells (sections 2.7.3 and 2.7.4  
respectively) were checked by performing experiments in which EcoRI cut pUC19, uncut 
pUCI 9, EcoRI cut pUCI 9 religated with T4 ligase and no DNA were introduced into the 
competent cells which were then plated out to grow overnight at 37°C. Once this was 
working satisfactorily, the BL0.9 insert was ligated into pUCI 9 using insert to plasmid 
molar DNA ratios of 1:1 and 3:1. The results of this subcloning can be seen in 
table 3.1.
All seven white colonies from plates 10 ,11  and 12 were picked, grown overnight in TYN 
and ampicillin (150ng/m l) and replated until completely white, pure colonies were 
obtained. When this had been performed only four of the seven were still positive. Plasmid 
DNA was prepared (section 2.7.3) and when this was cut with EcoRI, only one of the 
putative recombinant clones contained the 0.9kb insert. Figure 3.6 shows the 1% (w /v ) 
agarose gel of all four plasmid DNA preparations both intact and cut with EcoRI. It clearly 
demonstrates that in clone 4 the 0.9kb insert is present within the vector pUCI 9. It is also 
notable that the white colonies were found on plate 10 (table 3.1) indicating that the 1:1 
molar DNA ratio was the most favourable for ligation.
Table 3.1. Cloning Strategy and Results from BL0.9 Subcloning Experiment 113
Plate Total Volume 
Plated (\i\)
DNA
1 1 0 0 No DNA*
2 2 0 0 No DNA*
3 1 0 0 lOng pUCI 9 *+
4 2 0 0 lOng pUCI 9*+
5 1 0 0 lOng pUC19*
6 2 0 0 10ng pUCI 9 *
7 1 0 0 lOng pUCI9
8 2 0 0 lOng pUCI9
9 1 0 0 lOng pUCI9 /  
30ng insert
10 2 0 0 lOng pUCI9 /  
30ng insert
11 1 0 0 lOng pUCI9 /  
90ng insert
12 2 0 0 lOng pUCI9 /  
90ng insert
Molar Ratio Blue White
Colonies Colonies
558
1556
7
8 
816
1632
1:1 520 0
1:1 1269 4
1:3 481 2
1:3 1100 1
*  No T4 ligase included in these controls 
+ pUCI 9 not digested with EcoRI
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Fig. 3.6. Electrophoretic Analysis of the Putative pUCI 9 Subclones.
Lanes 1 & 10: X Hindlll DNA molecular weight markers (as for Fig. 3.3). 
Lanes 2, 4 & 5: Clones, cut with EcoRI.
Lane 3: Clone pBL0.9, cut with EcoRI.
Lanes 6, 8 & 9: Clones, uncut.
Lane 7: Clone pBL0.9, uncut.
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3.4.3 Isolation of Purified BL0.9 Insert
To further characterise the p-lyase cDNA and subsequently use the cDNA as a probe to 
examine modulation under different conditions it was necessary to perform a large scale 
plasmid preparation (section 2.7 .3) and then to purify enough of the insert so that it could 
be used for radioactive labelling (section 2 .11). Routinely, approximately 25^g of purified 
BL0.9 plasmid DNA (pBL0.9) was digested overnight with EcoRI and run on a 1% (w /v )
LMP agarose gel (usually in one long well rather than split into separate wells). The 
separated insert was purified by phenol extraction (section 2 .3 .8) and a yield of 
approximately 5^g was recovered.
3 .5  RESTRICTION ENZYME MAPPING OF THE RECOMBINANT PLASMID 
p B L 0 .9
The restriction enzymes Pst I, Bgl I, Sac I, Hind III and Xba I were used, by themselves and 
in conjunction with EcoRI, to map the pBL0.9 insert. These enzymes were chosen because 
they either cut pUCI 9 once (Pst I, Sac I, Hind III and Xba I) or twice (Bgl I). The DNA was 
digested overnight and run on a 4% (w /v ) agarose gel (sections 2.4 and 2.3.5 respectively) 
along with X Hindlll/^XI 74 Haelll DNA molecular weight markers. Figure 3 .7  shows this 
gel and it can be seen that all the enzymes cut the plasmid DNA although only Sac I appeared 
to have cut the insert DNA. Figure 3.8 shows a restriction map of the 0.9kb insert within 
pUCI 9 plasmid (pBL0.9) constructed from the information from this experiment. Because 
of the fact that only Sac I actually cut the plasmid DNA within the BL0.9 insert it was 
decided direct sequencing of this clone would provide more information than any further 
restriction mapping.
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Fig. 3.7. Electrophoretic Analysis of pBL0.9 Restriction Mapping.
Lanes 1 & 8: X Hindlll/<j>X174 Haelll DNA molecular weight markers (23.31 kb, 9.48kb, 
656kb, 4.36kb, 2.32kb, 2.03kb, 1.35kb, 1.08kb, O.BBkb, 0.60kb, 0.31 kb,
0.28kb, 0.27kb, 0.23kb, 0.19kb).
Lane 2: pBL0.9 DNA (4.0^g) cut with EcoRI.
Lanes 3 & 4: pBL0.9 DNA cut with Xbal/EcoRI and Xbal respectively.
Lanes 5 & 6: pBL0.9 DNA cut with Hindlll/EcoRI and Hindlll respectively.
Lanes 7 & 9: pBL0.9 DNA cut with Sacl/EcoRI and ScW respectively.
Lanes 10 & 11: pBL0.9 DNA cut with Bgll/EcoRI and Bgll respectively.
Lanes 12 & 13: pBL0.9 DNA cut with Pstl/EcoRI and Pstl respectively.
117
i Q .JDOOCNJ
g
I&
C03
03
5
u
N-CO
"Oc
±  _J
— Ddo o  CO u  
V J U J
Ss
u
<%
CD
u
<y>
3CÛ
Q .
O
Q .ro
co
0)
o :
ro
4->JZ
,5 >
E
0
T3
1
.5 >■o
C/5ro
5:
i
'3 -
Cdo
UJ
O )CÛ
<T>
3CÛ
00
CO
2
3
O )
Q
T3
Iro
o_
3.6  SEQUENCING OF THE 0.9Kb p-LYASE cDNA INSERT IN pBL0.9
3.6.1  Sequencing with the Universal and Reverse Primers
Plasmid DNA sequencing was performed using the Sequenase™ procedures described in 
section 2.8. The reverse primer worked very well and approximately 200  bases were read 
in the 3 '-5 ' direction (using both "short" and "long" gels and extension mixes - see sections
2.8.7 and 2.8.6 respectively). Figure 3.9 shows a typical autoradiograph obtained during 
the sequencing of pBLO.9 with the reverse primer. Problems were encountered with the 
universal primer in that the annealing step appeared not to be taking place (section 2.8.4). 
This was possibly due to a GC rich segment at the 5' end preventing single-stranding of the 
DNA. To try and rectify this the following were performed;
i. The DNA was heated to 65°C /750C after the drying down stage (section
2.8.3) for 5 minutes before addition of the primers.
ii. The DNA and the primers were heated to 85°C for 2 minutes followed by 
65°C for 2 minutes. These were then cooled to 37°C as in section 2.8.4.
iii. The DNA was denatured (section 2.8 .3) by the addition of 2M NaOH /  2M 
EDTA and incubating at 37°C for 30 minutes (rather than at room temperature for 5
None of these methods succeeded in producing any universal primer sequence data. It was 
decided to read the whole of the reverse primer sequence and elucidate the problem area 
from the other direction in order to comprehend the exact fault. Figure 3.10 shows the 
strategy used for sequencing the remainder of the BL0.9 cDNA.
On a few occasions some nucleotides could not be resolved due to compression artefacts 
(especially during sequencing with the extension mixes). To overcome this a nucleotide 
analogue of dGTP (dITP) was used in the sequencing reaction. dITP functions by forming a 
weaker secondary structure with the DNA which allows full dénaturation of GC rich regions 
during electrophoresis, therefore eliminating band compressions.
Fig. 3.9. Autoradiograph from the Sequencing of pBL0.9.
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3 .6 .2  Further Sequencing of the pBL0.9 cDNA Insert Using Internal 
O ligonucleotide Primers
To continue the sequencing of the pBL0.9 cDNA insert two oligonucleotides, of 20 base pairs 
length (2 0 mers), homologous to the newly determined sequence were synthesised and 
purified as in section 2.9.9.
CCCTGTCTCCACAIICITCA - to continue sequencing in the same strand as the
reverse primer from nucleotides 188-207.
CTATTGGGTTGGGGGCCAGT - to continue sequencing in the same strand as the
reverse primer from nucleotides 477 -496 .
Both oligonucleotides were checked against the rest of the sequenced plasmid insert to make 
sure of no other homologies than to the desired sequence. This was performed using the 
MicroGenie software (section 2.8 .10). In order to determine the optimum concentration of 
the oligonucleotides for use as primers, sequencing reactions were set up using pBL0.9.
Five different concentrations of oligonucleotide were used; 400, 80, 40, 20  and 4ng/^l (1, 
1 :5 , 1 :10 , 1:20  and 1 :100  dilutions of the original oligonucleotide solution respectively) 
and Ml 3 reverse primer as control. The approximate melting temperature (Tm) of the 
oligonucleotides was calculated using the equation;
Tm (°C) » 2 (A+T) + 4 (G+C)
This gave a value of 60°C for oligonucleotide 1 , so an annealing temperature of 55°C was 
employed. For oligonucleotide 1 the three highest concentrations worked well i.e. 400, 80  
and 4Ong/^|. These concentrations are high when compared to the universal and reverse 
primer concentrations supplied in the Sequenase™ kit (O.Spg per reaction). This increase 
in the effective concentration is possibly due to errors in the spectroscopic measurement of 
the oligonucleotide concentration or a decrease in the hybridisation of the oligonucleotide to 
its target sequence due to impurities in the DNA. For sequencing reactions using 
oligonucleotide 1, a concentration of 40ng/^l was used. By the utilisation of this 
oligonucleotide and 2x extension mixes, another 300  bases were read.
Optimum concentration experiments were also performed for oligonucleotide 2 at 55°C and 
the 80ng/|il concentration appeared to work best. However, even at this optimum 
concentration, the autoradiograph was very faint and so it was decided to determine the 
optimum annealing temperature to try to clarify the sequence. This was performed as for 
the optimum oligonucleotide concentration using temperatures of 50, 55 and 60°C. Both 55 
and 60°C worked but the sequencing reaction appeared to be terminating early and only a 
further 50 bases were determined by this method. To get round this premature 
termination, more enzyme was used (4^1 - see section 2.9 .5) but this failed to alleviate the 
problem, as did increasing the concentration of the labelling mix (section 2 .9 .5 ) by three­
fold.
It was decided that this problem would best be solved by recloning the 0.9kb insert (BL0.9) 
into pGEM™-7Zf(+) (section 2 .7 .1) as this method utilises the sequencing of single­
stranded DNA, thus removing any possible artefacts, like premature termination, caused by 
GC-rich regions and secondary structures. This method also does away with the need for 
internal oligonucleotide primers. The ligation of BL0.9 into pGEM™-7Zf(+) and its 
subsequent sequencing by the above methods was performed by Dr Marion MacFarlane in 
this laboratory.
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3.6.3 Analysis of BL0.9 cDNA Sequence Data
The complete sequence of the 0.9kb p-lyase cDNA fragment BL0.9 was compiled from the 
above information with the aid of the Microgenie software (section 2.8 .10). The incomplete 
sequence of BL0.9 in pUCI 9 and the complete sequence in pGEM™-7Zf(+) are shown in 
figures 3.11 and 3.12 respectively. Only one base difference was found between the two 
sequences (an extra C at position 342) but the pGEM™ sequence contained a long (98 bases) 
poly (A) tail at its 3 ’ end.
These sequences were compared with the Daresbury and GenBank databases (section 2.8.10) 
and no significant matches were found. Thus BLO.9 was assumed to be a novel cDNA 
sequence. The sequence appears to have an open reading frame (figure 3 .12) starting 377  
bases in from the start of the poly (A) tail and there is a polyadenylation site (AATAAA) at 
position 673 to 678. The sequence was checked for a pyridoxal phosphate binding sequence 
(see figure 3.24) but one was not found.
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10 20 30 40 50 60
CATGCCTGCA GGTCGACTCT AGAGGATCCC CGGGTACCGA GCTCTAATTC CCCCAGGGGA
70 80 90 100 110 120
GCTACTTCCT CATTGCAGAC ATCTCAGACT TCAAGAGCAA GATGCCTGAC CTGCCTGGAG
130 140 150 160 170 180
CTGAGGATGA GCCTTATGAC AGACGATTTG CCAAGTGGAT GATCAAAAAC ATGGGCTTGG
190 200 210 220 230 240
TGGGCATCCC TGTCTCCACA TTCTTCAGTC GGCCCCATCA GAAGGACTTT GACCACTACA
250 260 270 280 290 300
TCCGATTCTG TTTTGTCAAG CACAAGGCCA CACTCCAGGC CATGGATGAG AGACTGCGCA
310 320 330 340 350 360
AGTGGAAAGA GCTCCAACCC TGAGGAGGCT GCCCTCAGCC CACCTCGAAC ACAGGCCTCA
370 380 390 400 410 420
GCTATGCCTT AGCACAGGGA TGGCACTGGA GGGCCCAGCT GTGTGACTGC GCATGTTTCC
430 440 450 460 470 480
AGAAAAGAGG CCATGTCTTG GGGGTTGAAG CCATCCTTTC CCAGTGTCCA TCTGGACTAT
490 500 510 520 530 540
TGGGTTGGGG GCCAGTTCTG GGTCTCAGCC TACTCCTCTG TAGGTTGCCT GTAGGGTTTT
550
GATTGTT
Figure 3.11. Nucleotide Sequence of BLO.9 from the sequencing of pBL0.9
The BLO.9 sequence was determined using the dideoxy chain termination method as described 
in section 3.6. The underlined nucleotide sequences indicate the two oligonucleotides used as 
internal primers in section 3.6.2.
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1
CA TGC CTG GAG GTC GAG TCT AGA GGA TCC CCG GGT ACC GAG CTC GAA TTC CGC CAG GGG 
Cys Leu Gin Val Asp Ser Arg Gly Ser Pro Gly Thr Glu Leu Glu Phe Pro Gin Gly
60
AGC TAC TTC CTC ATT GCA CAG ATC TCA GAC TTC AAG AGC AAG ATG CCT GAC CTG CCT GGA 
Ser Tyr Phe Leu He Ala Asp Ile Ser Asp Phe Lys Ser Lys Met Pro Asp Leu Pro Gly
120
GCT GAG GAT GAG CCT TAT GAC AGA CGC TTT GCC AAG TGG ATG ATC AAA AAC ATG GGC TTG
Ala Glu Asp Glu Pro Tyr Asp Arg Arg Phe Ala Lys Trp Met He Lys Asn Met Gly Leu
180
GTG GGC ATC CCT GTC TCC ACA TTC TTC AGT CGG CCC CAT CAG AAG GAC TTT GAC CAC TAC 
Val Gly lie Pro Val Ser Thr Phe Phe Ser Arg Pro His Gin Lys Asp Phe Asp His Thr
240
ATC CGA TTC TGT TTT GTC AAG GAC AAG GCC ACA CTC CAG GCC ATG GAT GAG AGA CTG CGC
lie Arg Phe Cys Phe Val Lys Asp Lys Ala Thr Leu Gin Ala Met Asp Glu Arg Leu Arg
300
AAG TGG AAA GAG CTC CAA CCC TGA GGAGGCTGCCCTCAGCCCCACCTCGAACACAGGCCC 
Lys Trp Lys Glu Leu Gin Pro STOP
360
CAGCTATGCCTTAGCACAGGGATGGCACTGGAGGGCCCAGCTGTGTGACTGCGCATGTTT
420
CCAGAAAAGAGGCCATGTCTTGGGGGTTGAAGCCATCCTTTCCCAGTGTCCATCTGGACT
480
ATTGGGTTGGGGGCCAGTTCTGGGTCTCAGCCTACTCCTCTGTAGGTTGCCTGTAGGGTT
540
TTGATTGTTTCTGGCCTCTCTGCCTGGGGCAGGAAAGGGTGGAATATCAGGCCCGGTACC
600
ACCTTAACCCTGCCAAGGCTCTGTGGCTTCTCTACATCTTCTCCTGTGACCTCAGGATGT
660
TGCTACTGTTCCTAATAAAGTTTTAAGTTATTAGGACCCTCAAAAAAAAAAAAAAAAAAA
720
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
780
AAAAAAAAAAAAAAAAAAA
Figure 3.12. Complete Nucleotide Sequence of BL0.9 cDNA
The BL0.9 cDNA sequence was determined using the single-stranded Erase-a-base™ method 
(Henikoff, 1984; Promega manual, 1990). The deduced amino acid sequence is given below 
the nucleotide sequence. The underlined sequence indicates the polyadenylation signal 
sequence.
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3 .7  FURTHER CHARACTERISATION OF BLO.9 cDNA
3.7.1  Northern Blot Analysis
The authenticity of BLO.9 as a fragment of p-lyase cDNA was checked by Northern blot 
analysis of full-length mRNA size and kidney specificity of expression. Total RNA was 
isolated from male Wistar rat kidney and liver as in section 2.9.1. The A260/A 28O ratio of
all RNA samples used was ascertained and was usually in the region of 1.85 - 2.00, 
indicating them to be of high purity. This RNA was then subjected to Northern blot analysis 
(section 2.10.2). Following electrophoresis, the ethidium bromide stained gel was placed 
under UV illumination and showed two distinct bands in each sample lane (figure 3 .13). The 
higher of these two bands corresponded to the 28S ribosomal RNA subunit and the lower 
band to the 18S subunit (sometimes a third 5S RNA band could be seen in the region of the 
dye front). These bands were used to estimate the size of mRNA of interest as their 
respective sizes are well documented;
The banding was narrow with little or no smearing thus indicating that the rat liver and 
kidney RNA had not been degraded during isolation. It should be noted, however, that for 
some reason there appears to be at least 5>x as much kidney RNA as liver RNA on the 
gel. ____________
A second RNA gel was run with a more equal loading before Northern blotting and subsequent 
probing took place (not shown).
288 rRNA subunit 4781 bp
188 rRNA subunit 1874bp
58 RNA 120bp
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Fig. 3.13. Electrophoretic Analysis of Total Rat Kidney and Liver RNA.
Lanes 1 & 6: Total rat liver RNA (20^g).
Lanes 2 & 5: Total rat kidney RNA (20^g).
Lanes 3 & 4: RNA molecular weight markers (28s, 23s, 18s, 16s, 5s).
Note that the RNA markers appear to be degraded as a clear 238 band cannot be seen.
Figure 3.14 shows the autoradiograph of a Northern blot of Wistar rat kidney and liver that 
has been probed with 35S-labelled BLO.9 (section 2 .11). The blot shows the mRNA for p- 
lyase to have comigrated, approximately, with the 18s rRNA subunit and thus to be 
approximately 1.9kb in length. In order to allow for the discrepancy in the amounts of RNA 
loaded, the autoradiograph was overexposed so that any hybridisation to a liver mRNA would 
become apparent. No such band was observed indicating that expression of BLO.9 is kidney 
specific.
Further analysis of the p-lyase gene was performed on a Northern blot kindly donated by 
Professor James Stevens of the W. Alton Jones Science Center Inc., New York, USA. This 
Northern blot was of mRNA produced from rat kidney proximal tubules and from cultured 
confluent and non-confluent proximal tubule epithelial cells (5^g of each sample per lane). 
The glutamine transaminase K (GTK) activities of these tissues (performed by Prof. 
Stevens) showed that the GTK levels dropped very quickly (5 -10  fold) in culture. The 
Northern blot, probed with BLO.9, also show a decrease in a single band across the three 
lanes (figure 3 .15) which appears to be in approximately the same position as the band in 
the previous Northern blot (figure 3 .14). Unfortunately no molecular weight information 
on the blot was given so it was impossible to estimate the band size and make an accurate 
comparison.
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Fig. 3.14. Autoradiograph of a Northern Blot of Total Rat Kidney And Liver RNA Probed with 
Radiolabelled BLO.9.
Lane 1: Total rat liver RNA (20^g).
Lane 2: Total rat kidney RNA (20^g).
Lane 3: RNA molecular weight markers (as of Fig.3.13.).
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Fig. 3.15. Autoradiograph of a Northern Blot of mRNA from Non-Cultured and Cultured Rat 
Kidney Proximal Tubule Cells.
Lane 1: mRNA from rat kidney proximal tubule epithelial cells (5^g).
Lane 2: mRNA from cultured confluent rat kidney proximal tubule cells (S^g).
Lane 3: mRNA from cultured non-confluent rat kidney proximal tubule cells (5^g).
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3.7.2 Southern Blot Analysis
In order to establish Southern blotting banding patterns for the p-lyase gene a Southern blot
was performed (section 2.10.1) using rat kidney genomic DNA isolated as in section 2.9.3.
Agarose gel electrophoresis of the DNA prior to restriction enzyme digestion indicated that
high molecular weight genomic DNA had been isolated with little or no degradation to smaller
fragments (not shown). An overnight single digestion with the restriction enzyme EcoRI
(section 2 .4 ) followed by agarose gel electrophoresis gave a pattern indicating the
generation of many different sizes of DNA fragments (figure 3 .16). Figure 3 .17 shows the
autoradiograph of this Southern blot once probed with 35s-labelled BLO.9. A simple two
band pattern of hybridisation was observed consistent with the presence of only one p-lyase
gene in rat DNA (as opposed to a family of isoenzymes) with an estimated size of 7kb.
It is assumed that the homology between the probe and other potential p-lyase genes is high.
3 .8 IN VITRO TRANSLATION OF A mRNA CORRESPONDING TO THE BLO.9 cDNA 
FRAGMENT
To confirm the identity of the BLO.9 clone as that of part of the p-lyase gene it was decided to 
select the specific mRNA for BLO.9, from a total mRNA population, by hybridisation to  
immobilised BLO.9 DNA and to translate the selected mRNA into a radiolabelled protein.
This protein could then be detected both by autoradiography and with the anti-p-lyase 
antibody.
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Fig 3.16. Electrophoretic Analysis of Rat Kidney Genomic DNA.
Lane 1: DNA molecular weight markers (as of Fig 3.3.).
Lane 2: EcoRI cut rat kidney genomic DNA (lO^g).
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p-lyase
Bands
Fig. 3.17: Autoradiograph of a Rat Genomic DNA Southern Blot Probed With Radiolabelled
BLO.9.
Lane 1 : EcoRI cut rat kidney genomic DNA (1 O^g).
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3.8.1 Purification of Rat Kidney mRNA
Preparations of rat kidney mRNA were produced using the Quickprep™ kit (section 2.9.2). 
This method, however, was not as successful as was expected and produced insufficient 
amounts of the polyadenylated RNA for in vitro translation. After many attempts at this 
method (and consultations with the manufacturers) the procedure was abandoned in favour 
of a total RNA preparation (section 2,9 .1) followed by selection of the polyadenylated RNA 
by oligo(dT) cellulose column chromatography (section 2.9.2).
10mg of total RNA was loaded onto the column and 20 x 1 ml fractions collected and measured 
spectrophotometrically. Figure 3.18 shows a representative elution profile obtained in the 
isolation of poly[A+] RNA. After a second round of chromatography, the fractions containing 
the mRNA were pooled, precipitated and resuspended in 400|il of water. The concentration 
of mRNA was 750ng/y<l and the Azgq/A zso value was 1 .86  indicating the purity of the mRNA
to be high. This mRNA was then used for hybrid selection and in vitro translation.
3 .8 .2  In Vitro  Translation of Hybrid Selected mRNA
Four plasmids containing cDNA (sections 3.2 and 4 .2 ) were linearised and fixed to 
nitrocellulose. Hybrid selection of the polyadenylated RNA purified in the previous section 
was then performed as of section 2.13.
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Figure 3.18. Elution Profile of Poly (A+) RNA from the First Oligo (dT) Cellulose Column
Total mRNA yield from both column preparations was 300ng (2.7%  of total) with an 
Azgo/Azso of 1 .8 6 .
Prior to the in vitro translation of this hybrid-selected mRNA of BL0.9 (and the three 
clones isolated in chapter 4) the Amersham International rabbit reticulocyte lysate kit 
(section 2 .14 ) was tested by translating the tobacco mosaic virus (TMV) mRNA provided in 
the kit as a control. Figure 3.19 shows the time-course for L-[35S] methionine 
incorporation into TMV peptide by this method. It can be seen from the graph that a plateau 
region occurs after 60 minutes of incubation at 30°C. This time was chosen as the end point 
for all subsequent translations.
To ascertain the optimum salt (Mg2+ and K+) concentrations as described in section 2.14.1, 
the translation procedure was followed using rat kidney mRNA (section 2 .9 .2) and varying 
concentrations of Mg2+ and K+. Figure 3.20 shows the degree of activity obtained with the 
translation system over changing ion concentrations. For K+, the optimal concentration was 
within the region of 192.0mM (the residual level found in the translation system) although 
there was a similar peak at the lower concentration of 120.0mM. However, the difference in 
translation efficiencies (total radioactivity incorporated into protein/total radioactivity in 
the reaction x 1 0 0 ) between the two peaks was so insignificant ( 1 .6% compared to 1 .2 %) 
that it was far easier to leave the translation system at its residual level than to dilute it 
down to the lower salt concentration. With Mg2+ the optimal concentration was about 
2.5mM. Again there was a similar peak of activity at 1.6mM but this time the translation 
efficiencies of the two peaks were the same (3.5% ) and so the higher concentration was 
chosen for the same reason as above.
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Figure 3.19. Time Course for L-[35S] Methionine Incorporation Using TMV mRNA
The incubation was performed at 30°C.
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Figure 3.20. Optimisation of in vitro mRNA Translation: Influence of K+ and Mg2+ 
Concentration
Rat kidney poly (A+) RNA was translated at a concentration of 40ng/^l utilising O.SpiCi 35s- 
methionine/^l. In experiment a. the K+ concentration was 2.1 mM. In experiment b. the 
Mg2+ concentration was 192.0mM. Values represent duplicate determinations.
The four hybrid-selected mRNAs were then translated using these optimal concentrations. 
Two SDS-PAGE gels were run of the translation products (section 2 .5 .5) one of which was 
Western blotted and subject to immunological analysis (sections 2.5.6 and 2.6.3  
respectively) and the other dried down and subjected to autoradiography (section 2.3.9). 
Figure 3.21 shows the autoradiograph of the dried down gel after 30 days exposure at room 
temperature. As can be seen no bands specific to the hybrid-selected mRNAs are discernable 
yet the total mRNA track shows definite translation has taken place. Figure 3.22 shows the 
Western blot of the second gel after immunological analysis using the 
anti-p-lyase antibody. Again no bands specific to the hybrid-selected mRNA lanes are 
discernable and no specific bands are present in the total mRNA lane. The blot was allowed 
to overdevelop in order to ascertain the presence of any faint bands in the translated protein 
lanes. This can be seen in the control kidney cytosol lane by the appearance of more than 
just the 43KPband and also by the non-specific banding patterns in the blank mRNA and all 
other translation lanes.
In figure 3.21, it can be seen that very few proteins appear above 116kD and this could be 
due to degradation of mRNA. However, as the p-lyase band would not be expected to be 
observed in this high molecular weight region, this is unlikely to have affected the 
translation.
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Fig. 3.21. Autoradiograph of SDS-PAGE Gel of In Vitro Translation Products.
Lane 1: Total rat kidney mRNA (I.S^g).
Lane 2: Blank - no mRNA.
Lane 3: TMV mRNA (2.0ng).
Lanes 4, 5, 6 & 7: 0.3kb, 0.9kb (BL0.9), l.Okb and 2.9kb clone hybrid selected rat kidney 
mRNA respectively.
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Fig 3.22: Western Blot of In Vitro Translation Products.
Lanes 1 & 10: Protein molecular weight markers (as of Fig 3.1.).
Lane 2: Rat kidney cytosol (15|xg).
Lane 3: Total rat kidney mRNA (1.5ng).
Lane 4: Blank - no mRNA.
Lane 5: TMV mRNA (2.0|xg).
Lanes 6, 7, 8 & 9: 0.3kb, 0.9kb (BL0.9), l.Okb and 2.9kb clone hybrid selected rat kidney 
mRNA respectively.
3.9 DISCUSSION
The desorbed polyclonal antibody to rat kidney cytosolic cysteine conjugate p-lyase 
(MacFarlane et al, 1989) identified a single protein band of 43kD when used in the 
immunological analysis of rat kidney cytosol. This molecular weight was lower than had 
been previously reported. However, this type of protein sizing is known for its inaccuracy 
and recently in this laboratory a much purer acrylamide has been used for SDS-PAGE work. 
Differences in acrylamide batch and the linearity with respect to the percentage of 
acrylamide used may also be reasons for what is an apparent 7kD loss in weight from the 
work of MacFarlane (using the same purified p-lyase protein and antibody) to these results. 
Previous reports have given various molecular weights for p-lyase. For example, Lash et 
al (1990 ) showed that the molecular weight of human p-lyase was 45kD, Stevens (1 985b) 
showed that rat liver p-lyase is a dimer of 37kD and 43kD proteins and Jones e t al (1 9 88 ) 
has rat kidney cytosolic p-lyase located at the same position on an SDS-PAGE gel as the 
ovalbumin marker (43kD). Thus there is still some controversy over the actual size of p- 
lyase (especially in the case of Jones et al, 1988 as Stevens, who was part of the group, had 
previously found that the rat kidney cytosolic p-lyase had a monomeric molecular weight of
The anti-p-lyase antibody was deemed to be fully functional by inhibition of GTK activity. 
The relatively low inhibition (20% ) was due to the antibody being very dilute in solution. 
Nevertheless, the antibody was used successfully to isolate a cDNA clone of approximately 
0.9kb in length. The reason for only one cDNA clone being isolated was probably due to the 
low titre of the Xgtl 1 library. The library had been in storage at 4°C for a number of 
months and this may have affected the infectivity of the phage. The library may also not 
have been as representative of rat kidney mRNA as expected.
Isolation of a Xgtl 1 recombinant lysogen added weight to the premise that the clone isolated 
was indeed part of the p-lyase cDNA. However this is not in itself proof since demonstration 
that a cDNA encodes an antigenic determinant does not prove that it encodes the protein of 
interest. The smaller size of the p-lyase portion of the fusion protein (26kD) compared to 
the expected weight (i.e. three-quarters of the full p-lyase » 33kD) was first thought to due 
to the presence of 3' non-coding sequences in the DMA. However, when the full BL0.9 
sequence open reading frame data is considered (figure 3 .12) only 106 amino acid long 
peptide should have been translated (approximately 15kD). Taking this into account the 
fusion protein produced by the lysogen method now appears to be too large. The probable 
reason for this is again the inaccuracy of the SDS-PAGE sizing system especially as the p- 
galactosidase fusion peptide was located very high up on the gel, in the region of lowest 
mobility linearity.
One of the main problems encountered during subcloning of the BL0.9 cDNA fragment into 
plasmid vector was the lability of T4 ligase. The enzyme was not used if it was more than 
two months old, but quite often it was found to have lost activity before this time due to the 
lack of temperature control in a communal stock freezer. Only storage of aliquots of T4 DNA 
ligase in a personal freezer could prevent this.
In the BL0.9 subcloning experiment shown in table 3.1, a small number of blue E. coli 
colonies were observed in unligated EcoRI cut controls of pUCl 9 plasmid DNA. This 
indicated that either not all of the DNA had been linearised by the restriction enzyme or that 
spontaneous, non-enzymatic religation had occurred. In either case, the numbers of such 
colonies were so small that they did not affect the results.
Only one of the four white colonies picked contained plasmid with the desired 0.9kb insert 
and the other three were just religated pUCl 9 DNA (false positives). This was probably due 
to random loss of nucleotides from the cut ends of the plasmid DNA prior to ligation. This 
would disrupt the reading frame of the plasmid and hence prevent expression of the p- 
galactosidase gene causing white colony formation.
The main problem encountered with the sequencing of pBL0.9 was the failure of the Ml 3 
universal primer to produce a sequence in the 5' - 3* direction. A further (perhaps 
related) problem was encountered when the Ml 3 reverse primer reached approximately 
nucleotide 550 in the opposite direction. At first it was thought that this was due to a GC 
rich sequence in this region of the cDNA but when the full sequence was revealed using 
pGEM™ (figure 3.12) it was shown to be no more GC rich than the preceding sequence. It is 
possible, therefore, that the 98 base poly (A+) tail of BL0.9 prevented the universal 
primer sequencing due to strong AT interactions. However as the sequence from the 
secondary oligonucleotide primer onwards terminated 150 bases before the start of the poly 
(A+) tail this is unlikely to be the whole reason. What is more likely is that some sort of 
secondary structure formation prevented the further reading of the second oligonucleotide 
primed sequence (it is known that the modified T7 DNA polymerase is impeded by secondary 
structures (Tabor and Richardson, 1987)). A secondary structure might also reduce the 
binding of the universal primer. A further possibility is that the pBL0.9 DNA sample was 
not clean enough and some impurities caused the failure of the T7 DNA polymerase to read 
from nucleotide 550 onwards. As pGEM™ is a single-stranding vector, this would facilitate 
both the universal primer sequencing (no AT interactions or secondary structure 
formation) and DNA purification.
The Northern blot of total rat kidney and liver RNA (figure 3.14) showed that the BL0.9 
probe was highly specific for a single mRNA band in the rat kidney lane. This again adds 
weight to the conclusion that BL0.9 is part of the cDNA for rat kidney p-lyase. The size of 
the band, at 1.9kb, was larger than previously expected as a protein of 4 3 kD should be coded 
for by a mRNA of approximately 1,2kb. The reason for this 0.7kb difference is likely to be 
the presence of non-coding 5' and 3* sequences in the mRNA. Figure 3.12 shows the BL0.9 
sequence to have a 3' non-coding sequence of approximately 370 bases preceding the poly 
(A+) tail. Since most mRNAs have a 5' non-coding region of around 100 bases and inclusion 
of this in the calculation would give a mRNA for p-lyase of approximately 1.9kb, as 
observed.
Further confirmation that a part of the p-lyase cDNA had been isolated was obtained from 
probing of the proximal tubule mRNA Northern blot with pBLO.9 (figure 3 .15). The 
decrease in the intensity of the observed single band from uncultured rat kidney proximal 
tubule cells to cultured cells, which mirrors the 5 -10 fold decrease seen in the GTK levels 
in these cells, is strongly indicative of BL0.9 being part of the p-lyase cDNA.
The failure of the in vitro translation of hybrid selected mRNA to confirm the identity of the 
BL0.9 clone as part of the p-lyase cDNA may have been due to a number of factors. The 
hybrid selection method is limited in many ways, including a low rate of hybridisation of the 
poly (A+) RNA meaning that the completion of the hybridisation reaction is difficult to  
obtain (Britten and Davidson, 1985). The coupling procedures used to immobilise the 
plasmid DNA can also result in base substitution and require a large excess of the molecules. 
Typically only 50 - 70% of the plasmid DNA binds to the nitrocellulose. Further loss of 
DNA occurs by leakage under normal prehybridisation and hybridisation conditions 
(Bunemann and Westholf, 1983). Other common problems include degradation of the poly 
(A+) RNA during hybridisation and elution from the filters. It is therefore very likely that 
the 2 1^ solution added to the in vitro translation system contained little or no poly (A+) RNA 
and, as it was impossible to measure this beforehand, cannot be verified.
The in vitro translation system was also dependent on a number of factors. When calculating 
the optimal salt concentration for translation the results obtained were far from ideal. 
Identifiable peaks of translation efficiency were not observed (figure 3 .20 ) and the K+ and 
Mg2+ concentration values chosen still had very low translation efficiencies. However the 
autoradiograph of the in vitro translation (figure 3 .21 ) does show that translation did occur 
with total rat kidney poly (A+) RNA. This low level of translation seen may have been due to 
various elements. Hemin, a suppressor of an inhibitor of the initiation factor EIF2a, was 
not included in the reaction and in its absence protein synthesis in the reticulocyte lysate 
system ceases after a short period of time (Jackson and Hunt, 1983). The optimal RNA 
concentration of the system could not be calculated for the hybrid selected RNA and the RNA 
solution may have contained translation inhibitors such as oxidised thiols, low 
concentrations of double stranded RNA and polysaccharides. Calcium may also have been 
present in the reaction mixture, even though DEPC-treated MilliQ purified water was used, 
and this could have caused reactivation of micrococcal nuclease and thus degradation of the 
RNA template.
Ideally any translated protein should be immunoprecipitated prior to SDS-PAGE analysis. 
However the anti-p-lyase antibody was far too dilute and in too short supply for this 
procedure to be feasible. The dilution of the antibody is also the reason for the lack of any 
specific banding above background in the total rat kidney poly (A+) RNA lane of the in vitro 
translation Western blot (figure 3.22), despite the fact that translation of the RNA had 
indeed taken place.
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3.10 POSTSCRIPT
Since completion of this work another PhD student, Miss Sandra Perry, working in the 
laboratory has performed experiments using a Wistar rat kidney 5'-stretch cDNA library 
in Xgtl 0 (Clontech). This library was screened using 32p-radiolabelled BL0.9 as a cDNA 
probe, the poly (A+) tail having been excised by Avail digestion. A full length p-lyase cDNA 
was isolated, sequenced using the Erase-a-base system and found to match BL0.9, described 
by me herein, at its 3' end. The cDNA is 1867bp in length and so compares well with the 
calculated size of 1.9kb for the rat kidney p-lyase mRNA (section 3.7.1 ).
Further inspection of the sequence has revealed a consensus pyridoxal binding sequence 
between nucleotides 975 and 991. This compares favourably with other pyridoxal 
phosphate binding sequences (figure 3.23) with only single base changes responsible for 
amino acid differences. The positioning of this sequence within the 1867bp sequence 
explains its absence from BL0.9.
The open reading frame gives a protein of weight 47.7kD which is higher than the value 
produced by Western blot analysis in section 3.2.1 (yet lower than previous quoted values). 
The deduced amino acid sequence has been compared to the percentage amino acid residue 
content of purified rat kidney cytosolic p-lyase determined by Dr N. Vermeulen of Free 
University, Amsterdam (personal communication) and found to have an R2 value of 0.98  
indicating a virtually complete similarity.
The 1867bp cDNA has been ligated into the plasmid expression vector pEE6 and transfected 
into COS-1 cells. Western blot analysis of the transfected cells has demonstrated the 
synthesis of a 48kD protein. Cytosolic extracts from the transfected cells exhibited a 7-10  
fold increase in p-lyase activity (using DCVC and TFEC as substrates) which was inhibited 
by aminooxyacetic acid. The transfected cells also exhibited elevated glutamine 
transaminase activity compared to control cells.
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p-lyase Rat Ser Ala Gly Lys Ser Phe
AT Pig 
AspT Pig 
AspT Human 
AspT Pig Mitoch. 
AspT Human Mitoch.
Ser
Ser
Ser
Ser
Ser
Val
Phe
Phe
Tyr
Tyr
Ser
Ser
Ser
Ala
Ala
Lys
Lys
Lys
Lys
Lys
Gly
Asn
Asn
Asn
Asn
Phe
Phe
Phe
Met
Met
TAT Rat Ser Phe Leu Lys Ser Asn
Figure 3.23. Pyridoxal Phosphate Binding Sites
AT; Alanine Aminotransferase 
AspT; Aspartate Aminotransferase 
TAT; Tyrosine Aminotransferase
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This subsequent work has therefore confirmed that the cDNA BL0.9 described in this thesis 
is definitely part of the rat kidney cytosolic p-lyase cDNA. A report of this work has 
recently been published (Perry et al, 1993).
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CHAPTER 4
THE ISOLATION, CLONING AND CHARACTERISATION OF FURTHER p-LYASE
cDNAs
4.1 INTRODUCTION
The results in this chapter are from experiments performed on a Sprague-Dawley Xgtl 1 
rat kidney cDNA library (section 2.2 .4) to isolate further cDNA fragments of the p-lyase 
gene (as only one incomplete clone was isolated in the previous chapter). The work was 
performed in collaboration with Dr. M. MacFarlane and the final year undergraduate project 
students Ian Franklin and Sandra Baldwin. Further work was undertaken to compare the 
fragments obtained with each other and BL0.9 and also to characterise the gene.
4 .2  ISOLATION OF FURTHER RECOMBINANT cDNA CLONES FROM A RAT KIDNEY 
LIBRARY
4.2.1 Verification of the Anti-p-Lyase A ntibody
In order to confirm that the anti-p-lyase antibody raised against Wistar rat kidney 
cytosolic p-lyase protein (MacFarlane e t al, 1989) would cross-react with the p-lyase 
protein in Sprague-Dawley rat kidney cytosol, a Western blot of both Sprague-Dawley and 
Wistar rat kidney cytosol (1 5^g each) was performed. The kidney cytosols were produced 
by the method in section 2.5.2 and the Western blot performed as of section 2.5.6. The 
antibody reacted with a single band, of molecular weight 43 kD, in both lanes (figure 4 .1) 
showing the antibody to be valid for the screening of a Sprague-Dawley kidney Xgtl 1 
lib rary .
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Fig. 4.1. Western Blot of Wistar Rat Kidney Cytosol and Sprague-Dawley Rat Kidney 
Cytosol.
Lanes 1 & 4: Protein molecular weight markers («2 -macroglobulin, 1 80kD;
p-galactosidase, 116kD; fructose-6-phosphate kinase, 84kD; pyruvate kinase, 58kD; 
fumarase, 48.5kD; lactate dehydrogenase, 36.5kD; triosephosphate isomerase, 26.6kD). 
Lane 2: Wistar rat kidney cytosol (15^g).
Lane 3: Sprague-Dawley rat kidney cytosol (15(iig).
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4 .2 .2  Isolation of cDNA Clones Using the Anti-p-Lyase Antibody
The Sprague-Dawley rat kidney cDNA library (section 2 .2 .4 ) was titred using the method 
detailed in section 2.6.1 and using the Extravidin™-alkaline phosphatase detection system 
(section 2.2 .3). This showed the library to have a titre of 5 x 1 0 8  pfu/ml ( a much higher 
titre than the Wistar Xgtl 1 library but still lower than the titre of 1-9x109 pfu/ml quoted 
by the manufacturers). The library was then screened as described in section 2.6.3. From 
this initial screening of 100,000 plaques, 6 positive clones were identified and isolated. A 
second round of screening (section 2.6.4) was performed on these clones and only 4 of them 
reacted positively with the anti-p-lyase antibody. After a third round of screening the 
number of positive clones was reduced to 3 and these were used to prepare phage stocks as 
described in section 2 .6 .2 .
4 .2 .3  Determination of the Size of the cDNA Inserts
The 3 recombinant plaque-purified clones were used to prepare phage DNA from as 
described in section 2.6.5. The cDNAs were released from Xgtl 1 (figure 2.3) by digestion 
of the phage DNA with the restriction endonuclease EcoRI (section 2.4) and the digested 
material (10^g) run on a 1% (w /v) agarose gel (section 2.3 .5). Figure 4.2 shows the 
agarose gel visualised by ethidium bromide staining (section 2.3 .6) and demonstrates that 
the 3 cDNA inserts have been released. To determine the molecular weights of the cDNAs a 
graph (not shown) of the migration of the X Flind III DNA fragments against their molecular 
weights was plotted as in section 3.2.3 (figure 3.4).
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Fig. 4.2 Electrophoretic Analysis of the Sprague Dawley cDNA Clones.
Lanes 1 & 8: X Hindlll DNA molecular weight markers (23.31 kb, 9.48kb, 6.56kb, 4.36kb, 
2.32kb, 2.03kb, 0.60kb).
Lanes 2, 4 & 6: Uncut phage DNA of clones 1, 2 & 3 respectively (Hig).
Lanes 3, 5 & 7: EcoRI cut DNA of clones 1, 2 & 3 respectively (10^g) showing the insert 
sizes.
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The molecular weights of the cDNA inserts were then interpolated (table 4.1 ) from this 
standard graph and shown to be 1 .Okb, 0.45kb and 2.9kb respectively. The 1 .Okb and 
0.45kb were obviously not full length p-lyase cDNAs and the 2.9kb was approximately 
twice the expected length of the p-lyase cDNA calculated from the peptide molecular weight 
(43kD). These cDNAs will subsequently be referred to as BL1.0, BL0.5 and BL2.9 
respectively.
4 .3  ISOLATION AND CHARACTERISATION OF XGT11 RECOMBINANT LYSOGENS
So that the coding potential of the clones BL1.0, BL0.5 and BL2.9 could be ascertained and to 
elucidate whether the cDNAs isolated correspond to the p-lyase protein, lysogens were 
prepared using the 3 clones as detailed in section 2.6.7.
Crude lysate was prepared (section 2.4 .7) using 4 temperature sensitive Y1089 colonies of 
BL1.0, 2 colonies of BL2.9 and 1 colony of BL0.5. Again a crude lysate was also prepared 
from a colony that did not grow at 37°C and this was used as a non-lysogenic control for this 
experiment. The lysates were analysed for protein concentration by the Lowry method 
(section 2.5.1 ) and 30^g of each was loaded onto an SDS-PAGE gel and Western blotted 
(along with 1 O^g rat kidney cytosol as a control) as detailed in section 2.6.6. Figure 4.3  
shows this Western blot and it can be seen that the anti-p-lyase antibody recognised 3 
major protein bands corresponding to the 3 clones. Once again the lysogen lanes contained 
numerous bands, as did the cytosol lane, as explained in the previous chapter (section 3.3). 
The molecular weights of the fusion proteins were calculated from a semilog graph of the 
mobilities of the molecular weight markers versus their known weights (not shown). Once 
the 114kD size of p-galactosidase was subtracted this gave peptide weights of 38kD for 
BL1.0, 12kD for BL0.5 and 10kD for BL2.9 respectively. These weights correspond to the 
full length cDNAs of BL1.0 and BL0.5 being expressed but for the BL2.9 clone the expressed 
polypeptide was smaller than expected. This was possibly due to a stop codon within BL2.9 
terminating the translation process.
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Fig. 4.3. Western Blot of the Xgtl 1 Recombinant Lysogens in E. co//'Y1089.
Lane 1: Protein molecular weight markers (as of Fig. 4.1.).
Lanes 2, 3, 4 & 5: Crude protein extract from BL1.0 lysogénie Y1089 (30^g). 
Lane 6: Control, non-lysogenic Y1089 extract (3O^g).
Lane 7: Control, rat kidney cytosol (1 5^g).
Lane 8: Crude protein extract from BL0.5 lysogénie Y1089 (30^g).
Lanes 9 & 10: Crude protein extract from BL2.9 lysogénie Y1089 (SO^g).
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4 .4  SUBCLONING OF BL1.0, BL0.5 AND BL2.9 INTO THE PLASMID VECTOR 
pU C l 9
To continue with the investigation of the BL1.0, BL0.5 and BL2.9 the cDNA inserts were 
subcloned from the bacteriophage Xgtl 1 into the plasmid pUC19 as described in section 
2.7.1. This was performed for the reasons outlined in section 3.4., i.e. it is easier to 
recover substantial amounts of insert DNA from a plasmid preparation than a bacteriophage 
preparation and pUCl 9 is an ideal vector for the sequencing of the insert.
4.4.1 Preparation of Plasmid DNA and Recombinant Phage (B L1.0, BL0.5 
and B L2.9) DNA for Subcloning
pUC19 plasmid DNA was prepared and linearised as described in sections 2.7.2 and 2.7.1 
respectively. Recombinant phage DNA for all 3 Sprague-Dawley was also prepared by the 
method detailed in sections 2.6.6 and 2.7.1. Both the pUCl 9 DNA and phage DNA 
preparations were diluted with sterile distilled water to give a final concentration of 
5ng/jil.
4 .4 .2  Results of Subcloning Experiments
Again (as in section 3.4.2) the T4 ligase enzyme and competent cells (sections 2.7.3 and
2.7.4) were checked before subcloning took place. Once the system was working 
satisfactorily the 3 inserts were ligated into pUC19 using insert to plasmid molar DNA 
ratios of 1:1 and 3:1.
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A great number of problems were encountered with the subcloning of the 3 Sprague-Dawley 
phage inserts. The main problem appeared to be the production of false positives i.e. white 
colonies on X-gal plates which, when plasmid DNA was prepared and digested with EcoRI, 
contained no insert. Another problem was that the size of 2.9kb insert was very close to 
that of pUCl 9 DNA (2.7kb). Thus it was very difficult to distinguish between the two when 
they were run on an agarose gel. Various tactics were employed including digesting the 
plasmid/insert preparations with other enzymes, in addition to EcoRI, to try and fragment 
the pUCl 9 DNA whilst leaving the 2.9kb insert intact.
Eventually all 3 Sprague-Dawley inserts were subcloned into pUCl 9 although in doing so 
the BL2.9 cDNA appeared to have decreased in size to 2.7kb, possibly due to the presence of 
an EcoRI site very close to one end which had not been detected in the phage DNA digestion 
(section 4 .2 .3).
4 .4 .3  Isolation of Purified BL1.0, BL0.5 and BL2.9 inserts
In order that any cross-hybridisation between the 4 clones isolated so far (1 Wistar and 3 
Sprague-Dawley) could be ascertained and also to subsequently use the cDNAs as probes to 
examine any modulation of the p-lyase gene under different conditions (Chapters 5 and 6 ) it 
was necessary to perform large scale plasmid preparations (section 2.7 .3) and then to 
purify enough of the insert so that it could be used for radioactive labelling (section 2 .1 1 ). 
As in section 3.4.3, 25^g of plasmid DNA from the 3 clones was digested with EcoRI 
overnight and run in a single well on a 1% (w /v ) agarose gel for BL0.5 and BL1.0 and a 
0.6% (w /v ) agarose gel for BL2.9. The insert was then purified by the Geneclean™ method 
(section 2.3.8) and a yield of approximately 5^g recovered.
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4.4.4 Postscript
In later experiments (section 4 .7) the pUCl 9 derived plasmid pBLZ.9 (section 4 .4 .3 ) was 
purified and used to produce a radiolabelled probe. This was, in turn, used to probe a 
Northern blot of rat kidney and liver total RNA (sections 2.9.1 and 2.10.2 respectively). 
Figure 4.4 shows the result of this experiment. As can be seen the 2.7kb insert did not 
hybridise to either the rat kidney or liver RNA lanes and instead hybridised very strongly to 
the RNA molecular weight markers.
By this time part of the sequence of the pUCl 9 based pBL2.9 had been elucidated by Dr. M. 
MacFarlane using the Sequenase™ procedure (section 2.8). This was then compared, using 
the Microgenie software and Daresbury/Genbank databases (section 2.8 .10), with the 
sequences for £  coli ribosomal RNA (the 23s and 16s RNA markers used). The sequences 
matched exactly and thus it was inferred that the 2.7kb insert subcloned into pUCl 9 was, in 
fact, of £  coli origin and that something had gone wrong during the subcloning procedure. 
The cDNA insert from the Xgtl 1 clone BL2.9 was resubcloned into pGEM™-7Zf(+) (section
2.7.1 ) because of the problems encountered with pUCl 9 cloning and also because of the ease 
of sequencing (by the Erase-a-base method) of a plasmid insert of this size without the use 
of internal oligonucleotides.
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Fig. 4.4. Autoradiograph of a Northern Blot of Total Rat Kidney and Liver RNA Probed with 
Radiolabelled BL2.9.
Lanes 1 & 4: RNA molecular weight markers (28s, 23s, 18s, 16s, 5s).
Lane 2: Total rat liver RNA (2O^g).
Lane 3: Total rat kidney RNA (20^g).
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4 .5  RESTRICTION ENZYME MAPPING OF THE RECOMBINANT PLASMIDS 
pBLI.O  AND pBLO.5
As in section 3.5 the restriction enzymes Pst I, Bgl I, Sac I, Hind III and Xba I were used, by 
themselves and in conjunction with EcoRI, to map the plasmids pBLI.O and pBLO.5. The 
DNA was digested overnight and run on 4% (w /v) agarose gels (sections 2.4 and 2.3.5  
respectively). Figures 4.5 and 4.6 show the gels of pBLO.5 and pBLI.O respectively.
Figure 4.5 displays the fact that only Pst I and Bgl I cut the 0 .5kb insert DNA while figure
4.6 shows Pst I, Sac I and Bgl I were able to cut within the I.Okb insert DNA. Figures 4.7  
and 4.8 show restriction maps of the 0 .5kb and 1 .Okb inserts of pBLO.5 and pBLI .0 
respectively, both constructed from the above information.
The information from this experiment showed no immediately identifiable overlaps between 
the maps of pBL0.9, pBLO.5 and pBLI .0. However, because of the size of the mRNA 
predicted in section 3.7.1 (1.9kb) it was possible for the 3 DNA inserts to overlap at their 
ends where none of the restriction enzymes cut. For this reason cross-hybridisation 
experiments (section 4 .6 .2) were carried out.
4 .6  FURTHER CHARACTERISATION OF THE 3 SPRAGUE-DAWLEY CLONES 
BL0.5, BL1.0 AND BL2.9
4.6.1  Northern Blot Analysis
To ascertain the size of rat kidney mRNA hybridising to the 3 clones and to confirm that they 
were all, indeed, coding for p-lyase (i.e. they all hybridised to a single 1.9kb band in the rat 
kidney RNA lane only) total RNA was isolated from male Wistar rat kidney and liver as in 
section 2.9.1. The RNA was then subjected to Northern blot analysis (sections 2.10.2 and 
3 .7 .1 ).
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1 2 3 4 5 6 7 8 9 10 1 1 12 13 14
Fig. 4.5. Electrophoretic Analysis of pBLO.5 Restriction Mapping.
Lanes 1, 8 & 14: X Hindlll/<j>X174 Haelll DNA molecular weight markers (23.31 kb, 
9.48kb, 6.56kb, 4.36kb, 2.32kb, 2.03kb, 1.35kb, 1.08kb, 0.88kb, 0.60kb, 
0.31 kb, 0.28kb, 0.27kb, 0.23kb, 0.1 9kb).
Lane 2: pBLO.5 DNA (4.0|iig) cut with EcoRI.
Lanes 3 & 4: pBL0.5 DNA cut with Xbal/EcoRI and Xbal respectively.
Lanes 5 & 6: pBL0.5 DNA cut with Hindlll/EcoRI and Hindlll respectively.
Lanes 7 & 9: pBL0.5 DNA cut with Sacl/EcoRI and Seal respectively.
Lanes 10 & 11: pBL0.5 DNA cut with Bgll/EcoRI and Bgll respectively.
Lanes 12 & 13: pBL0.5 DNA cut with Pstl/EcoRI and Pstl respectively.
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Fig. 4.6. Electrophoretic Analysis of pBLI.O Restriction Mapping.
Lanes 1, 8 & 14: >. Hindlll/<j)X174 Haelll DNA molecular weight markers (23.31 kb, 
9.48kb, 656kb, 4.36kb, 2.32kb, 2.03kb, 1.35kb, 1.08kb, 0.88kb, 0.60kb,
0.31 kb, 0.28kb, 0.27kb, 0.23kb, 0.19kb).
Lane 2: pBLI.O DNA (4.0^g) cut with EcoRI.
Lanes 3 & 4: pBLI.O DNA cut with Xbal/EcoRI and Xbal respectively.
Lanes 5 & 6: pBLI .0 DNA cut with Hindlll/EcoRI and Hindlll respectively.
Lanes 7 & 9: pBLI.O DNA cut with Sacl/EcoRI and Seal respectively.
Lanes 10 & 11: pBLI.O DNA cut with Bgll/EcoRI and Bgll respectively.
Lanes 12 & 13: pBLI .0 DNA cut with Pstl/EcoRI and Pstl respectively.
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Once again the Azgq/A zqo ratios of all RNA samples were ascertained to be in the range 1.85 -
2.00 and the three 28s ribosomal RNA subunit, 18s RNA subunit and 5s RNA subunit bands 
were observed on the agarose gels following ethidium bromide staining.
Figures 4.9, 4 .10  and 4.11 show the autoradiographs of Northern blots of Wistar rat kidney 
and liver RNA probed with 35S-labelled BLO.5, BL1.0 and BL2.9 respectively. Using the 
known molecular weights of the 28s, 18s and 5s bands, as of section 3.7.1, the following 
information was obtained: The BLO.5 probe hybridised to a single 0.9kb band, in the kidney 
RNA lane only. The BL1.0 probe, however, hybridised to a single 2.5kb band (the presence 
of a lower fainter band was observed but this was very smeared), in the kidney RNA lane. 
Some uniform smearing could be seen in both the molecular weight marker and liver RNA 
lanes but this was probably non-specific binding of the radiolabelled DNA. Finally, the 
BL2.9 probe hybridised to a single 3.2kb band in the kidney RNA lane, with a faint band of 
the same size in the liver RNA lane.
4 .6 .2  Southern Blot Analysis
i. Cross-Hybridisation Studies
The radioactively labelled probes BLO.5, BL1.0 and BL2.9 (section 4 .4 .3 ) were used to 
probe Southern blots of EcoRI digests of the plasmids pBL0.9, pBL0.5, pBLI.O and pBL2.9, 
to reveal if there was any homology between the insert sequences. The amount of each 
plasmid digested was calculated so as to produce 500ng of insert on the gel.
1 2 3
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I
Fig. 4.9. Autoradiograph of a Northern Blot of Total Rat Kidney and Liver RNA Probed with 
Radiolabelled BLO.5.
Lane 1: Total rat liver RNA (ZO^g).
Lane 2: Total rat kidney RNA (20|ug).
Lane 3: RNA molecular weight markers (as of Fig.4.4.).
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Fig. 4.10. Autoradiograph of a Northern Blot of Total Rat Kidney and Liver RNA Probed with 
Radiolabelled BL1.0.
Lane 1: Total rat liver RNA (20^g).
Lane 2: Total rat kidney RNA (20|ug).
Lane 3: RNA molecular weight markers (as of Fig.4.4.).
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1 2 3
Fig. 4.11. Autoradiograph of a Northern Blot of Total Rat Kidney and Liver RNA Probed with 
Radiolabelled BL2.9.
Lane 1: Total rat liver RNA (20ng).
Lane 2: Total rat kidney RNA (20^g).
Lane 3: RNA molecular weight markers (as of Fig.4.4.).
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The plasmid digests were run on 1% (w /v ) agarose gels along with X Hind III markers.
These gels were then Southern blotted (section 2.10.1) and probed with the 4 plasmid 
i inserts (section 2.11) as indicated. The autoradiographs (not shown) of all 4 blots
indicated that there was no homology between any of the 4 plasmid inserts. This agreed with 
the information obtained from the restriction enzyme mapping studies performed in section 
4.5.
ii. Genomic DNA Studies
Rat kidney genomic DNA was isolated as of section 2.9.3 and was used to ascertain the 
Southern blotting banding patterns for the 3 Sprague-Dawley clones for comparison with 
each other and with the pattern produced by the BL0.9 clone (section 3.7.2). Once again the 
DNA was digested overnight with EcoRI and electrophoresed on a 1 % (w /v ) agarose gel. The 
ethidium bromide staining of this gel showed the genomic DNA to have been completely 
digested into a number of differently sized fragments (figure 3 .17)
Figures 4.12, 4.13 and 4.14 show the autoradiographs of this gel once Southern blotted and 
probed with 35S-labelled BLO.5, BL1.0 and BL2.9 respectively. Again simple patterns of 
hybridisation were observed, consistent with the presence of only one p-lyase protein in the 
kidney cytosol. However, with the exception of the patterns produced by BLO.5 and BL2.9 
which were very similar to each other, the banding patterns were different when compared 
with each other and with that produced by the radiolabelled BL0.9 clone (section 3.7 .2).
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1 2
Fig. 4.12: Autoradiograph of a Rat Genomic DNA Southern Blot Probed with Radiolabelled 
BLO.5.
Lane 1: DNA molecular weight markers (as of Fig. 4.2.).
Lane 2: EcoRI cut rat kidney genomic DNA ( l O^g).
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Fig. 4.13: Autoradiograph of a Rat Genomic DNA Southern Blot Probed with Radiolabelled 
BL1.0.
Lane 1: DNA molecular weight markers (as of Fig. 4.2.).
Lane 2: EcoRI cut rat kidney genomic DNA (1 O^g).
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1 2
Fig. 4.14: Autoradiograph of a Rat Genomic DNA Southern Blot Probed with Radiolabelled 
BL2.9.
Lane 1: DNA molecular weight markers (as of Fig. 4.2.).
Lane 2: EcoRI cut rat kidney genomic DNA (1 O^g).
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4 .7  SEQUENCING OF THE O.Skb, I.O kb  AND 2 .9kb  INSERTS IN THE PLASMIDS 
pBLO.5, pBLI.O  AND pBL2.9
For the pUC19 based plasmids pBLO.5 and pBLI.O plasmid DNA sequencing was performed 
using the Sequenase™ procedures described in section 2.8. For the pGEM plasmid pBL2.9 
the Erase-a-base™ procedure was used, due to the size of the insert (section 2.7.1).
Using these two methods the sequences for the 3 inserts were elucidated. No problems were 
encountered during the sequencing of any of the 3 clones and the O.Skb (O.Skb) clone was 
sequenced without the need for the use of internal oligonucleotides. The actual lengths of the 
inserts were shown to be: BLO.5; 298bp, BL1.0; 995kb and BL2.9;
Again the sequences of the inserts BLO.5, BL1.0 and BL2.9 were compiled from the above 
data with the aid of the Microgenie software (section 2.8.10). These sequences (not shown) 
were compared with the Daresbury and Genbank databases (section 2.8 .10) and also with 
each other. No sections of the 3 Sprague-Dawley sequences were found to be homologous 
with the each other or with the sequence for BLO.9 (figure 3.11) which again agreed with 
the data obtained in section 4.5. On comparison with the Daresbury and Genbank databases it 
was found that BL1.0 was, in fact, part of the sequence for a mouse y-interferon receptor 
gene. BLO.5 and BL2.9, however, showed no significant matches and were therefore 
assumed to be novel DNA sequences.
4 .8  IN VITRO TRANSLATION OF THE BLO.5, BL1.0 AND BL2.9 CLONES
To finally establish whether BLO.5, BL1.0 and BL2.9 were actually part of the p-lyase gene 
(along with the BL0.9 clone isolated in Chapter 3) it was decided to hybrid select the 
specific mRNA for each clone and then to translate this selected mRNA into protein to be 
detected by autoradiography and the anti-p-lyase antibody.
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The results for these experiments have already been presented in sections 3.8.1 and 3.8.2 
and will not be reiterated here.
4 .9  DISCUSSION
In this chapter, as in the previous chapter, a Xgtl 1 cDNA library was screened to produce 
several presumptive clones. These clones were then subjected to various assays to verify 
that their sequences were derived from the gene of interest i.e. rat kidney cytosolic cysteine 
conjugate p-lyase.
Firstly, the desorbed polyclonal antibody to Wistar rat kidney cytosolic p-lyase 
(MacFarlane et al, 1989), used previously, was tested for its antigenicity to Sprague- 
Dawley kidney cytosolic p-lyase (section 4 .2 .1 ) and was found to produce a single protein 
band, on a Western blot, of molecular weight 4 3 kD. This agreed with the size previously 
obtained for the Wistar p-lyase and so it was taken that there was no significant difference 
in kidney p-lyase between the two strains. The antibody was therefore used for the 
screening of a Sprague-Dawley kidney Xgtl 1 cDNA library.
3 clones were obtained from this library (3 more being false positives upon further rounds 
of screening) which was an adequate number of clones to expect given that the titre of the 
library was 10x lower than the manufacturers protocol. Of the three clones obtained by 
this method 2 were well within the size expected. The third, however, appeared to be 
excessively large, at 2.9kb, when compared to both the expected lengths of the p-lyase cDNA 
(1 .2kb) and the mRNA from section 3.7.1 (1.9kb). No reason could be seen for this, other 
than BL2.9 not being p-lyase in origin or there being a redundant EcoRI site within its 
sequence preventing it from being cleaved, at that point, during the determination of the 
inserts' sizes (section 4.2 .3).
Isolation of 3 Xgtl 1 lysogens (section 4.3) showed the sequences to produce proteins 
detected by the anti-p-lyase antibody. However, as stated previously, this was just the 
reidentification of the same property used to select the clones originally (Kimmel, 1987b). 
Despite this, BLO.5 and BL1.0 both produced proteins equivalent to their full length coding 
potential but BL2.9 produced a very small protein (10kD) for its large molecular weight. 
This was, again, probably due to a stop codon within its coding sequence.
As in chapter 3, all subcloning experiments included controls and the T4 ligase used was
checked for its viability beforehand. Because of these precautions no major problems were 
encountered during these procedures (section 4.4). Again, small numbers of blue E  coli 
colonies were seen in the unligated, EcoRI cut controls due to spontaneous religation and 
false positives caused by exonuclease activity were a complication when it came to screening 
the putative transformants but, so it appeared, all 3 inserts were ligated into pUCI 9 quite 
easily. However, this was not the case and somehow, during the preparation of phage DNA 
for BL2.9 (section 2 .6 .6 ), E  coli DNA was coproduced. Upon isolation of the BL2.9 cDNA 
insert with EcoRI (section 2.7.1) a 2.7kb fragment of E  co//DNA was also isolated and it 
was this second fragment that was subcloned into pUCI 9. The slight change in molecular 
weight was observed but this was thought to be due to discrepancies in the accuracy of the 
agarose gel sizing. Northern blot homology and sequencing of the 2.7kb insert proved it to 
be E  coli in origin which was a substantial setback in the characterisation of the clones.
The results of the enzyme mapping of the 3 inserts (section 4.5) implied that BLO.5, BL1.0 
and BL0.9 (from the previous chapter) were not related, although it was still possible at 
this stage to envision the 3 clones overlapping at their 5' and 3' ends (where the restriction 
enzymes used did not cleave). Added together in this fashion their combined molecular 
weights would have been approximately 2.Okb, which compared well with the 1.9kb mRNA 
from section 3.7.1. It was not known how this data fitted in with BL2.9, as this clone was 
still being resubcloned at that time.
The Northern blots of total rat kidney and liver RNA (figures 4.9, 4 .10  and 4 .11) showed 
the radioactively-labelled clones BLO.5 and BL1.0 to be specific for single bands in rat 
kidney whereas BL2.9 picked up a faint band in the liver that was the same size as the single 
kidney band. The differing sizes of the mRNAs hybridised to by the cDNA probes again 
indicated that they were of different origins from each other. At 0.9kb, the BLO.5 mRNA 
was considered too small to code for p-lyase. The sizes of the BL1.0 and BL2.9 mRNAs 
(2.5kb and 3.2kb respectively) appeared to be too large for p-lyase.
The cross-hybridisation studies (section 4 .6 .2) demonstrated the lack of homology between 
all 4 clones isolated, a conclusion intimated by the restriction enzyme mapping performed 
previously (section 4.5). From this data alone it was still theoretically possible, at this 
stage, for all the clones to be derived from p-lyase and to be non-overlapping contigs. 
However, in light of the preceding information this was not probable.
The banding patterns produced by the 3 radiolabelled Sprague-Dawley inserts on Southern 
blots of total genomic DNA from rat kidney (section 4.6.2) again showed the clones isolated 
to be from dissimilar genes. The patterns of BLO.5 and BL2.9 appeared to be analogous but 
all previous data would suggest otherwise.
The sequencing of the Sprague-Dawley clones (section 4.7) posed no major problems. By 
this point of the characterisation strategy it was almost certain that the Sprague-Dawley 
and Wistar clones were heterologous and the sequencing data only served to vindicate this 
conclusion.
The failure of the in vitro translation of hybrid selected mRNA (section 4 .8 ) has already 
been discussed at length in section 3.9. The fact that the 3 Sprague-Dawley clones were not 
p-lyase does not invalidate this analysis but it clearly lessens its overall importance to this 
discussion.
All of the evidence in this chapter points to one fact; the anti-p-lyase antibody used to 
screen the Xgtl 1 Sprague-Dawley rat kidney library cross-reacted with 3 proteins that 
were not p-lyase. In fact, one of these is now known to be a mouse y-interferon receptor 
gene (it is probable that the rat equivalent has yet to be sequenced and so the database 
produced the closest match possible) though the origins of the other 2 clones is 
unknown.
The reasons why this could have occurred are many and varied. In this study a polyclonal 
antibody against p-lyase was used. It was not known to which part of the amino acid 
sequence of p-lyase the antibody bound, binding to post translational modifications obviously 
being undesirable (Kimmel, 1987a). The main disadvantage of using polyclonal antibodies 
is that it could lead to high backgrounds during screening of phage plagues, a problem seen 
in the screening of both the Sprague-Dawley and Wistar cDNA libraries (sections 4.2 and
3.2 respectively). If the amount of immunoreactive material per plaque was low this too 
would have caused an increased signal to noise ratio.
These high backgrounds, that could have lead to false positive recognition, could also have 
been due to the fact that most antisera contain IgG components that bind to E  coli proteins. 
This can be seen on the Western blot of the recombinant lysogen preparations (figure 4.3). 
The high sensitivity of the alkaline phosphatase detection system can amplify this 
contamination of primary antibody with anti-E coli IgG and make it appear more 
pronounced or it can cause minor specifications within a polyclonal serum to reveal more 
recombinants corresponding to contaminants in the original antigen preparation 
(Mierendorf et al, 1987). It is also a possibility that the filters were insufficiently 
blocked with BSA leading to high non-specific binding of the antibody.
One of the desired properties of an antibody used for screening purposes is a high titre. The 
anti-p-lyase antibody did not have such a high titre, as can be seen from the GTK inhibition 
studies (section 3.2.1), and this may have been a contributory factor in the problems 
encountered later. However, it has also been stated (Mierendorf e t al, 1987) that an 
antibody that produces good signals on Western blots should also produce good signals in 
screening procedures at similar dilutions. The Western blot of the Sprague-Dawley and 
Wistar rat kidney cytosols (figure 4.1 ) shows that, if allowed to overdevelop slightly, the 
anti-p-lyase antibody hybridised to further protein bands in the cytosol that were both 
smaller and larger than the p-lyase band. If the screening filters were allowed to 
overdevelop, as indeed occurred to overcome the high backgrounds encountered, it may be 
that plaques containing DNA for one or more of these proteins could have been wrongly 
identified as p-lyase cDNA-containing phage.
The 3 clones then produced very intense single bands with the anti-p-lyase antibody when 
their Xgtl 1 recombinant lysogens were Western blotted. So, despite the problems 
associated with high backgrounds and false positives, these two last pieces of information 
indicate a definite cross-reactivity of the fusion protein with the antibody and this has to 
have been due to common epitopes within the protein sequences or a broad specificity of the 
antibody.
In conclusion it can be said that 3 clones were isolated from a Xgtl 1 cDNA library using a 
polyclonal anti-p-lyase antibody. This selection process was not sufficient to prove that the 
sequences isolated were derived from the gene of interest and so further methods of 
characterisation were employed. The best method, that of the comparison of the DNA 
sequences of the clones with the amino acid sequence of the p-lyase protein, was not 
available and the next best, the in vitro translation of hybrid selected mRNAs, did not 
produce acceptable results. However, with the characterisation procedures that were 
available it has been shown that the 3 clones did not, in all probability, code for p-lyase. 
Therefore all further work described in this thesis uses the Wistar clone BL0.9 isolated and 
characterised in Chapter 3. As noted in Chapter 3, this clone has now been definitely shown 
to be part of the p-lyase cDNA.
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CHAPTER 5
THE TISSUE DISTRIBUTION OF RAT KIDNEY CYSTEINE CONJUGATE p-LYASE
5.1 INTRODUCTION
The enzyme cysteine conjugate p-lyase is known to exist in multiple forms with both kidney 
and liver cytosol exhibiting p-lyase activity (Stevens, 1985a). In addition, DCVC 
administration causes mitochondrial respiration inhibition in other organs in addition to  
kidney damage (Parker, 1965). However, very few studies have been performed on the 
distribution of the kidney enzyme in extrarenal and extra hepatic tissues.
Tateishi and Shimizu (1 9 8 0 ) used S-2,4-dinitrophenyl-L-[35S]cysteine (DNP-cysteine) 
as the model substrate in eight tissues of the rat. Liver had the highest enzymic activity, 
with the kidney having approximately half of this and all the other tissues having negligible 
p-lyase activities. Jones et al (1988 ) measured both glutamine transaminase (GTK) 
activity and DCVC metabolism (p-lyase activity) in ten rat tissues and found the kidney to be 
the highest in both cases, with liver second and the other tissues having lower, but not 
negligible, levels. In addition, the order of the activities of GTK did not mirror the order of 
DCVC metabolism. Immunocytochemistry had limited sensitivity, with the liver the only 
extrarenal tissue to exhibit any significant degree of staining.
Accordingly, the present study was initiated with a view to comparing these previous studies 
with the GTK and p-lyase activities of six tissues from male Wistar rat. In addition to these 
activities the tissue p-lyase protein levels were investigated by Western blotting (using the 
anti-p-lyase antibody) and p-lyase mRNA distribution by Northern blotting (using the 
BL0.9 radiolabelled probe).
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5.2 MEASUREMENT OF p-LYASE AND GTK ACTIVITY IN SIX RAT TISSUES
Four male Wistar albino rats (250g) were killed and the brain, heart, kidney, liver, right 
lung and skeletal muscle (right thigh) removed. The tissues from two animals were snap- 
frozen in liquid nitrogen for the subsequent preparation of RNA (section 5.4). The 
remaining tissues were used to produce cytosol by the method detailed in section 2.5.2.
5 .2 .1  Protein Determ ination
The total amount of protein in each tissue cytosol was measured by the method detailed in 
section 2.5.1. Table 5.1 shows the results of these assays.
5 .2 .2  Measurement of Glutamine Transaminase (GTK) A ctiv ity
The metabolism of a-keto-y-methiolbutyrate (a-KMB) and L-phenylalanine by the 
cytosolic fractions, isolated from six rat tissues, was investigated using the method detailed 
in section 2.5.3. Figure 5.1 shows the GTK activities of the six tissues and figure 5.2 gives 
the specific activities of these tissues, calculated from the gradients in figure 5.1.
Cytosolic GTK activity was detected in all the tissues studied. From the information given in 
figure 5.2 a rank order of specific transaminase activities in tissue cytosol can be 
constructed as follows;
Kidney > Brain a Heart > Liver > Muscle > Lung.
All extrarenal GTK activities were between 11 and 21% of the kidney cytosolic activity.
Table 5.1 Spectroscopic Determination of Cytosolic Protein Concentration 182
Initial Concentration 
(m g /m l)
Brain 2.91
Heart 2 .8 8
Kidney 9 .50
Liver 2 0 .5 4
Lung 7.42
Muscle 4.97
X Value; Absorbance value at 720nm (blank corrected). 
Correlation coefficient of standards = 0.9996.
Each tissue cytosol and all the standards were measured in duplicate.
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Figure 5.1
GTK Activity 
(mmol/min)
Glutamine Transaminase (GTK) Activities of Six Rat Tissue Cytosols.
20
0.40.0 0.1 0.2 0.3 0.5
Brain
Heart
Kidney
Liver
Lung
Muscle
Cytosol (mg)
Each GTK activity for each tissue cytosol was measured in duplicate.
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Figure 5.2 Specific GTK Activities of the Six Rat Tissue Cytosols
300 - I
200 -
Specific Activity  
(nmol/min 
/m g protein)
100 -
Brain Heart Kidney Liver Lung Muscle 
Tissue
*Numbers at the top of each column refer to the relative GTK activity, 
taking the kidney value as 100%
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5.2.3 Determination of p-Lyase Activity using DCVC as Substrate
The metabolism of S-(1,2-dichlorovinyl)-cysteine (DCVC) by cytosolic fractions of six 
tissues, isolated from male Wistar rats, in the presence of added a-keto-y-methiolbutyrate 
(a-KMB), was investigated. a-KMB (0.1 mM) was included in the p-lyase assays as it is 
known that the rat kidney cytosolic enzyme accumulates in the inactive pyridoxamine form 
of the enzyme after half-transamination, when an inadequate supply of a-keto acid acceptor 
is present (Stevens et al, 1986b, 1988).
Because of the limited amount of DCVC substrate available each tissue assay was performed 
in duplicate on 1 mg cytosolic protein only. Figure 5.3 shows the specific activities of (3- 
lyase for all six tissues. Using DCVC as substrate cytosolic p-lyase activity was detected in 
all six tissues and from the information given in figure 5.3 the descending rank order of 
tissue activities was as follows;
Kidney > Liver > Brain > Heart > Lung > Muscle.
All extrarenal p-lyase activities were between 5 and 67% of the kidney cytosolic activity.
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Figure 5.3 Specific B-Lyase Activities of the Six Rat tissue Cytosols
Specific Activity 
(nmol/min 
/m g protein)
4 0 0  i
3 0 0  -
200  -
100 -
Brain Heart Kidney Liver Lung Muscle 
T is s u e
^Numbers at the top of each column refer to the relative p-lyase activity, 
taking the kidney value as 1 0 0 %.
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5.3 WESTERN BLOT ANALYSIS OF CYSTEINE CONJUGATE p-LYASE CONTENT IN 
SIX TISSUE CYTOSOLS
The techniques of SDS-PAGE and Western blotting (sections 2.5.5 and 2.5.6 respectively) 
were utilised as a means of immunochemical detection in order to identify the presence of 
cysteine conjugate p-lyase protein in cytosol isolated from six rat tissues.
In order to assess p-lyase protein content in the tissue cytosols 20mg of renal cytosol was 
applied to the respective well (figure 5.4). An appropriate concentration of each extrarenal 
tissue cytosol protein, representing an equal amount of p-lyase activity (calculated from the 
values in section 5.2), was applied to the respective wells each being made up to 75ml with 
water and 150ml with 2x loading buffer before loading. Figure 5.4 shows that, at these 
antigen levels, the affinity purified anti-p-lyase antibody (MacFarlane e t al, 1989) reacted 
with a single protein, of molecular weight 43kD, in all six tissue cytosols.
In general, excess protein loading resulted in a general distortion of the immunoprecipitated 
bands. However it can be seen that the kidney cytosol produced a protein band that was much 
darker than any other of the tissues, despite applying a 1.5 to 18 fold higher concentration 
of each extrarenal tissue cytosol relative to the concentration of kidney cytosol. The brain, 
heart and liver bands all appeared to be darker than the lung and muscle bands, which were 
very faint.
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1 2 3 4 5 6 7
Fig. 5.4. Western Blot of Six Rat Tissue Cytosols
Lane 1 : Protein molecular weight markers (a2-macroglobulin, 1 80kD; p-galactosidase,
116kD; fructose-6-phosphate kinase, 84kD; pyruvate kinase, 58kD; fumarase, 48.5kD; 
lactate dehydrogenase, 36.5kD; triosephosphate isomerase, 26.6kD).
Lane 2: Brain cytosol (41 ^g).
Lane 3: Heart cytosol (100|iig).
Lane 4: Kidney cytosol (20^g).
Lane 5: Liver cytosol (30|iig).
Lane 6: Lung cytosol (201 ^g).
Lane 7: Muscle cytosol (365^g).
Differing amounts of cytosol were loaded to give equal levels of p-lyase activity per lane.
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5 .4  NORTHERN BLOT ANALYSIS OF CYSTEINE CONJUGATE p-LYASE mRNA 
LEVELS IN SIX RAT TISSUES
Northern blot analysis of total RNA isolated from the six male Wistar tissues (section 
2.9.1) was performed in order to ascertain the levels of p-lyase mRNA in each tissue and 
compare it to the p-lyase protein levels and GTK/p-lyase activities measured previously. 
Total RNA was isolated from the six snap-frozen tissues as in section 2:9.1. This RNA was 
subjected to spectrophotometric analysis to check its purity as of section 3.7.1 and then 
electrophoresed as of section 2.9.1. Following this electrophoresis and ethidium bromide 
staining, the gel was observed under UV illumination (figure 5.5) and this showed the RNA 
to be intact and to have been loaded in equal amounts in all six lanes.
Figure 5.6 shows the autoradiograph of the Northern blot probed with 35S-labelled BL0.9 
DNA (section 2.11). The blot shows a single band of approximately 1.9kb in length in the 
kidney lane alone, despite equal amounts of total RNA being loaded in the five extrarenal 
lanes. This agrees with the Northern blot in section 3.7.1 (figure 3.14).
Fig. 5.5. Electrophoretic Analysis of Six Rat Tissue Total RNAs (20^g total RNA each lane).
Lane 1 : Brain total RNA. 
Lane 2: Heart RNA.
Lane 3: Kidney RNA. 
Lane 4: Liver RNA.
Lane 5: Lung RNA.
Lane 6: Muscle RNA.
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Fig. 5.6. Autoradiograph of a Northern Blot of Six Rat Tissue Total RNAs (Figure 5.4) 
Probed with Radiolabelled BL0.9 (20^g total RNA each lane).
Lane 1 : Brain total RNA.
Lane 2: Heart RNA.
Lane 3: Kidney RNA.
Lane 4: Liver RNA.
Lane 5: Lung RNA.
Lane 6: Muscle RNA.
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5.5 DISCUSSION
In this chapter the levels of GTK/p-lyase activity, p-lyase protein and p-lyase mRNA have 
been investigated in six tissue cytosols isolated from male Wistar rats. Cysteine conjugate p- 
lyase purified from rat kidney cytosol has been reported to exhibit transaminase activity 
and is, in fact, identical to the soluble form of glutamine transaminase K (Stevens et al,
1986b). In the present study both glutamine transaminase K (GTK) and p-lyase activity 
has been determined in the cytosol of six rat tissues. Cytosolic transaminase activity, with 
L-phenylalanine and a-KMB as substrates, and p-lyase activity, with DCVC as substrate, 
was detected in all the tissues investigated (figures 5.1 and 5.2 respectively), with the 
kidney having by far the highest activities for both enzymes. The liver showed a substantial 
amount of glutamine transaminase activity consistent with the data of Cooper and Meister 
(1981) who showed that rat liver contains a glutamine transaminase designated the L-type 
as well as smaller amounts of GTK.
When the GTK : p-lyase ratios of all six tissues were compared the liver and brain were 
considerably lower (with liver being the lowest) than the other four tissues. This may 
suggest that less of the p-lyase activity in these tissues is contributed by a glutamine 
transaminase type enzyme. This is certainly consistent, in the case of the liver, with the 
previous observation that part of the p-lyase activity in rat liver is contributed by the 
pyridoxal phosphate dependent enzyme kynureninase (Stevens, 1985b). The brain, 
however, has very little kynureninase activity when compared to both liver and kidney 
(Kawai, 1988) so a different enzyme may account for its p-lyase activity.
The GTK/p-lyase results from this study compare well with those of Jones et al (1988), 
who found that kidney had the highest GTK/p-lyase activities. Testis, spleen, heart, muscle 
and pancreas all had GTK levels similar to the liver but there was less p-lyase activity in 
these tissues than in the liver. Only the high GTK/p-lyase levels in the brain found in this 
study disagree with the work of Jones et al (1988) and no reason can be seen for this 
discrepancy.
Immunochemical detection of p-lyase protein in the six tissue cytosols showed a band of the 
same weight (43kD) as that of kidney cytosolic p-lyase. To achieve this, however, a 1.5 - 
18 fold higher concentration of the extrarenal cytosolic proteins had to be applied to the 
Western blot relative to that used for the analysis of rat kidney cytosol. Even then the p- 
lyase band in the kidney cytosol lane was much darker showing the anti-p-lyase antibody to 
have a higher affinity for this protein compared to the other tissue cytosol p-lyase bands. 
This, again, compares well with the immunohistochemical staining studies of Jones et al 
(1988 ) and also points to the kidney cytosolic form of p-lyase having a structural 
difference to the extrarenal forms of the enzyme. Other factors may have affected the 
staining of the Western blot bands, the main one being the fact that the differences in the 
loading proportions of the tissue cytosols may not have been strictly accurate, based as they 
were on duplicate data points only. However, this is unlikely to be the major factor and the 
result still points to differences in the extrarenal p-lyase antigenicities.
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The detection of p-lyase mRNA by the 35S-labelled BL0.9 probe proved unsuccessful in all 
extrarenal tissues and this agrees with the results of an earlier Western blot (not shown). 
When equal amounts of cytosolic protein were loaded on this Western blot the anti-p-lyase 
antibody could only pick up a 4 3 kD protein band in the kidney cytosol lane. It therefore 
appears that the BL0.9 probe is, to all intents and purposes, kidney specific (in agreement 
with the results in section 3.7.1). Had amounts of RNA equal to the tissue cytosol p-lyase 
activities been loaded on the Northern blot (as was performed on the Western blot in figure 
5.4) the radiolabelled BL0.9 probe may have hybridised to p-lyase mRNA bands in the 
extrarenal tissues. However, this was impossible to perform due to the amounts of RNA 
available and the constraints of the RNA gel parameters. The information gained from this 
Northern blot (figure 5.6) again suggests that the kidney form of cytosolic p-lyase is a 
different form of the enzyme to that found in extrarenal tissues.
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CHAPTER 6
THE INDUCTION OF RAT KIDNEY p-LYASE BY CYSTEINE CONJUGATES OF
HALOGENATED ALKENES.
6.1 INTRODUCTION
As discussed in the main introduction to this thesis, cysteine conjugate p-lyase is an 
important enzyme in the toxicological activation of many chemicals, including halogenated 
alkenes such as hexachloro-1,3-butadiene (HCBD). Following glutathione conjugation and 
peptidase processing, the cysteine conjugates of these compounds can either be detoxified, by 
N-acetylation and excreted as the mercapturic acid (Duffel & Jacoby, 1982; Reichert & 
Schütz, 1986), or alternatively, can produce toxic metabolites, via the p-lyase enzyme 
(Commandeur & Vermeulen, 1990; Nash e t al, 1984; Lock, 1988). Thus, the 
nephrotoxicity of these halogenated xenobiotics is influenced by the relative balance of the 
detoxication/toxification pathways and the regulation of the N-acetylase and p-lyase 
enzymes involved, respectively, is therefore important. Our knowledge of regulation of 
these two enzymes is limited and only recently have the regulatory aspects of the p-lyase 
enzyme been discussed.
As mentioned in chapter 5, the p-lyase enzyme also exhibits transaminase activity (Stevens 
et al, 1986a; MacFarlane et al, 1989). Thus the p-lyase component of this bi-functional 
enzyme may be regulated by concurrent transaminase activity (Stevens e t al, 1986a). By 
analogy to many other xenobiotic-metabolising enzymes, it may be anticipated that kidney p- 
lyase activity is inducible by xenobiotics. However, preliminary (unpublished) 
observations in these laboratories indicated that classic inducers such as phénobarbital, p- 
napthoflavone, hexachlorobenzene or Aroclor 1254 did not induce the p-lyase enzyme 
activity in female rat kidney preparations. This has lead to consideration of the possibility 
for substrate-dependent induction of the enzyme.
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The purpose of the experiments performed in this chapter was therefore to determine 
whether substrate regulation of female rat kidney cysteine conjugate p-lyase occurred upon 
in vivo administration of the N-acetyl cysteine derivative of HCBD (NAc-PCBD). The 
animals were dosed and treated as of section 2.15.1. The results in this chapter were 
produced in collaboration with Dr. M. MacFarlane and two undergraduate students Liliane 
Roelandt and Nicola Parker. A description of this work has been published (MacFarlane et 
ai, 1993).
6 .2  MEASUREMENT OF ENZYME ACTIVITIES AND BIOCHEMICAL ANALYSES
6.2.1  Measurement o f Glutamine Transaminase K (GTK) A ctiv ity
The metabolism of a-keto-y-methiolbutyrate (a-KMB) and L-phenylalanine by female rat 
kidney cytosol (section 2.5.3) was investigated and the results are shown in table 6.1. This 
data shows that a 3mg/kg dose of NAc-PCBD produced an increase in kidney cytosolic GTK 
activity. By contrast, the higher 10mg/kg dose resulted in no change in the GTK activity. 
Neither the low nor high dose of NAc-PCBD had any effect on the GTK activity in kidney 
mitochondrial preparations (data not shown).
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6 .2 .2  Determination of p-lyase A ctiv ity  using DCVC, TFEC and BTC as 
S u b s tra tes
The metabolism of S-(1,2-dichlorovinyl)-cysteine (DCVC),
S -(1 ,1 ,2,2-tetrafluoroethyl)-L-cysteine (TFEC) and S-(2-benzothiazolyl)-L-cysteine  
(BTC) by female rat kidney cytosol was also investigated (section 2 .5 .4) and the results 
shown in table 6.1. The lower dose of NAc-PCBD (3m g/kg) produced an increase in kidney 
cytosolic cysteine conjugate p-lyase activity for all three substrates examined, which is in 
agreement with the kidney cytosolic GTK data. The 10mg/kg dose of NAc-PCBD, however, 
resulted in a decrease in both DCVC- and BTC-dependent activities whereas, when TFEC was 
used to assay p-lyase activity, no change was observed - again in agreement with the GTK 
data. Mitochondrial p-lyase activity towards all three substrates was not affected by either 
dosage regimen.
6 .2 .3  Detection of Renal Damage
To determine the extent of renal damage following the treatment of female rats with NAc- 
PCBD, blood urea nitrogen (BUN) levels were investigated following the method in section 
2.15.2. The results in table 6.1 confirmed that treatment with lOmg/Kg NAc-PCBD 
produced nephrotoxicity as assessed by an increase in the BUN whereas the lower dose of 
3mg/Kg did not produce a statistically significant effect on this parameter.
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6 .3  MEASUREMENT OF p-LYASE PROTEIN LEVELS
In order to ascertain whether the enzyme activity results were due to the direct 
activation/inhibition of pre-existing p-lyase/GTK activity or caused by the effect of NAc- 
PCBD on enzyme protein or mRNA synthesis, both Western blotting and ELISA analysis of the 
kidney cytosols were performed (as of sections 2.5.6 and 2.15.3 respectively). The 
Western blot data (figure 6.1), using the monospecific antibody from section 2.2.3 
(MacFarlane et al, 1989), supports the latter theory as it can be seen that treatment with 
3 mg/kg of NAc-PCBD appears to increase the enzyme protein levels whereas treatment at 
the higher, toxic dose of 1 Omg/kg results in lower p-lyase protein levels. The ELISA data 
(table 6.2) supports this semi-quantitative Western blot data as, again, the 3 mg/kg and 
1 Omg/kg doses resulted in significantly increased and decreased levels of p-lyase protein 
respectively.
6 .4  MEASUREMENT OF p-LYASE mRNA LEVELS
All the previous data suggests that NAc-PCBD administration has a dose-dependent effect on 
enzyme protein levels/enzyme activities. However, this may come about by protein 
stabilisation or by an effect of the NAc-conjugate on the corresponding p-lyase mRNA levels. 
In order to discern by which mechanism the changes in activity/protein levels were being 
effected, total kidney RNA was isolated from control, 3mg/kg and 1 Omg/kg treated rats (as 
of section 2.9.1).
Fig, 6.1 a. Western Blot of Rat Kidney Cytosol after NAc-PCBD Treatment (3mg/kg).
Lane 1: Kidney cytosol p-lyase protein (10^g).
Lanes 2-5: Kidney cytosol from 4 animals (control) (25ug).
Lanes 6-9: Kidney cytosol from 4 animals (3m g/Kg NAc-PCBD) (25^g).
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Fig. 6.1 b. Western Blot of Rat Kidney Cytosol after NAc-PCBD Treatment (1 Omg/kg).
Lane 1: Kidney cytosol (3-lyase protein (10ug).
Lanes 2-5: Kidney cytosol from 4 animals (control) (25^g).
Lanes 6-9: Kidney cytosol from 4 animals (10m g/K g NAc-PCBD) (25ug).
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Treatment Spectral Absorbance [A490 (x IO 2)] 
Cytosol Mitochondria
Control
NAc-PCBD, 3mg/Kg 
NAc-PCBD, 10mg/Kg
2.1 ± 0 .1  3.4 ± 1 .3
3.0 ±  0 .1 * 3.2 ± 0 .5
1.5 ±  0 .3 * 3.0 ± 0 .4
Table 6.2 Influence of NAc-PCBD on ELISA-detectable p-Lyase Protein Levels in Rat Kidney 
Cytosol and Mitochondria
Results are expressed as the absorbance values at 490nm (xi 02) and are the mean ±  SEM 
of 4 animals
150ng/well and 600ng/well of cytosolic and mitochondrial protein respectively 
were analysed by the ELISA method.
*  Significantly different from the control group at p< 0.05.
The RNA was then subjected to the slot blot procedure (section 2.10.3) followed by 
hybridisation with the radioactively-labelled BL0.9 cDNA probe (section 3 .3 .3). The 
autoradiograph results produced by these procedures are shown in figure 6.2 (a and b) and 
indicate an increase in cysteine conjugate p-lyase mRNA at the lower 3 mg/kg dose level and 
a decrease at the higher 10mg/kg dose, denoting that the changes previously observed in 
both enzyme activity and enzyme protein level probably arose due to changes in the steady 
state level of p-lyase mRNA.
In order to normalise these results with respect to the total amount of RNA loaded per slot, 
the filters were stripped (section 2 .10.4) and rehybridised with a human actin cDNA probe 
(section 2.2.4). The results of these rehybridisations are shown in figure 6.3 (a and b) and 
they show a fairly equal loading of the RNA with the exception of the third control slots in 
both cases. This, however, is mirrored in the density of the same slots in figure 6.2 and 
this is obviously due to miscalculation of the RNA concentration and subsequent RNA 
overloading.
Both sets of BL0.9/actin probed autoradiographs were subjected to densitometry (section 
2.10.5) in order to quantify the RNA variations between control and test groups. 
Representative densitometer scans for both control /  3mg/kg and control /  10mg/kg slot 
blots are shown in figures 6.4 and 6.5 respectively and using this "area under the curve" 
data the 3mg/kg and 10mg/kg results were normalised to unit actin ratios (figure 6.6).
The histogram shows, quantitatively, what was inferred by the BLO.9 probing alone. That is 
that the changes in p-lyase enzyme activity/protein levels were probably due to a 
concurrent 1.5 fold increase (3 mg/kg NAc-PCBD) and 1.8 fold decrease (1 Omg/kg NAc- 
PCBD) in the p-lyase mRNA steady state levels compared to the control.
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Fig. 6.2a. Autoradiograph of a Slot Blot of Rat Kidney Total RNA After NAc-PCBD Treatment 
Probed with Radiolabelled BL0.9.
Lanes 1-4: Kidney total RNA (control).
Lanes 5-8: Kidney to ta l RNA (3m g/Kg NAc-PCBD).
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Fig. 6.2b. Autoradiograph of a Slot Blot of Rat Kidney Total RNA After NAc-PCBD Treatment 
Probed with Radiolabelled BL0.9.
Lanes 1-4: Kidney total RNA (control).
Lanes 5-8: Kidney to ta l RNA (1 Omg/Kg NAc-PCBD).
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Fig. 6.3a. Autoradiograph of a Slot Blot of Rat Kidney Total RNA After NAc-PCBD Treatment 
Probed with Radiolabelled Actin.
Lanes 1-4: Kidney total RNA (control).
Lanes 5-8: Kidney total RNA (3mg/Kg NAc-PCBD).
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Fig. 6.3b. Autoradiograph of a Slot Blot of Rat Kidney Total RNA After NAc-PCBD Treatment 
Probed with Radiolabelled Actin.
Lanes 1-4: Kidney total RNA (control).
Lanes 5-8: Kidney tota l RNA (lO m g/K g NAc-PCBD).
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6.5 DISCUSSION
In this chapter the effect of the administration of a single intraperitoneal (i.p.) dose of NAc- 
PCBD on female rat kidney cytosolic and mitochondrial p-lyase has been investigated. The 
doses (3 mg/kg and 10mg/kg) were chosen by reference to previous work by Ishmael and 
Lock (1986). In that study it was shown that 3mg/kg NAc-PCBD caused no noticeable 
change in kidney function nor BUN levels, whereas 10mg/kg caused renal damage as assayed 
by increased BUN levels. In the present study female rats were used because of the marked 
sex difference seen in response to HCBD and its metabolites, females being four times more 
susceptible than males (Hook et al, 1983; Ishmael and Lock, 1986). NAc-PCBD was used as 
it produces similar effects to HCBD but at substantially lower doses, it being further along 
the glutathione processing chain than its precursor (Lock and Ishmael, 1979) and also 
being one of the forms of HCBD actively taken up by the kidney. Additionally HCBD was not 
available in sufficient quantities for animal dosing experiments, whereas NAc-PCBD 
was.
The results in this chapter have shown that a single i.p. non-toxic dose of 3 mg/kg NAc- 
PCBD caused a statistically significant increase in kidney cytosolic cysteine conjugate p- 
lyase and associated glutamine transaminase K activity, as assessed by enzyme activity, 
enzyme protein levels and the corresponding mRNA levels (table 6.1, figures 6.1 and 6.6 
respectively). The lack of effect of this single 3 mg/kg dose on BUN levels i.e. renal damage 
(table 6 .1) agrees with the results of Ishmael and Lock (1986).
In contrast, the 10mg/kg dose of NAc-PCBD caused a statistically significant decrease in two 
of the p-lyase activities (DCVC and BTC) and a smaller non-significant decrease in the other 
(TFEC). No change was seen in GTK enzyme activity. The 10mg/kg dose had a damaging 
effect on the kidney as seen from the significant increase in the BUN levels, again in 
agreement with Ishmael and Lock (1986). It is probable that any dose-dependent induction 
of p-lyase at this high dose level was masked by the appearance of this nephrotoxicity. At 
both doses the p-lyase activity when metabolising the three substrates was in the rank 
order: TFEC>DCVC>BTC. This was to be expected as BTC is a better substrate for the 
mitochondrial form of p-lyase than the cytosolic form (Stevens 1985a).
The Western blotting/ELISA data (figure 6.1 and table 6.2 respectively) showed that the 
induction/depression of enzyme activities by the 3 mg/kg and lOmg/kg doses of NAc-PCBD 
were probably due to raised/lowered enzyme protein synthesis levels respectively, rather 
than the activation/inhibition of the relevant enzyme activities by NAc-PCBD. In the rat 
kidney cytosol (figure 6 .1) the purified anti-p-lyase antibody (MacFarlane e t al, 1989) 
cross-reacted with a protein subunit of molecular weight 50kD (in agreement with 
MacFarlane e t al, 1989), identical to that of the authentic cytosolic p-lyase. This difference 
in size compared to the apparent 43kD molecular weight of p-lyase in chapter 3 and is 
probably due to the purer acrylamide used in this study and the inaccuracy of the actual 
sizing method described previously (section 3.9).
The slot blot analysis revealed a statistically significant variation in the p-lyase mRNA 
levels for both the nontoxic and toxic doses of NAc-PCBD. The 1.5 fold increase in the mRNA 
levels for the nontoxic dose was in agreement with the 1 . 5 - 3  fold increase in enzyme 
activity/protein levels and the 1.8 fold decrease in mRNA levels after administration of the 
toxic dose also agreed with the 1.4 - 2.2 fold decrease in the p-lyase activity/protein levels. 
This suggested that the induction of the enzyme activities/protein levels was due to the effect 
of the NAc-PCBD on the corresponding mRNA levels rather than by any protein stabilisation 
effect. The actual slot blots of the two dose-regimens, when probed with radiolabelled BL0.9 
(figure 6.2), were inconclusive although they appeared to confirm the previous results. 
However, once they were reprobed with actin to estimate RNA loading (figure 6.3) and the 
densitometry results "normalised" the induction/repression effect was clearly evident 
(figure 6 .6 ).
The question of whether the administered conjugate NAc-PCBD is the immediate inducer of 
cysteine conjugate p-lyase or if a metabolite is the active species remains to be determined. 
The situation is complicated by the contribution of several organs and different enzymes to 
the overall disposition and biotransformation of the parent compound (Dekant e t al, 1990; 
Lock, 1988; Schrenk e t al, 1988). The administration of NAc-PCBD is likely to lead to N- 
deacetylation and subsequent formation of S-pentachlorobutadienyl cysteine (the 
corresponding cysteine conjugate). This conjugate is a substrate for kidney p-lyase and 
thus it is possible that this metabolite is at least partly responsible for the enzyme 
induction observed. This substrate-dependent induction would then clear the xenobiotic and 
bring about cellular homeostasis.
The lack of induction observed in the mitochondrial form of p-lyase may also be explained by 
this hypothesis since S-pentachlorobutadienyl cysteine is not an ideal substrate for this 
enzyme form, which prefers the potentially non-toxic BTC (Lash e t a/, 1986a). Thus there 
is no reason for homeostatic induction of mitochondrial p-lyase as it is less able to 
metabolise the S-cysteine conjugate compared to the cytosolic enzyme. Protection of the 
mitochondrial p-lyase from the toxicity of the 10mg/kg dose of NAc-PCBD is also possibly 
due to its metabolic preferences. As the nephrotoxicity of the S-cysteine conjugate may 
affect the cells adjacent to its site of metabolism (MacFarlane e t a/, 1989) then the lack of 
metabolism of the S-conjugate by the mitochondrial enzyme may afford it some protection. 
This homeostatic regulatory mechanism is not inconsistent with the unpublished 
observations that neither phénobarbital, p-napthoflavone, hexachlorobenzene nor Aroclor 
1254 induced rat kidney cytosolic p-lyase, compounds which are well known for the 
induction of other xenobiotic metabolising enzyme systems.
In conclusion, the results presented in this chapter have demonstrated preliminary dose- 
dependent induction or reduction of kidney cytosolic cysteine conjugate p-lyase. The 
influence of this modulation on the toxicity of xenobiotics metabolised via the glutathione 
pathway remains to be evaluated further, by examining the dose-induction relationships for 
several structurally diverse cysteine conjugates which encompass a broad range of 
substrate turnover and also kidney toxicities.
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CHAPTER 7
DISCUSSION
7.1 INTRODUCTION AND AIMS
Many drugs and xenobiotics produce toxicity which is directed specifically towards the 
kidney. Because the kidney is an organ with several physiologically, pharmacologically and 
toxicologically important functions, nephrotoxicity may have severe or even fatal 
consequences for the organism. The formation of S-glutathione conjugates and their 
processing to mercapturic acids, via S-cysteine conjugation, is a major route for the 
detoxication of drugs and xenobiotics. However, it has been shown that nephrotoxic S- 
cysteine and S-glutathione conjugates arise during mercapturic acid biosynthesis of certain 
halogenated alkenes (Elfarra and Anders, 1984). Therefore the mercapturic pathway 
appears to function both as a detoxication and toxification system.
The enzyme cysteine conjugate p-lyase (p-lyase) cleaves certain S-cysteine conjugates by p- 
elimination and has been implicated in the site-specific renal toxicity of some S-glutathione 
conjugates (Lock and Ishmael, 1985; Elfarra e t a/, 1986a; Stevens e ta /, 1986a). Although 
both liver and kidney have p-lyase activity, the kidney is the target organ for toxicity.
In recent years, toxicology has been directed more and more to the explanation of toxicity in 
terms of mechanisms. In line with this, molecular toxicology, a relatively new 
subdiscipline of toxicology, is aiming primarily at understanding target cell toxicity at the 
molecular and biochemical level. From this it may be possible to provide a rational basis to 
design safer drugs and improve hazard identification and risk assessment in chemical safety 
evaluation studies.
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The aims of this investigation were to gain a more precise understanding of the 
toxicologically important enzyme cysteine conjugate p-lyase by isolating both cDNA and 
human genomic probes to p-lyase with the particular end point of identifying and 
characterising the human enzyme. This was split into two phases:
1. Screening of a Xgtl 1 rat kidney cDNA library using the specific antibody 
to p-lyase (MacFarlane et al, 1989) to isolate the full length cDNA coding sequence.
2. Probing of a human genomic library with cDNA fragments/synthetic 
oligonucleotides. Genomic material was to be further subcloned and characterised.
In this final discussion the results in chapters 3 through 6 are briefly reviewed and collated 
to assess them in terms of the above aims.
7 .2  RESULTS
Initially (chapter 3) the polyclonal antibody to rat kidney (MacFarlane e t al, 1989) was 
used to screen a Xgtl 1 rat kidney cDNA library. Prior to this, the antibody had been shown 
to identify a single protein band in the immunological analysis of rat kidney cytosol and to 
inhibit GTK activity, and thus was deemed fully functional. The isolation of only one clone 
was thought to be due to the length of storage time of the cDNA library. The single clone was 
used to produce a Xgtl 1 recombinant lysogen and its accompanying p-galactosidase fusion 
protein was detected with the original antibody, thus indicating the clone to be part of the p- 
lyase cDNA.
The single clone was discovered to have a 0.9kb insert (BL0.9)and was therefore not a full 
length p-lyase cDNA. Nevertheless, the insert was subcloned into plasmid DNA in order to 
sequence it and to produce large quantities for further experimentation. Only 550  
nucleotides of the BL0.9 sequence was readable by internal primer sequencing due, 
probably, to secondary structure. The remaining 250 nucleotides were sequenced and the 
full 0 .9kb open reading frame elucidated using pGEM™.
Northern and Southern blot analysis of total rat kidney RNA and genomic DNA respectively, 
using BL0.9 as a radiolabelled probe, showed the BL0.9 to be highly specific for a single 
mRNA in kidney and to give a simple hybridisation pattern with genomic DNA, indicative of a 
single p-lyase enzyme being present in rat kidney cytosol.
All the data so far indicated strongly that the clone isolated was indeed part of the p-lyase 
cDNA. It was therefore attempted to get concrete evidence of this via the in vitro translation 
of hybrid selected mRNA. Unfortunately, this could not be successfully performed due to a 
number of factors explained in detail in section 3.9. Thus, at the end of this initial 
experimentation the identity of BL0.9 remained to be confirmed.
Because of the failure of the original cDNA library to produce a full-length p-lyase cDNA, a 
second Xgtl 1 cDNA library was purchased and the anti-p-lyase antibody again used to screen 
it (chapter 4). This time three clones were isolated and again their recombinant lysogen 
fusion proteins were identified with the antibody. Their inserts were shown to be 0.45kb,
I.Okb and 2.9kb in length (BL0.5, BL1.0 and BL2.9 respectively).
Again, all three inserts were subcloned into plasmid DNA. Restriction enzyme mapping and 
Southern blot cross-hybridisation studies demonstrated a lack of homology between all the 
four clones isolated thus far, although it was still possible for them to be non-overlapping 
contigs of the same cDNA. Genomic Southern blotting and Northern blotting analysis showed 
the clones to be from dissimilar genes and once sequencing was performed it conclusively 
showed the BL0.5, BL1.0 and BL2.9 clones to not be p-lyase in origin. The reason for this 
was probably due the use of a polyclonal antibody, high backgrounds, false positive 
recognition, the low titre of the antibody and the possibility of common epitopes within 
other peptides, all of which would have occurred at the initial screening stage.
In chapter 5, the tissue distribution of rat kidney p-lyase was investigated using the 0.9kb 
cDNA clone isolated in chapter 3. Using both GTK and p-lyase enzyme activities rank orders 
of the level of p-lyase activity in six different rat tissues were obtained. Western blotting 
showed that the kidney p-lyase protein appeared to have a structural difference when 
compared to extrarenal forms of the enzyme. The Northern blotting data (using the 0.9kb 
clone as a radiolabelled probe) was also in agreement with this finding.
In chapter 6, the induction/reduction of rat kidney p-lyase by NAc-PCBD was investigated, 
again using the 0.9kb cDNA clone isolated in chapter 3. It was demonstrated that a single i.p. 
dose of 3 mg/kg NAc-PCBD (shown to be non-toxic by BUN levels) caused a statistically 
significant increase in kidney cytosolic p-lyase and associated GTK, as assessed by enzyme 
activity, enzyme protein levels and the corresponding mRNA levels. In contrast, the 
1 Omg/kg dose of NAc-PCBD (shown to be toxic by BUN levels) caused a statistically 
significant decrease in two of the p-lyase substrate activities and a smaller, non-significant 
decrease in the third. No change was observed in the GTK enzyme activity. Decreases in both 
the enzyme protein and mRNA levels were observed. The induction/inhibition observed was 
suggested to be via NAc-PCBD on the corresponding mRNA levels directly. The question of 
NAc-PCBD being the primary active species was discussed.
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7.3 CONCLUSIONS
A 0.9kb segment of the rat kidney cytosolic cysteine conjugate p-lyase cDNA has been 
isolated by the use of an anti-p-lyase antibody. Attempts to isolate further cDNA clones to 
complete the sequence have proved unsuccessful. However the 0.9kb cDNA has been used 
successfully to demonstrate the tissue distribution of rat kidney cytosolic p-lyase mRNA as 
compared to the enzyme activity and protein levels. The cDNA has also been used to show the 
induction/repression of rat kidney cytosolic p-lyase by non-toxic/toxic doses of one of the 
enzyme's substrates (MacFarlane etal, 1992). This induction effect has been shown to due 
to the effect of the halogenated alkene on mRNA levels rather than by other mechanisms such 
as protein stabilisation.
Thus it can be seen that, of the two original aims, the first has been almost fully achieved. 
Although a full length cDNA has not been isolated, the clone obtained can and has been used to 
investigate modulation of the enzyme under various conditions. As stated previously, the 
current postgraduate student working on this project (Miss Sandra Perry) has subsequently 
isolated the full-length cDNA for rat kidney cytosolic p-lyase using this 0.9kb segment 
(Perry et al, 1993) and is now in the process of screening a human genomic library with 
the full-length rat cDNA. This should ultimately lead to the end-point of the identification 
and characterisation of the human enzyme. Further to this, the production of human 
genomic probes will provide an insight into the safety aspects of this toxicologically 
important enzyme.
The work in this thesis clearly demonstrates the isolation, cloning and characterisation of a 
sizeable fragment of the rat kidney cytosolic p-lyase cDNA and is the first known p-lyase 
cDNA to be described. Without the results described herein the further work described in 
Perry et al, 1993 would not have taken place and, therefore, I present it as a major 
contribution to the progress of the Molecular Toxicology Group at the University of Surrey 
within this field.
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APPENDIX  
SOLUTIONS, MEDIA AND BUFFERS
Agar and Agarose:
15g/l Bacto-Agar in media (for plates)
7g/l Bacto-Agar in media (for top agar)
7g/l Agarose in media (for top agarose).
Alkaline Phosphatase Buffer:
2.5ml 1M Tris-HCI, pH 9.5 
2.5ml IM N aC I 
125 .Oui 1M MgCI2
Add distilled water to 25ml.
1M Ammediol Buffer:
105.1g Aminomethyl propanediol-HCI
Add 800ml distilled water, adjust the pH to 9.0 with HCI and add distilled water to
11. Sterilise by autoclaving.
Ampicillin Stock Solution:
100m g/m l in distilled water, sterilise by filtration.
Store at -20°C.
Use at 150fig/ml in growth media for selection of resistant bacteria.
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Brij/D O C  Solution:
(1% (w /v ) Brij 58, 0.4%  (w /v ) Sodium Deoxycholate in TE, pH8.0)
1g Brij 58 (Sigma)
0.4g Sodium Deoxycholate
Add TE, pH 8.0 to 100ml, store at 4°C.
Chloroform : Isoamyl Alcohol:
49ml Chloroform 
1 ml Pentan-2-ol.
Deionised Formamide:
Add 5g Ion Exchange Resin (Analytical Grade Mixed Bed, 20-50  mesh, AG-501-X8. 
Biorad) to each 100ml of Formamide. Stir at 4°C for three hours and filter into a 
lightproof bottle.
Store at -70°C.
5OX Denhardt's Solution:
10g Bovine Serum Albumin
10g Ficoll 400 ,000
10g Polyvinyl Pyrrolidone 40 ,000
Add distilled water to 11, sterilise by filtration
Store at -20°C.
Denaturing Buffer for Southern blotting:
(0.5M NaOH, 1.5M NaCI)
20g NaOH 
87.66g NaCI
Add distilled water to 11, sterilise by autoclaving.
1 M D ith io th re ito l Stock Solution:
Dissolve 3.09g DTT in 20ml 0.01 M Sodium acetate, pH 5.2 
Sterilise by filtration, store in aliquots at -20°C.
Dye Markers fo r Electrophoresis:
DNA: 10% Bromophenol Blue in 50% Sucrose Solution 
RNA: 4% Bromophenol Blue 
4% Xylene Cyanol 
10mM EDTA 
Sterilise by autoclaving.
0.5M EDTA Stock Solution:
186.1g/1 Na2EDTA
Adjust to pH 8.0 using approx. 20g NaOH pellets.
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1 Ox Electrophoresis Buffer for DNA gels (TAE):
(400mM Tris.acetate, 20mM EDTA, pH 8.3)
48.4g Tris.
40ml 0.5M EDTA pHB
11.42ml Glacial Acetic Acid
Add distilled water to 11, check the pH is 8.3.
lO x Electrophoresis Buffer for RNA gels:
(400mM MOPS, 10OmM Sodium acetate, 10mM EDTA)
83.71 g MOPS
33.3ml Sodium acetate 3M pH4.8 
20ml EDTA 0.5M pHB
Add distilled water to 11, add 0.2% (v /v ) DEPC 2 hours before autoclaving.
Ethidium Bromide:
Stock solution of 3 mg/ml in TE
Use at 3^g/ml in gel running buffer for staining DNA and RNA gels.
Genomic DNA Digestion Buffer:
50ml 1M Tris-HCI, pH 8.0
50ml 3M NaCI
200ml 0.5M EDTA, pHB.O
Add distilled water to 11, sterilise by autoclaving.
Hybrid Selection Buffer A:
5mM Tris-HCI, pH 7.5 
1 mM EDTA.
Hybrid Selection Solution B:
5mM KCI 
2mM EDTA
10mg/ml Calf Liver tRNA.
Hybridisation Solution (N orthern  B lots):
20ml 5Ox Denhardt's 
250ml 20x SSC 
500ml Deionised Formamide 
200ml 50% Dextran Sulphate
10ml 10mg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
18ml Distilled Water
0.5ml @ 20mg/ml poly A, 20mg/ml poly C. Store at -20°C.
Hybridisation Solution (Southern Blots):
30ml 2Ox SSC
2ml 0.2M NaP04, pH 6.5
0.5M EDTA
10ml 5Ox Denhardt's solution 
1 ml lOmg/ml Herring Sperm DNA 
5ml 10% (w /v ) SDS 
50ml Distilled Water 
Store at -20°C.
IPTG (10m M  Stock Solution):
95.0mg IPTG in 40ml distilled water.
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1M KCI:
74.6g KCI
Add distilled water to 11, sterilise by autoclaving.
LB Medium:
10g Tryptone 
1 Og NaCI 
5g Yeast Extract
Add distilled water to 11, sterilise by autoclaving.
(for LBMg-broth, add 10ml 1M MgS0 4  per litre medium).
10x M ultiprim e Buffer:
2M HEPES, pH 6.6 
2mM Tris-HCI, pH 7.0  
0.1 mM EDTA 
4mg/ml BSA.
Neutralising Solution for Southern Blotting:
(3M NaCI, 0.5M Tris.HCI pH7.5)
120g NaCI
500ml 1M Tris.HCI pH7.5
Add distilled water to 11, sterilise by autoclaving.
Nick Column Buffer:
10mM Tris-HCI, pH 7.5 
1 mM EDTA
Sterilise by autoclaving.
10x PBS:
80g NaCI 
2g KH2PO4
29g Na2HP04
2g KCI
Add distilled water to 11, sterilise by autoclaving.
PB S-G T:
100ml 10x PBS 
10g Gelatin 
0.5ml Tween 20  
Add distilled water to 11.
Phage B uffer (SM):
3g KH2PO4
7g Na2HP04
5g NaCI 
246mg MgS04
10mg CaCI2
10mg Gelatin
Add distilled water to 11, sterilise by autoclaving.
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Phenol Preparation:
100ml of redistilled phenol is melted and an equal volume of TE and 0.1% (w /v) 
8-hydroxyquinoline is added. The mixture is shaken to dissolve the 
hydroxyquinoline and ensure saturation of the phenol by TE. Use the lower, yellow, 
phenol layer.
Store at 4°C. Do not use if the yellow colour changes.
Phosphate Buffer:
3.55g Na2HPC>4 in 250ml distilled water (A)
3.90g NaH2P04  in 250ml distilled water (B)
Adjust pH of A to 7.4 by adding B, sterilise by autoclaving.
Prehybridisation Solution fo r General Use:
100ml 5Ox Denhardts 
250ml 2Ox SSC 
500ml Deionised Formamide 
123ml Distilled water 
0.5ml 20mg/ml tRNA 
0.5ml 20mg/ml poly A 
0.5ml 20mg/ml poly C
25ml lOmg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
Store at -20°C.
Proteinase K Buffer:
5.84g NaCI
10ml 1M Tris-HCI, pH 8.0  
500ml 0.5M EDTA, pH 8.0  
Add distilled water to 11, sterilise by autoclaving.
Qiagen™ Buffer P I:
100 mg/ml RNAase A in 50mM Tri-HCI, 10mM EDTA, pH 8.0  
Store at 4e C
Qiagen™ Buffer P2:
200mM NaOH 
1% (w /v ) SDS.
Qiagen™ Buffer P3:
2.55M KAc, pH 4.8.
Qiagen™ Buffer QBT:
750mM NaCI 
50mM MOPS, pH 7.0  
15% (v /v ) Ethanol 
0.15%  (v /v ) Triton X-100.
Qiagen™ Buffer QC:
1.0M NaCI
50mM MOPS, pH 7.0  
15% (v /v ) Ethanol.
Qiagen™ Buffer QF:
1.25M NaCI 
50mM MOPS, pH 8.2 
15% (v /v ) Ethanol.
QuickPrep™ Elution Buffer:
10mM Tris-HCI, pH 7.4  
1 mM EDTA.
QuickPrep™ Glycogen Solution:
10mg/ml glycogen in DEPC-treated distilled water.
QuickPrep™ High-Salt Buffer:
1 OmM Tris-HCI, pH 7.4  
1 mM EDTA 
0.5M NaCI.
QuickPrep™ Low -Salt Buffer:
1 OmM Tris-HCI, pH 7.4  
1 mM EDTA 
0.1 M NaCI.
QuickPrep™ Potassium A cetate  Solution:
2.5M Potassium Acetate.
230
QuickPrep™ Sample Buffer:
10mM Tris-HCI, pH 7.4  
1 mM EDTA 
3.0M NaCI.
RNA Lysis Buffer:
59.08g Guanidine Isothiocyanate
2.0ml 0.5M EDTA
5.0ml 1M Tris-HCI, pH 7.5
Add distilled water to 100ml, sterilise by filtration.
SDS-PAGE Electrode Buffer:
12 .12g Tris 
57.64g Glycine 
40ml 10% (w /v ) SDS 
Add distilled water to 41.
SDS-PAGE Sample Buffer:
7.5ml Glycerol
2.5ml p-Mercaptoethanol
1 1.5ml 10% (w /v ) SDS
0.5ml 0.1% (w /v ) Bromophenol Blue
0.88g Tris
Add 40ml distilled water, adjust the pH to 6.8 with HCI and add distilled water to 
50m l.
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SDS-PAGE Transfer Buffer:
7.26g Tris 
33.78g Glycine 
600ml Methanol 
Add distilled water to 31.
40m M  Sperm idine:
1.02g Spermidine Trihydrochloride
Add distilled water to 100ml, sterilise by filtration, store at -20°C.
2 Ox SSC:
(3M NaCI, 0.3M Sodium citrate, pH7)
175.32g NaCI 
88.23g Sodium citrate
Add distilled water to 11, sterilise by autoclaving.
ST ET Solution:
8g sucrose 
5ml Triton-X -100  
10ml 0.5M EDTA, pH 8.0  
5ml 1M Tris-HCI, pH 8.0  
Add distilled water to 100ml
STET/Lysozym e Solution:
Add 4 mg/ml lysozyme to STET solution. Use fresh.
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1 Ox TBS:
500ml 1M Tris, pH 8.0  
87.7g NaCI
Add distilled water to 11, sterilise by autoclaving.
T B S -B T :
100ml 10x TBS 
500^1 Tween 20  
10g BSA
Add distilled water to 11.
T B S -T :
100ml 10x TBS 
500^1 Tween 20  
Add distilled water to 11.
Tris-HCI, 1 M Stock:
121.1 g Tris in 800ml distilled water
Add conc. HCI to the desired pH
(pH 7.4 - 70ml, pH 7.6 - 60ml, pH 8.0 - 42ml)
Add distilled water to 11, sterilise by autoclaving.
1 Ox Tris-B orate  Buffer (TBE):
(0.89M Tris, 0.89M boric acid, 0.02M EDTA)
108g Tris 
55g boric acid 
40ml 0.5M EDTA, pH 8.0  
Add distilled water to 11
TE Buffer:
(1 OmM Tris-HCI, Im M EDTA)
2ml 0.5M EDTA, pH 8.0 
10ml 1M Tris-HCI
Add distilled water to 11, sterilise by autoclaving.
TYN Broth:
10g Tryptone 
10g Yeast Extract 
5g NaCI
Add distilled water to 11, sterilise by autoclaving.
X -G a l:
Stock solution of 20mg/ml in dimethylformamide.
Use in agar plates at a final concentration of AO^g/ml.
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